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ABSTRACT  
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
characterized by the death of motor neurons, generally leading to paralysis and 
death within 3-5 years of onset.  Over 50 different mutations in the gene 
encoding FUS/TLS (or FUS) will result in ALS, accounting for ~4% of all inherited 
cases.  FUS is a multifunctional protein with important functions in DNA/RNA 
processing and stress response.  How these mutations affect the structure or 
function of FUS protein and ultimately cause ALS is not known.  The fact that 
mutations cause the protein to mislocalize from the nucleus to the cytoplasm of 
cells suggests that ALS pathogenesis may occur through a loss of nuclear 
function, gain of toxic cytoplasmic function, or both.  Several FUS knockout 
animal models have been utilized for investigating a loss of function hypothesis 
and show phenotypes such as early lethality, reduced lifespan, and locomotor 
defects.   
To uncover cellular pathways affected by loss of FUS function, I have 
characterized the knockdown of FUS in a motor neuron-like cell line, NSC-34.  In 
NSC-34 cells, the depletion of FUS severely impacts cellular proliferation and 
potentially causes increased levels of DNA damage.  A quantitative proteomics 
analysis performed on cells undergoing various degrees of FUS knockdown 
revealed protein expression changes for known RNA targets of FUS, consistent 
with a loss of FUS function with respect to RNA processing.  Proteins that 
changed in expression as a function of FUS knockdown were associated with 
vii 
 
 
multiple processes, some of which influence cell proliferation including cell-cycle 
regulation, cytoskeletal organization, oxidative stress and energy homeostasis.  
Importantly, cellular proliferation could be rescued by the re-expression of FUS 
and by treatment with the small-molecule, rolipram, indicative of potential 
therapeutic approaches. 
Collectively, the work presented in this dissertation demonstrates the 
importance of FUS for cell health and homeostasis, is suggestive of a role for 
FUS in DNA damage repair and identifies additional cellular pathways influenced 
by FUS depletion. Overall, this work provides mechanistic insight into ALS 
pathogenesis through loss of FUS/TLS function. 
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CHAPTER I: INTRODUCTION 
 
Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease, is a 
neurodegenerative disorder characterized by the specific death of upper and 
lower motor neurons. This neuronal loss results in impairment of motor abilities 
causing paralysis and eventually death, resulting from respiratory failure.  The 
disease is rapidly progressive, with death occurring usually 3-5 years after 
symptom onset (NINDS, 2013). Not only is there no cure for this disease, but 
treatments are very limited as well with only one in existence, Riluzole, that 
prolongs life by only a few months (Bensimon et al., 1994; Lacomblez et al., 
1996). It is estimated that each year 5,000 people in the United States are 
diagnosed with ALS (NINDS, 2013). Approximately 90-95% of cases are 
sporadic, occurring without familial inheritance (Renton et al., 2014).  That the 
disease occurs in people mainly between the ages of 50 and 60, in conjunction 
with its fast progression and the inability to predict its targets, make it especially 
devastating and an increasingly important area of research.  The following 
sections provide additional information on the nature of this disease and a theory 
of its pathogenesis.  
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Clinical symptoms and diagnosis 
Early signs of ALS are subtle and depend on the site and type of onset. Limb 
onset occurs in the arms or legs and is apparent by difficulty in performing simple 
tasks, such as writing, or an increased frequency of stumbling while walking 
(Gordon, 2013). Bulbar onset is the second type, accounting for 25% of cases. 
These individuals first experience difficulty swallowing or speaking, with a 
tendency to slur their words (Gordon, 2013). Regardless of the type of onset, 
symptoms quickly progress to other muscle types within the body and become 
more pronounced over time. Eventually patients are unable to walk or stand, eat 
without assistance, or even speak. As many of the symptoms of ALS are 
common in other disease, such as multiple sclerosis, Lyme disease, and spinal 
muscular atrophy, physicians must proceed with caution when diagnosing ALS. 
Since there is currently no biomarker of ALS, diagnosis is typically achieved by 
tracking the progression of symptoms and using specific tests, such as an 
electromyography (EMG) or a nerve conduction study (NCS), to rule out the 
diagnosis of other neurological diseases or disorders (NINDS, 2013).  
 
Genetic and cellular contributions 
There are two forms of ALS: familial and sporadic.  Familial ALS (or fALS) is 
defined by inheritance of a mutated gene causative for ALS and accounts for 
~10% of cases, while sporadic ALS (or sALS) has no evidence of a genetic 
linkage and comprises the remaining ~90%.  The first gene associated with ALS 
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was Cu, Zn superoxide dismutase-1 (SOD1) in 1993 (Rosen et al., 1993).  There 
are over 160 mutations in SOD1 that cause ALS and mutations in this gene 
alone account for ~20% of fALS. Over the past two decades many more genes 
have been identified, bringing the list to over 30 (Sreedharan and Brown, 2013).  
Within this list is TDP-43 (TAR-DNA binding protein-43), FUS/TLS (fused in 
sarcoma/translocated in liposarcoma), and the most recently discovered 
C9ORF72, which accounts for approximately 30% of fALS. Together, these four 
genes are credited with causing 60% of fALS cases (Chen et al., 2013). Also 
important to note, is that while ALS is predominantly a mid-life disease, several 
genes have been associated with rare cases of juvenile onset, occurring between 
the ages of 6 and 26.  These genes include ALSIN (Hadano et al., 2001), 
senataxin (SETX) (Chance et al., 1998), spatacsin (SPG) (Hentati et al., 1998; 
Stevanin et al., 2007), ubiquilin 2 (UBQLN2) (Deng et al., 2011), and FUS/TLS 
(Baumer et al., 2010).     
While all of these genes are clearly involved in the pathogenesis of ALS, it 
is still unclear whether their involvement is through a common cellular pathway. 
Several cellular events have been associated with ALS, including protein 
aggregation, aberrant RNA processing, oxidative stress, axonal dysfunction, 
mitochondrial disruption, metabolic disturbance, microglia activation, and 
aberrant activation of the apoptosis pathway (reviewed in (Chen et al., 2013; 
Sreedharan and Brown, 2013)). Two of the more prominently studied 
mechanisms are protein aggregation and aberrant RNA processing (reviewed in 
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(Sreedharan and Brown, 2013)).  Studies of protein aggregation emerged with 
the very first identified ALS gene: SOD1.  Mutant SOD1 obtains a misfolded 
conformation and accumulates as oligomers, ultimately becoming aggregates.  
This misfolded protein disrupts normal function of several cellular events, such as 
protein degradation (Bendotti et al., 2012; Chen et al., 2012) and axonal 
transport (Morfini et al., 2013).  Wild-type SOD1 purified from sporadic ALS 
tissue also adopts a misfolded conformation and disrupts axonal transport 
(Bosco et al., 2010b), suggesting involvement of misfolded SOD1 in both familial 
and sporadic ALS (reviewed in Rotunno and Bosco, 2013).  Other ALS-linked 
proteins that effect protein degradation and axonal function include ubiquilin 2 
and valosin-containing protein (reviewed in Robberecht and Philips, 2013) and 
profilin-1 (Wu et al., 2012), respectively.  Similarly, several ALS-genes have 
overlapping functions in RNA processing.  These genes include TDP-43 
(Kabashi et al., 2008; Sreedharan et al., 2008), FUS/TLS (Kwiatkowski et al., 
2009; Vance et al., 2009), and C9ORF72 (DeJesus-Hernandez et al., 2011; 
Renton et al., 2011).  How RNA processing is affected by mutations in these 
genes is not fully understood, but evidence suggests misregulation of 
transcription, splicing, and RNA editing (Polymenidou et al., 2012).   
While several ALS-associated proteins can be linked to a common 
pathogenic mechanism, not one mechanism can account for every reported ALS 
gene (Figure I-1).  This raises the question of whether ALS is a single disease 
that can be treated with a specific therapy or rather a more complex disorder 
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caused by separate pathogenic events.  That age of onset, clinical phenotypes, 
and progression of the disease vary greatly between patients suggest the latter.  
Furthermore, progression and clinical phenotypes can be predicted by genetics.  
For example, mutations in FUS are associated with early age of onset, bulbar 
onset, and rapid progression while repeat expansions in C9ORF are associated 
with shorter survival and cognitive and behavioral changes (reviewed in (Al-
Chalabi and Hardiman, 2013)). The end result of motor neuron death is the same 
regardless of genetic factors, but the therapeutic strategy may need to differ 
based on the genetic and cellular events involved, such as intercepting the 
downstream effects of protein aggregation for patients harboring SOD1 
mutations or correcting RNA processing defects for patients having FUS or TDP-
43 mutations. 
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Figure I-1.  The heterogeneity of ALS pathogenesis.  Shown in purple are various 
ALS-linked genes and the pathogenic mechanisms with which they are associated. 
 
With permission from BioMed Central, this figure was reproduced from:  Chen S, 
Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update. 
Mol Neurodegener 8:28. 
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Environmental factors and epidemiology studies 
Sporadic ALS cases are rarely (~11%) attributed to mutations in the genes 
causative for fALS (Renton et al., 2014). As ~90% of all ALS cases are sporadic, 
this equates to ~10% of all ALS cases being accounted for by known genetic 
mutations. While studying fALS genes and the associated cellular phenotypes 
provides valuable insight into the cellular pathogenesis of ALS, efforts have been 
made to determine the environmental causes or risk factors of sporadic ALS.  
Most epidemiological studies have been performed on European cohorts and 
have determined sex and age as the most common risk factors (Al-Chalabi and 
Hardiman, 2013).  Men are diagnosed with ALS more frequently by a factor 
between 1.2 and 1.5, providing a lifetime risk of 1:350 for men and 1:400 for 
women (Al-Chalabi and Hardiman, 2013).  The risk for ALS increases with age, 
but only up to an age of 75 where it plateaus and may even decline.  This plateau 
affect however, may be due to the decreased likelihood of ALS being identified in 
older patients who may accept their symptoms as a normal sign of aging (Al-
Chalabi and Hardiman, 2013).   
Environmental factors have also been evaluated as risk factors for ALS, 
but these studies are hard to control as variables cannot be isolated and 
evidence is often circumstantial.  The most frequently evaluated factors include 
exercise level (Scarmeas et al., 2002), participation in soccer (Chio et al., 2005), 
smoking (Wang et al., 2011a), occupation and participation in the armed services 
(McGuire et al., 1997), electric shock, and exposure to heavy metals, pesticides 
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or cyanotoxins (Armon, 2003).  Despite this extensive list, no conclusive 
evidence of an environmental risk factor has been identified (reviewed in (Al-
Chalabi and Hardiman, 2013)).    
 
Overlap with Frontotemporal dementia (FTD) 
It has become increasingly apparent that ALS is part of a continuum of 
neurodegenerative diseases, having overlapping features with frontotemporal 
dementia (FTD, pathologically known as frontotemporal lobar degeneration or 
FTLD). FTD accounts for 5-15% of dementia and is caused by degeneration of 
the frontal and temporal lobes.  It is characterized clinically by a decline in 
behavior, personality, and language and molecularly by inclusions of various 
disease-specific proteins in neurons and glia, such as hyperphosphorylated tau 
protein, TDP-43 and FUS (reviewed in (Rademakers et al., 2012)). It is estimated 
that 15% of ALS patients meet the criteria for FTD (Ringholz et al., 2005) and 
15% of FTD patients meet the criteria for ALS. In both instances, protein 
inclusions are a hallmark of the disease.  In FTD, 35% of cases show aggregated 
microtubule-associated protein tau and the majority of cases negative for tau 
contain inclusions immunoreactive for ubiquitin (reviewed in (Rademakers et al., 
2012)), which is also observed in motor neurons of ALS patients.    In 2006, TDP-
43 was discovered to be the main protein present in these ubiquitinated 
inclusions of both ALS and FTD patients (Arai et al., 2006; Neumann et al., 
2006). Soon after, mutations in TDP-43 were found to be causative for familial 
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and sporadic ALS (Kabashi et al., 2008; Sreedharan et al., 2008). Additional 
evidence of an overlap between these diseases came with the discovery of a 
genetic link between FUS and ALS (Kwiatkowski et al., 2009; Vance et al., 2009) 
followed by the identification of FUS as a main component of FTLD inclusions 
negative for tau or TDP-43 (Neumann et al., 2009b). Most recently, a 
hexanucleotide repeat expansion in C9ORF72 was found to account for ~25-50% 
of familial ALS, 10-30% of familial FTD, and also ~80% of cases having features 
of both FTD and ALS, further solidifying a relationship between these two 
disorders (DeJesus-Hernandez et al., 2011; Renton et al., 2011).    
 
Disease pathogenesis 
When contemplating the development of ALS, a few disease characteristics 
stand out:  onset occurs later in life, the majority of cases are sporadic, and only 
a very small percentage of cases are attributed to genetic mutations. Clearly 
genetics is a causative factor, but that genetic mutations can exist since birth and 
not cause ALS until late adulthood suggests environmental factors are a 
contributing factor as well.  Moreover, the majority of cases are not linked to 
genetic mutations, which further supports a role for environmental insults in 
pathogenesis. These facts support the division of ALS development into three 
scenarios, based on various contributions of cell damage occurring over time, 
genetics, and environmental factors.  These three scenarios, put forth by Drs. Al-
Chalabi and Hardiman, are described as monogenic ALS, oligogenic or polygenic 
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ALS, and gene x environment interaction (Al-Chalabi and Hardiman, 2013).  In 
monogenic ALS, a mutation in a single gene, such as SOD1, accounts for the 
majority of the risk.  To reach a threshold for disease onset, only a small 
contribution is needed from environmental factors, such as ultraviolet radiation 
which increases cellular reactive oxygen species (Devasagayam et al., 2004) 
normally controlled by SOD1.  Oligogenic or polygenic ALS, takes into account 
the 100+ genes identified as risk factors for ALS (Abel et al., 2012). In this 
scenario, mutations in these genes alone do not cause ALS, but in combination 
these mutations can put the cell at risk. For instance, several genes associated 
with protein degradation may be mutated, each slightly affecting the efficiency of 
this pathway.  If these genes are mutated individually the cell can still function 
normally. In combination however, and in association with environmental factors 
that contribute to protein aggregation for example, the cell’s protein degradation 
machinery becomes less efficient.  Over time, misfolded protein will accumulate 
until a threshold for cell death occurs and disease onset ensues.   In the final 
scenario, the presence of a specific genetic predisposition in combination with a 
specific environmental insult is required for the burden to reach the threshold for 
disease onset.  An example may be a mutation in a gene that is required for DNA 
damage repair followed by exposure to a toxin that damages DNA. The authors 
further propose that after disease onset occurs, a self-perpetuating process 
follows, causing a rapid decline in health. In summary, these three scenarios help 
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explain the relationship between time, environment, and genetic predisposition 
that collectively contribute to the onset of ALS.   
 
Fused in Sarcoma/Translocated in Liposarcoma (FUS/TLS) 
Fused in Sarcoma/Translocated in Liposarcoma (FUS/TLS), or FUS, was first 
discovered in 1993 as a fusion oncoprotein in myxoid liposarcoma (Crozat et al., 
1993; Rabbitts et al., 1993).  During the remainder of the 20th century, FUS-
related research focused on characterizing its involvement in sarcomas and its 
nucleic acid associations, with a role in RNA splicing being the dominant interest 
through the mid 2000’s (Lerga et al., 2001; Rapp et al., 2002; Meissner et al., 
2003; Delva et al., 2004; Belly et al., 2005).  During the 15 years following its 
discovery in sarcomas, an average of ~2.5 FUS-related publications were 
produced a year. In February of 2009, mutations in FUS were found to be 
causative for ALS (Kwiatkowski et al., 2009; Vance et al., 2009) and since then 
the average number of FUS-associated publications per year has risen to an 
astounding 50!   FUS has proven to be a complex multifunctional protein 
important for numerous cellular processes fundamental to cell health and 
homeostasis. The sections below provide a description of the physical properties 
of FUS, its functions in the nucleus and cytoplasm, and its role in disease with a 
focus on ALS. 
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Functional domains and structure 
FUS is a 55 kDa protein consisting of 526 amino acids. It is an RNA/DNA binding 
protein that functions at all stages of gene expression from transcription to 
protein translation (Sama et al., 2014) and belongs to the FET (formerly TET) 
family of proteins, also consisting of Ewing’s Sarcoma (EWS) and TATA box 
binding protein associated factor 68 kDa (TAF15) (Tan and Manley, 2009a). 
Based on sequence determinants, FUS consists of an N-terminal QGSY-rich 
(“prion-like”) domain, glycine-rich region, RNA-recognition motif (RRM), zinc-
finger domain, C-terminal arginine-glycine-glycine (RGG)-rich domains, and 
nuclear export and localization signals (Figure I-2).  Biochemical and structural 
studies have determined that overall FUS is highly unstructured with organization 
apparent only in the zinc-finger and RRM domains (Iko et al., 2004). The flexible 
nature of the protein may be important in allowing FUS to interact with nucleic 
acids and various proteins essential for the host of functions it performs. In fact, 
every domain of FUS contributes to the protein’s myriad of functions performed 
throughout the cell (Figure I-2). 
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Figure I-2.  The functional domains of FUS.  FUS binds DNA, RNA and 
proteins to perform a diverse array of functions.  Summarized here are the 
known functions of FUS annotated onto the domain structure of the protein. 
(QGSY-rich, glutamine-glycine-serine-tyrosine-rich or “prion-like” domain; Gly-
rich, glycine-rich; RGG, arginine-glycine-glycine-rich; RRM, RNA recognition 
motif; ZFD, zinc-finger domain; NLS, nuclear localization signal). 
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Nuclear and cytoplasmic functions 
FUS is a multifunctional protein involved in a diverse array of cellular processes. 
As a resident of the nucleus, FUS binds both DNA and RNA. Interactions with 
DNA form the basis for several putative functions of FUS in the context of DNA 
processing (Figure I-3). For example, FUS directly binds both single- and 
double-stranded DNA (Baechtold et al., 1999; Liu et al., 2013), localizes to 
RNAPII promoters (Tan et al., 2012) and telomeres (Dejardin and Kingston, 
2009; Takahama et al., 2009) and is associated with higher order DNA 
structures, such as G-quadruplexes (Baechtold et al., 1999; Takahama and 
Oyoshi, 2013; Takahama et al., 2013). These associations underlie the roles of 
FUS in modulating transcription, telomere length, and DNA damage repair 
(Takahama et al., 2013) (reviewed in: (Sama et al., 2014)). Additionally, 
interactions between RNA and FUS coincide with several important functions of 
FUS in RNA processing. For example, FUS binds long introns (Hoell et al., 2011; 
Ishigaki et al., 2012; Lagier-Tourenne et al., 2012; Rogelj et al., 2012) consistent 
with a role for FUS in pre-mRNA splicing (reviewed in (Ling et al., 2013)). FUS 
binding sites were also identified within the 3’UTR of target genes (Lagier-
Tourenne et al., 2012), which may contribute to mRNA export from the nucleus 
and localization within the cell for local translation (Barrett et al., 2012). In fact, 
FUS is also known as hnRNP P2 (heterogeneous ribonucleoprotein P2) (Calvio 
et al., 1995), and collectively hnRNPs are known to function in mRNA splicing, 
packaging, trafficking/nuclear export, stability, and translation (Han et al., 2010).  
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Figure I-3.  FUS directly binds DNA.  (A)  FUS binds the promoters of >1000 
genes, indicative of a role in transcriptional regulation.  (B)  FUS binds both 
single- and double-strand DNA and is important for two critical steps in 
homologous recombination: D-loop formation and homologous DNA pairing.  
When a double-strand break occurs in DNA, the 5’ end of the break is trimmed 
back to create a 3’ overhang of single-stranded DNA.  This 3’ single-stranded 
DNA then binds a complementary sequence within duplex DNA of a 
homologous chromosome or sister chromatid, a process called strand invasion 
(reviewed in (Li and Heyer, 2008)).  (C)  FUS binds G-quadruplexes in 
telomeres.  (D)  Analogous to the role of FUS in D-loop formation, FUS may 
also be important for T-loop formation at the ends of telomeres. T-loops are 
formed when a single-strand, G-rich DNA overhang at the end of a 
chromosome forms a loop and anneals to a complementary 5’ C-rich 
sequence ((Griffith et al., 1999) and reviewed in (Greider, 1999)). 
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The classification of FUS as an hnRNP highlights its ability to shuttle between the 
nucleus and cytoplasm (Zinszner et al., 1997; Fujii and Takumi, 2005) and its 
importance in both compartments. In the cytoplasm in fact, FUS is  found in 
neuronal dendrites (Belly et al., 2005; Fujii et al., 2005; Yoshimura et al., 2006; 
Aoki et al., 2012) where it translocates with mRNAs important for the 
development and function of spines (reviewed in (Dormann and Haass, 2013)).  
FUS is also found in translationally active RNA/protein foci (Yasuda et al., 2013) 
within the cytoplasm, as well as stress granules formed in response to osmotic 
stress ((Sama et al., 2013) See also Appendix II), further demonstrating the 
cytoplasmic importance of FUS. 
 
FUS/TLS in disease 
As its name implies, FUS is part of an onco-fusion protein that causes malignant 
myxoid liposarcoma. The N-terminal transcriptional activation domain of FUS is 
fused to the transcription factor CHOP (also known as DDIT3), forming FUS-
CHOP (Crozat et al., 1993; Rabbitts et al., 1993) which accounts for more than 
90% of myxoid liposarcoma cases (Antonescu et al., 2000). In some cases of 
Ewing’s sarcoma family tumors, FUS is fused to the transcription factor ERG 
(Shing et al., 2003). A similar fusion of FUS and ERG, with inclusion of different 
exons, has also been found in rare cases of acute myeloid leukemia (Ichikawa et 
al., 1994; Panagopoulos et al., 1994). Additionally, fusion of FUS with ATF1 and 
BBF2H7 will cause angiomatoid fibrous histiocytoma (Waters et al., 2000; 
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Raddaoui et al., 2002) and low-grade fibromyxoid sarcoma (Storlazzi et al., 
2003), respectively. Fusion proteins containing FUS, or family members EWS 
and TAF15, actually participate in nearly half of all sarcomas (Riggi et al., 2007). 
FUS also has a strong presence in neurological disorders (Figure I-4).   In 2009, 
mutations in FUS were found to be associated with ALS (Kwiatkowski et al., 
2009; Vance et al., 2009) with over 40 pathogenic mutations identified to-date 
(Dormann and Haass, 2013). Additionally, FUS is closely associated with 
frontotemporal dementia (FTD; pathologically defined as frontotemporal lobar 
degeneration, FTLD) as a component of pathological protein inclusions (Munoz 
et al., 2009; Neumann et al., 2009b; Neumann et al., 2009a; Urwin et al., 2010). 
While all cases of ALS-FUS are associated with genetic mutations, FTLD-FUS is 
characterized by neuronal FUS inclusions (Rademakers et al., 2012) with only 
rare cases associated with genetic FUS abnormalities (Van Langenhove et al., 
2010). FUS inclusions now define several different subtypes of FTLD 
(Rademakers et al., 2012), including atypical FTLD-U (Neumann et al., 2009b; 
Urwin et al., 2010), neuronal intermediate filament inclusion disease (Neumann 
et al., 2009a), and basophilic inclusion body disease (Munoz et al., 2009); 
collectively referred to as FTLD-FUS (Mackenzie et al., 2010). 
Most recently, several mutations in FUS were linked to essential tremor 
(ET) (Merner et al., 2012; Rajput et al., 2013; Wu et al., 2013; Zheng et al., 
2013), an adult onset movement disorder having clinical overlap with Parkinson’s 
disease (Benito-Leon and Louis, 2006).  Historically, ET has been classified as 
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monosymptomatic, mainly characterized by a kinetic arm tremor, and it is 
estimated that 30-50% of cases are misdiagnosed as Parkinson’s disease or 
other forms of tremor (Benito-Leon and Louis, 2006).  More recently however, it 
was recognized that cognitive symptoms, such as loss of memory, depression, 
and deficits in executive function are associated with ET (reviewed in (Bermejo-
Pareja and Puertas-Martin, 2013)).  Pathologically, this disease is associated 
with cerebellar degeneration, accumulation of Lewy bodies in the brainstem, and 
accumulation of neurofilament in Purkinje cell axons (Benito-Leon and Louis, 
2006). Until recently however, post-mortem brain examinations were uncommon 
so an exact pathological description of the disease is still unavailable.  
Genetically, familial inheritance is a risk factor for ET, but other than several 
mutations in FUS, no clear genetic links to the disease have been made aside 
from the identification of a few chromosomal susceptibility loci (Benito-Leon and 
Louis, 2006).  The most commonly ET-associated mutation in FUS is G290X, 
which results in a truncated transcript (Merner et al., 2012).  This truncated 
transcript appears to be degraded by nonsense-mediated decays, effectively 
decreasing expression of FUS (Merner et al., 2012), suggestive of loss of FUS 
function contributing to disease pathogenesis.  That several other groups have 
not identified FUS mutations in their ET cohorts however, may imply FUS 
mutations are causative for ET only in rare cases (Parmalee et al., 2012; Hedera 
et al., 2013; Labbe et al., 2013; Ortega-Cubero et al., 2013). 
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Figure I-4.  Disease associated mutations in FUS/TLS.  Mutations in FUS 
are linked to familial and sporadic amyotrophic lateral sclerosis (fALS and 
sALS), frontotemporal lobar degeneration, and essential tremor.  Summarized 
here are the known mutations associated with each disease, annotated onto 
the domain structure of the protein. Mutations identified in a single patient are 
denoted by asterisks. (QGSY-rich, glutamine-glycine-serine-tyrosine-rich; Gly-
rich, glycine-rich; NES, nuclear export signal; RRM, RNA recognition motif; 
RGG, arginine-glycine-glycine-rich; ZFD, zinc-finger domain; NLS, nuclear 
localization signal). 
 
Information in this figure was compiled from the following sources: 
Deng H, Gao K, Jankovic J (2014) The role of FUS gene variants in 
neurodegenerative diseases. Nat Rev Neurol 10:337-348. 
 
Dormann D, Haass C (2013) Fused in sarcoma (FUS): An oncogene goes 
awry in neurodegeneration. Mol Cell Neurosci 56:475-486. 
 
Lattante S, Rouleau GA, Kabashi E (2013) TARDBP and FUS mutations 
associated with amyotrophic lateral sclerosis: summary and update. Hum 
Mutat 34:812-826. 
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Mechanism of FUS/TLS in Amyotrophic Lateral Sclerosis 
In 2009 two groups simultaneously published the discovery of a genetic linkage 
between FUS and ALS (Kwiatkowski et al., 2009; Vance et al., 2009). Over the 
following years, ~25 additional groups published findings of FUS mutations in 
ALS patients from French, Italian, Belgian, German, Japanese, Dutch, Spanish, 
Taiwanese and Chinese populations demonstrating the global contribution of 
mutant FUS to ALS.  Currently, over 50 ALS-linked mutations in FUS have been 
identified, contributing to both sporadic and familial ALS. Overall, FUS mutations 
account for ~4% of familial ALS, ~1% of sporadic ALS, and is also attributed with 
being a main contributor of juvenile ALS (Chen et al., 2013).  While the 
mechanism behind FUS pathogenesis in ALS is not known, data is consistent 
with both a gain of toxic function and a loss of normal function for FUS variants.  
 
Gain of function hypothesis 
The fact that mutations in FUS cause the protein to mislocalize to the cytoplasm 
and the degree of this mislocalization correlates with age of onset (Dormann et 
al., 2010), makes a gain of toxic function in the cytoplasm an attractive 
hypothesis. That FUS binds both nucleic acid and proteins could predict aberrant 
interactions of FUS with various cytoplasmic species, interfering with normal 
cytoplasmic processes. An aberrant interaction that has drawn considerable 
attention within the field over the past few years is the assembly of ALS-linked 
mutant FUS into cytoplasmic puncta called stress granules (reviewed in 
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(Wolozin, 2012; Bentmann et al., 2013; Li et al., 2013)). Stress granules are 
stalled translational complexes that form in response to environmental or 
metabolic stress. The proposed function of stress granules is the triage of 
mRNAs, dictating their fate for expression, degradation, or suppression in order 
to express the appropriate repertoire of proteins to re-establish homeostasis 
(Anderson and Kedersha, 2008; Kedersha et al., 2013). Cytoplasmically localized 
mutant FUS is consistently detected within stress granules under conditions of 
protein over-expression, oxidative stress, heat-shock and endoplasmic reticulum 
(ER)-stress (Bosco et al., 2010a; Dormann et al., 2010; Gal et al., 2011; Kino et 
al., 2011; Bentmann et al., 2012). The association of FUS with stress granules 
correlates with its cytoplasmic expression, with variants such as FUS P525L and 
R495X exhibiting the most robust levels of both cytoplasmic mislocalization and 
stress granule incorporation (Bosco et al., 2010a; Dormann et al., 2010). Baron 
et al. demonstrated that the presence of mutant-FUS in stress granules alters 
several properties that may be important for stress granule function ((Baron et 
al., 2013) see also Appendix III). Under conditions of sodium arsenite, an inducer 
of oxidative stress, the expression of mutant FUS delays the assembly and 
expedites the disassembly of stress granules. Furthermore, the size and 
abundance of stress granules are enhanced by mutant-FUS, which may be an 
outcome of the increased protein- and/or mRNA load within these structures 
caused by mutant FUS-specific interactions (Baron et al., 2013). Intriguingly, 
stress granule marker proteins have been detected in pathological aggregates of 
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post-mortem tissues from individuals with ALS and FTLD (Dormann et al., 2010; 
Liu-Yesucevitz et al., 2010; Bentmann et al., 2013; Kim et al., 2013), suggesting 
that these granules may accumulate during chronic stress and thus serve as 
precursors to the end-stage pathological aggregates seen in these disorders 
(Wolozin, 2012).  
 
Loss of nuclear function hypothesis 
That not all ALS-causing mutant FUS proteins mislocalize to the cytoplasm 
argues against a purely gain of toxic cytoplasmic function mechanism for FUS in 
ALS.  A gain of toxic function could also occur in the nucleus, or alternatively, 
mutations in FUS could mediate disease through a loss of proper FUS function in 
the nucleus.  Suggestive of the latter is the correlation between disease severity 
and the degree of nuclear FUS depletion (Dormann et al., 2010).  Furthermore, 
FUS is predominantly a nuclear protein and has numerous nuclear functions 
important for cellular processes fundamental to cell health and homeostasis, 
such as the repair of damaged DNA and regulation of transcription and splicing 
(Sama et al., 2014).  Disruption of any of these processes could have a 
detrimental impact on cellular viability.  
 
In vivo models:  To assess the effects of a complete loss of FUS function several 
groups have established in vivo models of FUS depletion through targeted 
knockdown with RNAi or creating null alleles for complete knockout of the protein 
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(Table I-1).  In Drosophila models, knockdown or knockout of cabeza, the 
Drosophila homolog of FUS (Stolow and Haynes, 1995), caused temperature 
dependent pupal lethality, physiological defects such as eye degeneration and 
wing defects, locomotor defects in both larvae and adult flies, and a shorter adult 
lifespan (Wang et al., 2011b; Sasayama et al., 2012; Xia et al., 2012).  Zebrafish 
injected with antisense morpholino oligonucleotides targeting FUS showed signs 
of motor defects in that they lacked a touch-evoked escape response.  
Additionally, the outgrowth and length of hyperbranched and unbranched axons 
of motor neurons were reduced with FUS knockdown, supportive of a 
neurodegenerative phenotype in these animals (Kabashi et al., 2011). To test a 
loss of function hypothesis, wild-type FUS and mutant FUS variants were 
expressed in both the Drosophila and zebrafish models and assessed for their 
ability to rescue the phenotypes caused by FUS depletion.  While the 
reintroduction of wild-type FUS rescued pupal lethality, locomotor speed, and 
adult lifespan in Drosophila, expression of FUS variants R522G or P525L was 
unable to rescue locomotor speed or median lifespan of adult flies (Wang et al., 
2011b), demonstrating loss of function of these variants.  In the zebrafish model, 
R521H demonstrated no ability to rescue, R521C only partially rescued, and the 
S57deletion mutant rescued the phenotypes to a similar degree as the 
expression of wild-type FUS (Kabashi et al., 2011).  The S57deletion mutation is 
a rare variant identified in only one sporadic ALS case, suggesting it may not be 
a pathogenic mutant, which could explain its wild-type-like nature in this model.  
24 
 
 
Variants R521H and R521C however, demonstrated phenotypes consistent with 
a loss of function model.  
Two knockout mouse models of FUS have also previously been studied. 
Kuroda et al. generated a FUS-/- mouse model that lived to adulthood, but were 
smaller in size, showed sensitivity to ionizing radiation, and demonstrated male 
sterility and reduced female fertility (Kuroda et al., 2000).  An additional FUS-/- 
line, created in an inbred background, was perinatal lethal and defective in B-cell 
development.  Furthermore, these mice showed several signs of chromosomal 
instability, such as chromosome breakage, aneuploidy, and centromeric fusions 
(Hicks et al., 2000).  These lines were created nine years before the discovery of 
FUS in ALS and therefore it is unlikely that they were monitored for signs of 
motor-neuron degeneration.  Consistent between both lines however, were signs 
of genomic instability, suggestive of a role for FUS in maintaining DNA integrity.   
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Table I-1. Summary of investigations of FUS knockdown/knockout models.   
System Publication Method of FUS depletion Summary of results 
in vivo 
Flies 
(Machamer et 
al., 2014) Caz null; or RNAi in neurons increased synaptic activity 
(Xia et al., 2012) Caz null; or RNAi 
physiological defects, neuromuscular 
junction structure defects, reduced 
locomotion, reduced viability 
(Sasayama et 
al., 2012) RNAi in neurons 
reduced locomotion, shorter lifespan, 
shorter axon length 
(Wang et al., 
2011b) Caz null 
physiological defects, reduced 
locomotion, shorter lifespan 
Fish (Kabashi et al., 2011) 
antisense morpholino 
oligonucleotide 
reduced locomotion, shorter 
hyperbranched and unbranched axons 
Mice 
(Hicks et al., 
2000) 
interrupted gene in exon 12 (inbred 
background) 
perinatal death, reduced number of 
lymphocytes, defective B-cell 
development, numerous signs of 
genomic instability 
(Kuroda et al., 
2000) 
interrupted gene in exon 8 (outbred 
background) 
male sterility due to defective 
spermatogenesis, reduced female 
fertility, sensitivity to ionizing radiation 
in vitro 
Neuronal 
cells in 
culture 
(Fujii et al., 
2005) 
hippocampal neurons from 
knockout mice (Hicks et al., 2000) 
abnormal dendritic branching and 
spine morphology 
(Ishigaki et al., 
2012) 
lentiviral transduction of shRNA into 
E15 cortical neurons                         
(6 days, 80% knockdown) 
alterations in mRNA expression and 
pre-mRNA splicing 
(Nakaya et al., 
2013) 
siRNA transfection of ES cell-
derived neurons (3 days, 44% 
knockdown) 
alterations in mRNA expression and 
pre-mRNA splicing 
(Orozco et al., 
2012) 
lentiviral transduction of shRNA into 
rat hippocampal neurons (7 days) 
no overt toxicity; lack of exon 10 
splicing in Tau; axons were shorter 
and had enlarged growth cones 
Non-
neuronal 
cells in 
culture 
(Hoell et al., 
2011) 
siRNA transfection into HEK cells  
(3 days) mRNA expression unchanged 
(Kim et al., 
2010) 
siRNA transfection into HEK or 
HeLa cells (2days) 
decreased HDAC6 mRNA and protein 
levels 
(Tan et al., 
2012) siRNA transfection into HEK cells altered expression of candidate genes 
(van Blitterswijk 
et al., 2013) 
siRNA transfection into HEK cells  
(2 days) 
alterations in mRNA expression and 
pre-mRNA splicing 
(Yamazaki et al., 
2012) 
lentiviral transduction of shRNA into 
HeLa cells reduction in SMN nuclear bodies 
(Wang et al., 
2013) siRNA transfection into U2OS cells  
reduced efficiency of DNA damage 
repair pathways 
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DNA damage models:  Recently, the importance of FUS in the DNA damage 
repair pathway was firmly established after several groups demonstrated a 
localization of FUS to sites of DNA damage and a deficiency in DNA damage 
repair in the absence of FUS.  Collectively, six fALS-linked mutant FUS proteins 
were evaluated in these assays. With the exception of one for which there was 
conflicting results (Rulten et al., 2013), all of the variants localized to sites of DNA 
damage to a similar degree as wild-type FUS (Mastrocola et al., 2013; Wang et 
al., 2013).  In assessing the ability of mutant FUS to function in DNA damage 
repair, mutant FUS protein was expressed in cells devoid of FUS.  FUS 
knockdown decreases the efficiency of two common double-strand break repair 
pathways: homologous recombination (HR) and non-homologous end-joining 
(NHEJ).  All of the FUS variants tested (R244C, R514S, H517Q, R521C) were 
unable to rescue the defect in HR-mediated DNA repair observed with FUS 
knockdown (Wang et al., 2013). Efficiency of NHEJ was also not fully rescued by 
mutant FUS, although the deficit was greater for HR (Wang et al., 2013). This 
demonstrates a loss of DNA damage repair function by mutant FUS despite 
proper localization of the protein to sites of DNA damage (Figure I-5).  As 
damaged DNA accumulates normally as a function of age (Gorbunova et al., 
2007), inefficient DNA repair due to FUS mutations could have an additive effect 
over time, leading to neuronal death later in life as a result of unrepaired DNA.  
FUS in the DNA damage response is discussed further in Chapter II. 
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Figure I-5.  FUS is recruited to sites of DNA damage and contributes to 
DNA-damage repair.  Under normal conditions FUS (green oval) and 
common repair proteins (triangles) localize to sites of laser induced DNA 
damage (yellow star).  Under conditions of FUS knock-down (KD), these repair 
proteins are not recruited to sites of DNA damage and the efficiency of both 
homologous recombination (HR) and non-homologous end joining (NHEJ) is 
reduced.  Mutant-FUS (red ovals) is still able to localize to sites of damage in 
the absence of endogenous FUS (**discrepancy in the literature for the degree 
of localization of variant R521G). Exogenous mutant-FUS does not fully 
rescue DNA-damage repair when endogenous FUS is knocked-down 
(*exception, FUS H517Q), although mutant-FUS is able to recover NHEJ to a 
greater extent than HR (*NHEH is fully recovered by FUS H517Q). 
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 As nuclear functions of FUS also include transcriptional regulation and pre-
mRNA splicing, several groups have investigated the effects of FUS depletion on 
mRNA abundance and splicing events (Table I-2). As a transcriptional co-
regulator, FUS interacts with several transcription factors (Hallier et al., 1998; 
Uranishi et al., 2001; Sato et al., 2005; Kim et al., 2010; Du et al., 2011) as well 
as RNA Polymerase II (RNAP2) (Immanuel et al., 1995; Bertolotti et al., 1996; 
Bertolotti et al., 1998; Schwartz et al., 2012) and RNA Polymerase III (RNAP3) 
(Tan and Manley, 2009b) and regulates the expression of their target genes. The 
ability of FUS to interact with and regulate the transcriptional activity of RNA 
polymerases suggests a general role for FUS in cellular transcriptional 
regulation.  In fact, FUS chromatin immunoprecipitation of HeLa lysates followed 
by promoter microarray analyses revealed that FUS directly binds DNA in 
promoter regions.  This study found that FUS bound to 1,161 promoter regions 
for genes involved in various cellular processes, including gene expression, cell 
cycle, and neuronal functions (Tan et al., 2012).  Not surprisingly therefore, 
several groups using genome-wide expression array analyses reported 
alterations in mRNA abundance upon FUS knockdown in a variety of cell types 
using different FUS depletion strategies  ((Hoell et al., 2011; Ishigaki et al., 2012; 
Lagier-Tourenne et al., 2012; Rogelj et al., 2012; Nakaya et al., 2013; van 
Blitterswijk et al., 2013)) and reviewed in (Ling et al., 2013)).  Additionally, global 
effects on alternative splicing has been revealed through genome-wide exon 
array analyses (reviewed in (Ling et al., 2013)) of FUS depletion in primary 
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neurons (Ishigaki et al., 2012; Lagier-Tourenne et al., 2012; Rogelj et al., 2012; 
Nakaya et al., 2013) as well as non-neuronal cells (van Blitterswijk et al., 2013), 
demonstrating that FUS likely plays a general role in splicing in various cell 
types.   Whether mutant FUS mimics FUS knockdown and exerts the same 
effects on transcriptional regulation and splicing has yet to be determined.  
 
Summary 
Five years after the discovery of FUS mutations in ALS, the question still 
remains whether these mutations result in a gain of toxic function or a loss of 
normal function.  The work presented in this thesis investigates a loss of function 
hypothesis, modeled by FUS knockdown in mammalian cells in culture. Chapter 
II introduces this knockdown system and a reduced cellular proliferation 
phenotype that results from FUS depletion.  As a candidate approach to 
providing mechanistic insight into this phenotype, DNA damage repair was 
investigated.  Upon FUS knockdown, levels of phosphorylated H2AX, a common 
marker of DNA damage, are elevated in a FUS dependent manner, 
demonstrating a correlation between FUS levels and DNA damage accumulation.  
Chapter III takes a broader approach to providing mechanistic insight and uses 
quantitative proteomics to identify proteins differentially expressed upon FUS 
knockdown.  Several fundamental cellular pathways were enriched within the 
functions of differentially expressed proteins, including cell-cycle regulation, 
cytoskeletal organization, oxidative stress and energy homeostasis. Further, the 
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work in Chapter III demonstrates therapeutic potential for the treatment of cellular 
deficiencies associated with loss of FUS function by showing reversal of the 
phenotype by FUS re-expression or treatment with the small molecule, rolipram. 
Collectively, the work presented in this dissertation demonstrates the importance 
of FUS for cell health and homeostasis, supports a role for FUS in DNA damage 
repair and identifies additional cellular pathways influenced by loss of FUS 
function as relevant to the pathogenesis of ALS. 
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 Investigations of FUS in RNA processes 
Publication: 
General description 
mRNA 
Expression 
(method) 
mRNA 
Splicing 
(method) 
Binding 
targets 
(method) 
RNA 
binding 
specificity 
Key categories identified by 
Gene Ontology (GO) Term 
analysisVI 
Hoell et 
al., 2011 
Comparison of 
FET family and 
mutant FUS 
RNA targets 
FUS 
knockdown in 
HEK-293 cells  
(microarray) 
N/A 
HA-tagged 
WT, R521H 
or R521G in 
HEK-293 
cells  
(PAR-CLIPi) 
Introns; AU-
rich stem 
loops (15-
fold higher 
affinity than 
GGU 
repeat) 
RNAs uniquely bound by mutant-
FUS: endoplasmic reticulum and 
ubiquitin-proteasome related  
 
Colombrita 
et al., 
2012 
Comparison of 
FUS and TDP-
43 RNA targets 
N/A N/A 
Cytoplasmic 
fraction of 
NSC-34 
(RIP-CHIPii) 
3'UTR; 
limited 
sequence 
specificity 
RNAs bound by FUS: 
transcriptional regulation, cell cycle, 
ribonucleoprotein biogenesis, RNA 
splicing, stress response/ DNA 
repair, purine ribonucleotide binding 
and ubiquitin-mediated proteolysis 
Ishigaki et 
al., 2012 
RNA binding 
specificity of 
FUS; 
expression and 
splicing 
regulation by 
FUS 
FUS 
knockdown in 
primary cortical 
neurons  
(exon array) 
FUS 
knockdown in 
primary cortical 
neurons  
(exon array) 
mouse 
cerebellum  
(HITS-
CLIPiii) 
Introns and 
3'UTR; 
regions with 
secondary 
structure 
Changes in mRNA abundance: 
signaling cascades and metabolic 
processes 
Alterna ively spliced mRNA: vesicle 
transport, neuronal impulse and 
neuronal projection 
Rogelj et 
al., 2012 
Comparison of 
FUS and TDP-
43 RNA 
targets; 
expression and 
splicing 
regulation by 
FUS 
FUS -/- 
embryonic 
mouse brain  
(splice-junction 
microarray) 
FUS -/- 
embryonic 
mouse brain  
(splice-junction 
microarray) 
embryonic 
mouse 
brain  
(iCLIPiv) 
Long 
introns; no 
preference 
for stem-
loops; 
limited 
sequence 
specificity 
Alternatively spliced mRNA: cell 
adhesion, apoptosis, neuronal 
development and axonogenesis 
Lagier-
Tourenne 
et al., 
2012 
Species 
comparison of 
FUS RNA 
targets; 
comparison of 
targets, 
expression and 
splicing 
regulation 
between FUS 
and TDP-43 
FUS 
knockdown in 
adult mouse 
brain and 
spinal cord 
(RNA-seq) 
FUS -/- 
embryonic 
mouse brain; 
FUS 
knockdown in 
adult mouse 
brain  
(splicing-
sensitive 
microarrays) 
Naïve 
mouse 
brain; non-
disease 
human 
brain  
(CLIP-seqv) 
Long introns 
and 3'UTR; 
GUGGU is 
an enriched 
RNA 
sequence 
motif 
RNAs bound by FUS: components 
of the synapse and molecules 
residing in neuronal projections 
Nakaya et 
al., 2013 
Species 
comparison of 
FUS RNA 
targets; 
expression and 
splicing 
regulation by 
FUS 
FUS 
knockdown in 
embryonic 
stem cell 
(ESC) derived 
mouse 
neurons  
(RNA-seq) 
FUS 
knockdown in 
ESC derived 
mouse 
neurons  
(RNA-seq) 
human 
temporal 
lobe 
cortices; 
ESC 
derived 
mouse 
neurons  
(HITS-
CLIPiii) 
Introns; 
limited 
sequence 
specificity 
RNAs bound by FUS: synapse, cell 
adhesion, neuronal projection and 
neuronal recognition processes 
van 
Blitterswijk 
et al., 
2013 
Comparison of 
FUS 
overexpression, 
FUS 
knockdown and 
expression of 
mutant-FUS on 
mRNA 
expression and 
splicing 
FUS 
knockdown; 
overexpression 
of WT, R521G 
or R522G in 
HEK-293 cells  
(RNA-seq) 
FUS 
knockdown; 
overexpression 
of WT, R521G 
or R522G in 
HEK-293 cells  
(RNA-seq) 
N/A N/A 
Changes in mRNA abundance: 
ribosome, spliceosome, mismatch 
repair and DNA replication 
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Table I-2. Summary of investigations of FUS involvement in RNA 
processes. 
iPAR-CLIP – photoactivatable ribonucleoside-enhanced crosslinking and 
immunoprecipitation 
iiRIP-Chip - RNA-binding protein immunopurification, microarray 
iiiHITS-CLIP - High-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation 
iviCLIP – individual-nucleotide resolution crosslinking and immunoprecipitation 
vCLIP-seq – crosslinking immunoprecipitation, high-throughput RNA sequencing 
(RNA-seq) 
VIgene categories that are highlighted in the original work, see original publication 
for a full list of GO terms 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
 
PREFACE TO CHAPTER II: 
 
The work presented in this chapter was performed by Catherine L. Ward with the 
exception of the immunofluorescence images in figures 2 and 3 which were 
acquired by Dr. Desiree Baron. 
 
The work presented in this Chapter intended to uncover a role for FUS in DNA 
damage repair and investigate the functional capacity of ALS-linked mutant FUS.  
Despite exhaustive troubleshooting and experimental optimizations, the findings 
were suggestive, but largely inconclusive and were not pursued for publication.  
Following the termination of this project, three groups published conclusive 
evidence of a functional role for FUS in double-strand break repair, which is 
disrupted when FUS contains ALS-linked mutations.  Collectively, investigations 
of a role for FUS in DNA damage repair are discussed herein. 
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CHAPTER II:  A LOSS OF DNA DAMAGE REPAIR FUNCTION OF FUS/TLS IN 
AMYOTROPHIC LATERAL SCLEROSIS 
 
Introduction 
Over 50 mutations in the gene Fused in sarcoma/translocated in 
liposarcoma (FUS/TLS, or FUS) have been identified as causative for 
amyotrophic lateral sclerosis, or ALS.  FUS is a multifunctional protein involved in 
a host of cellular processes related to DNA and RNA metabolism and cellular 
stress response (Sama et al., 2014). Since the discovery of FUS mutations in 
ALS (Kwiatkowski et al., 2009; Vance et al., 2009) much research has been 
focused on determining the related pathogenic mechanism(s).  An initial 
observation was the cytoplasmic mislocalization of FUS mutant protein 
(Kwiatkowski et al., 2009; Vance et al., 2009) which appears to correlate with 
disease severity (Dormann et al., 2010).  This is characteristic of mutations within 
the nuclear localization signal (NLS) of the protein, which account for nearly half 
of all mutations (Figure I-4).  This observation has led to many researchers 
investigating a gain of toxic function as a pathogenic mechanism for cytoplasmic 
variants (Hoell et al., 2011; Huang et al., 2011; Baron et al., 2013).  In addition to 
mutations within the NLS, 25% of mutations are clustered in the glycine-rich 
region of FUS (Figure I-4) and these proteins retain proper nuclear localization 
(Dormann et al., 2010). This evidence argues against a purely gain of toxic 
function in the cytoplasm and instead could predict a loss of nuclear function as 
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the pathogenic mechanism.  FUS is predominantly localized to the nucleus and 
functions in transcriptional regulation, pre-mRNA splicing, and DNA damage 
repair (Sama et al., 2014). Loss of function in any of these pathways could have 
detrimental consequences for cell health and homeostasis.  In fact, several in 
vivo models have demonstrated lethality upon FUS knockout.  In mice, FUS 
knockout is perinatal lethal (Hicks et al., 2000) and Drosophila models exhibit 
pupal lethality and/or a shortened adult lifespan (Wang et al., 2011b; Sasayama 
et al., 2012; Xia et al., 2012).  To directly assess a loss of function from ALS-
linked mutations, Wang et al. expressed mutated FUS in a Drosophila null model 
and found ALS-linked variants R522G and P525L were unable to fully rescue the 
lifespan of adult flies as compared to the re-expression of wild-type.  These 
variants were also unable to rescue other loss of function phenotypes, such as 
locomotor speed (Wang et al., 2011b).  This study supported a loss of function 
hypothesis for mutant FUS in ALS pathogenesis. 
While several animal models have demonstrated the necessity of FUS for 
viability, the necessity of FUS at the cellular level has not been fully elucidated.  
FUS is involved in numerous cellular pathways, but whether these pathways are 
dependent on FUS function is not known. To study the influence of FUS 
depletion on cell health and homeostasis at the cellular level, I characterized an 
inducible FUS knockdown system in NSC-34 cells (neuroblastoma x spinal cord 
hybrid) and discovered a defect in cellular proliferation upon FUS depletion. 
Several nuclear functions of FUS could contribute to this response. As a 
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candidate approach I chose to investigate a defect in DNA damage repair as a 
causative factor, as FUS knockout mice demonstrated early lethality associated 
with exposure to ionizing radiation (Kuroda et al., 2000). Finally, to investigate 
the functional capacity of ALS FUS variants, I developed a system that allowed 
for the knockdown of endogenous FUS in cultured mammalian cells with 
simultaneous expression of exogenous wild-type or mutant FUS. 
    
Results 
FUS depletion induces a defect in cell proliferation. To determine the effect of 
FUS depletion in mammalian cells, I utilized NSC-34 cell lines (neuroblastoma x 
spinal cord hybrid) containing stable inducible shRNA targeted to either the open 
reading frame of FUS (shFUS) or a scrambled control sequence (shSC) (Sama 
et al., 2013).  After four days of induction, FUS levels were depleted >90% in the 
shFUS line while remaining at endogenous levels in the shSC line (Figure II-1A).  
Observation of cell confluency after four days of shRNA induction revealed a 
striking reduction in cell abundance for the cell line expressing shFUS. 
Quantification of cell number revealed a 50% decrease in the shFUS line 
compared to either uninduced cells or cells expressing shSC (Figure II-1B). This 
finding was supported by an MTT assay of cell viability which showed ~50% 
reduction in viability in shFUS cells compared to only a ~20% reduction in shSC 
cells (Figure III-1C).  Together with a lack of observable cell death, this data 
demonstrates a defect in cell proliferation upon the knockdown of FUS.   
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Figure II-1.  FUS knockdown causes a decrease in cellular proliferation.  
NSC-34 cells stably expressing inducible shRNA targeting exon 5 of FUS 
(shFUS) or a scrambled control sequence (shSC) were used to model the 
effects of loss of FUS function. (A) Representative western blot demonstrating 
>90% FUS knockdown after induction with 1μg/ml doxycycline in cells 
expressing shFUS. Tubulin serves as a loading control. (B-C) Four days of 
FUS knockdown by induction of shFUS resulted in ~50% reduction in cell 
proliferation, compared to uninduced cells or cells expressing shSC, as 
determined by cell counting (B) or MTT assay (C). Data shown are the 
average of 3 independent experiments + standard error. Statistical 
significance was determined by a student’s t-test (*P <0.05; **P <0.01). 
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Assessing the functional capacity of mutant FUS.  We next sought to determine 
whether mutant FUS could rescue the proliferation defect produced by 
knockdown of endogenous wild-type FUS.  To this end, I established NSC-34 
cells stably expressing exogenous human wild-type FUS or mutant R495X 
(Baron et al., 2013).  R495X is a clinically severe mutation and has a high degree 
of cytoplasmic mislocalization (Bosco et al., 2010a), making it an ideal variant for 
studying loss of nuclear function.  To knockdown endogenous FUS while 
simultaneously expressing exogenous FUS, siRNA targeting the 3’ untranslated 
region (3’UTR) of murine FUS was designed and proved to be more efficient at 
knocking down endogenous wild-type FUS (endo-WT) than the exogenous 
human variants (exo-WT or exo-R495X) (Figure II-2A).  Four days after siRNA 
transfection, MTT assays were performed to assess the ability of exogenous 
wild-type or mutant FUS to inhibit a proliferation defect from occurring during the 
knockdown of endogenous FUS.   In cells expressing exogenous WT- or R495X-
FUS, MTT levels were still reduced ~40-50% after knockdown of FUS, compared 
to transfection of scrambled control siRNA (Figure II-2B).  
The lack of rescue by exogenous human wild-type FUS could suggest that 
the proliferation defect is an off-target effect of siRNA and not truly an effect of 
FUS depletion.  To address this,  we knocked-down FUS in two different cell 
lines using a total of four different siRNA sequences and consistently observed a 
proliferation defect (Chapter III: Figure III-1).  Thus, the lack of rescue could be 
due to either inefficient expression levels of the exogenous protein or the inability 
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of human FUS to function as murine FUS.  Despite the lack of a 3’UTR in the 
exogenous constructs, there was a significant degree of knockdown of the 
exogenous protein (Figure II-2A). This is presumably through the production of 
siRNA during degradation of the murine transcript that can target human FUS. 
Despite continued attempts to increase exogenous levels of wild-type FUS, we 
were never able to maintain near-endogenous levels.   
To navigate the possibility of human FUS being unable to rescue the 
knockdown of mouse FUS, we attempted the same rescue experiment in HEK-
293T cell lines stably expressing inducible GFP-tagged human wild-type FUS or 
mutant R495X (Bosco et al., 2010a).  Expression of exogenous protein was 
induced one day prior to the transfection of siRNA and in this system exogenous 
levels remained high while endogenous levels of FUS were depleted (Figure II-
2C).  MTT levels however, were not rescued by either the expression of 
exogenous wild-type or mutant protein (Figure II-2D).  While the exogenous 
protein was expressed at near-endogenous levels and was the same species as 
the endogenous protein, the addition of a GFP-tag could have potentially 
conflicted with the proper folding of FUS or altered relevant FUS interactions 
within the cell.  As a final attempt, I developed HEK-293T cells stably expressing 
HA-tagged exogenous FUS, but was unable to achieve high levels of the 
exogenous protein.  In the end, despite numerous attempts and extensive 
troubleshooting, I was unable to produce a reliable model system to study the 
functional capacity of mutant FUS. 
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Figure II-2. Testing the functional capacity of ALS-linked mutant FUS. (A) 
Western blot analysis of the indicated cell lysates. Endogenous wild-type FUS 
(endo-WT) in NSC-34 cells was knocked-down by the transfection of siRNA 
targeting the 3’UTR of FUS.  Exogenously expressed human wild-type FUS 
(exo-WT; left) or mutant R495X (exo-R495X; right) is still expressed after the 
knockdown of endogenous wild-type. (B) Expression of exogenous human 
FUS protein, wild-type or mutant R495X, was unable to rescue the ~50 % 
proliferation defect caused by knockdown of endogenous mouse FUS. (C) 
Exogenous GFP-tagged FUS, either wild-type (exo-WT; left) or mutant R495X 
(exo-R495X; right), was expressed in HEK-293T cells.  Transient transfection 
of siRNA targeting the 3’UTR of FUS caused a specific knockdown of 
endogenous wild-type FUS, while leaving exogenous protein expression 
unaffected. (D) Expression of exogenous protein, either wild-type (left) or 
mutant R495X (right), was unable to rescue the proliferation defect induced by 
knockdown of endogenous FUS. 
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FUS depletion induces elevated levels of phosphorylated H2AX (γH2AX), a 
marker of DNA damage. In addition to FUS-/- mice being sensitive to ionizing 
radiation (Kuroda et al., 2000), evidence of the importance of FUS in homologous 
DNA pairing (Akhmedov et al., 1995; Bertrand et al., 1999) and D-loop formation 
(Baechtold et al., 1999), supports a role for FUS in DNA damage repair, as these 
are essential steps of homologous recombination.   Since cell cycle arrest is a 
component of the DNA repair process (reviewed in (Zhou and Elledge, 2000)), 
we investigated whether the FUS knockdown-induced defect in cell proliferation 
was occurring as a consequence of damaged DNA.  To this end, we monitored 
levels of phosphorylated H2AX (γH2AX), a common marker of DNA damage. 
Four days after induction of FUS knockdown in NSC-34 cells, γH2AX levels were 
increased as compared to control cells expressing shSC (Figure II-3A).  This 
finding was recapitulated in HEK-293T cells after transient transfection of siRNA 
targeting a unique sequence of FUS (Figure II-3B), indicating this result was not 
an off-target effect or specific to FUS knockdown in NSC-34 cells.  Furthermore, 
γH2AX levels remained elevated over the course of 10 days with continued FUS 
knockdown, but if FUS levels were allowed to recover by the washout of shRNA 
induction, γH2AX levels returned to baseline (Figure II-3C). Together, this data 
demonstrates a direct correlation between FUS levels and γH2AX elevation. 
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Figure II-3.  FUS knockdown causes elevated levels of γH2AX. (A) 
Representative immunofluorescence images demonstrating increased γH2AX 
foci in cells with knocked-down FUS expression four days after induction of 
shFUS. (B) Western blot analysis of HEK-293T lysates after four days of the 
indicated siRNA treatment. Increased expression of γH2AX is present in 
lysates having knocked-down expression of FUS.  Tubulin serves as a loading 
control. (C) NSC-34 cells expressing inducible shRNA were either 
continuously induced or induced for 24h after which induction was washed-
out. Western blot analysis of the indicated lysates demonstrates an increase in 
γH2AX, correlating with FUS knockdown (left; continuous induction), which is 
recovered as FUS levels return to baseline (right; induction + washout). 
Tubulin serves as a loading control. 
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In addition to being a marker of DNA damage, γH2AX is also elevated as 
a result of DNA fragmentation in the later stages of apoptosis (Rogakou et al., 
2000).  To determine whether γH2AX was elevated as a result of apoptosis, we 
probed for early markers of apoptosis, specifically cleaved caspase-3 and 
cleaved-PARP, for their temporal relationship to γH2AX.   While increased 
γH2AX was evident as early as 48h by immunofluorescence (Figure II-4A) and 
60h by western analysis (Figure II-4B), cleaved caspase-3 and cleaved-PARP 
remained nearly undetectable throughout 96h of FUS knockdown.  Furthermore, 
DNA harvested at 48 and 96h of FUS knockdown had an identical pattern to 
DNA harvested at 0h of FUS knockdown, differing from that of a positive control 
demonstrating a typical pattern of fragmented DNA (Figure II-4C).  Together, this 
data suggests γH2AX is elevated upon FUS depletion as a consequence of 
increased DNA damage, independent of apoptosis.  
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Figure II-4. FUS knockdown-induced γH2AX is independent of apoptosis.  
NSC-34 cells were induced to express shFUS for the knockdown of FUS 
expression and monitored over time for the presence of apoptosis markers. 
(A) Representative immunofluorescence images demonstrate increased 
γH2AX foci by 48h of shFUS induction without evidence of cleaved caspase-3. 
Cells treated with 1μM staurosporine (ST) for 2h serve as a control for positive 
cleaved caspase-3 staining.  (B) Western blot analysis of the indicated lysates 
reveals increased levels of γH2AX correlating with decreased FUS expression 
while levels of cleaved-PARP and cleaved caspase-3 remain unchanged. (C) 
DNA harvested from cells after 0, 48, or 96h of shFUS expression was 
separated by electrophoresis. DNA fragmentation, as demonstrated by a 
positive control (+), is not present after FUS knockdown (M = DNA size 
marker). 
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Next, we sought to determine the mechanism associated with the elevated 
levels of DNA damage.  Was this phenomenon due to a higher rate of DNA 
damage, a lower rate of DNA repair, or both?  In order to assess physical DNA 
damage and track levels and repair rates over time, we sought to employ the 
Comet assay, a gel electrophoresis method used to measure the abundance of 
double strand breaks in the DNA of individual cells.  The Comet assay reports 
baseline DNA damage as well as tracks the repair of damaged DNA after an 
insult such as ionizing radiation (Olive and Banath, 2006; Wood et al., 2010). 
While in the process of establishing this method within the lab, inconsistencies 
arose in the reproducibility of γH2AX elevation following FUS knockdown. In 
these experiments, γH2AX reports the level of DNA damage that occurs 
spontaneously during the normal life of cells in culture, without the addition of 
DNA damaging agents.  It would stand to reason then, that the culture condition 
of the cells had been altered, leading to less exposure to spontaneous DNA 
damage. Despite troubleshooting numerous variables, such as components of 
growth media, incubator conditions and the integrity of our cell lines, we were 
unfortunately unable to resolve this issue and further investigations were not 
pursued. 
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Discussion 
While several groups have investigated the effects of FUS knockdown in 
both neuronal (Ishigaki et al., 2012; Orozco et al., 2012; Nakaya et al., 2013) and 
replicating cells (Kim et al., 2010; Hoell et al., 2011; Tan et al., 2012; Yamazaki 
et al., 2012; van Blitterswijk et al., 2013), our work is the first to report an effect 
on cell health or proliferation.  Our knockdown system is unique from other 
studies in that every cell stably expresses an inducible shRNA construct targeting 
FUS, ensuring a homogeneous FUS knockdown, in contrast to transient 
transfections which vary based on transfection efficiencies.  The homogenous 
knockdown of FUS in our system allows for any resulting phenotype to be 
widespread and more evident.  Moreover, our studies were carried out for four 
days while others were assessed after only two or three when an alteration in cell 
abundance would be less apparent.  That a proliferation defect was detected in 
our hands using four different FUS RNAi sequences in two different cells lines 
(data shown in Chapter III) supports this finding as a direct cause of FUS 
depletion and not an off-target effect of the experimental approach.  
 To investigate the cellular events leading to the FUS knockdown-induced 
proliferation defect, we took a candidate approach and measured levels of DNA 
damage, as several lines of evidence implicate FUS in DNA damage repair 
(Akhmedov et al., 1995; Baechtold et al., 1999; Bertrand et al., 1999; Kuroda et 
al., 2000).  Although our work remains inconclusive due to a lack of 
reproducibility in our experimental system, our results are suggestive of an 
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accumulation of unrepaired DNA as a result of FUS depletion. Shortly after this 
project was halted, a role for FUS in the DNA damage repair process was firmly 
established when three independent groups reported the localization of FUS to 
sites of damaged DNA (Mastrocola et al., 2013; Rulten et al., 2013; Wang et al., 
2013). Furthermore, in the absence of FUS the efficiency of DNA double-strand 
break repair pathways, specifically homologous recombination (HR) and non-
homologous end-joining (NHEJ), were decreased 30-50%.  This reduction is 
thought to be significant considering a ~50% reduction in these repair processes 
is observed when the expression of known DNA-repair proteins is reduced 
(Mastrocola et al., 2013; Wang et al., 2013).  In primary mouse cortical neurons, 
cells that mainly utilize the NHEJ pathway for DNA double strand break repair 
((Sharma, 2007) and reviewed in (Rao, 2007)), FUS depletion resulted in a ~65-
80% reduction in repair efficiency as well as an increase in levels of damaged 
DNA, as determined by the Comet assay (Wang et al., 2013).  Together, these 
findings confirmed FUS is important for efficient DNA damage repair in both 
proliferating cells and in post-mitotic, non-proliferating cells such as neurons. 
 In addition to confirming the requirement of FUS in DNA damage repair, 
Wang et al. determined that FUS functions upstream of many common DNA 
damage repair proteins.  For instance, the redistribution of FUS to sites of DNA 
damage occurred prior to that of other key DNA-repair proteins, including NBS1 
(Nijmegen breakage syndrome-1), p-ATM (phosphorylated-ataxia telanogiectasia 
mutated), γH2AX (phosphorylated histone 2A.X) and Ku70 (Wang et al., 2013).  
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Additionally, the abundance of γH2AX foci was reduced when FUS expression 
was knocked-down, despite an increase in DNA damage reported by the Comet 
assay (Wang et al., 2013).  This finding was in contrast to what we had seen in 
NSC-34 and HEK cells (Figure II-2), as in our hands the knockdown of FUS 
resulted in an elevation of γH2AX foci.  An important difference between these 
two studies was in the induction of DNA damage.  While Wang et al. elicited the 
DNA damage response through treatment with etoposide, an inducer of double 
strand breaks, our study lacked experimental induction of DNA damage.  
Together these studies may indicate that FUS plays various roles in the DNA 
damage response depending on the level and type of damage that has occurred. 
While the capacity of mutant FUS to function in the models presented here 
was inconclusive due to the lack of a proper system, several other models have 
addressed a loss of function hypothesis for mutant FUS. In studies of DNA 
damage repair, Wang, et al. knocked-down the expression of endogenous FUS 
in U2OS cells and directly examined the ability of several ALS-linked variants to 
perform either HR- or NHEJ-mediated DNA repair.  All of the FUS variants tested 
(R244C, R514S, H517Q, R521C) were deficient in HR-mediated DNA repair 
relative to wild-type FUS. Overall, the impaired role of FUS variants in DNA 
repair was more pronounced in HR than NHEJ, where in the latter pathway 
nuclear FUS H517Q fully rescued the loss of WT FUS expression (Wang et al., 
2013). With the exception of mutant R521G for which there are conflicting results 
(Rulten et al., 2013), all FUS variants tested (R244C, R514S, H517Q, R521C, 
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R521G, and R524S) were recruited to sites of DNA damage (Mastrocola et al., 
2013; Wang et al., 2013). Therefore, in the context of DNA damage repair mutant 
FUS displayed proper localization, but was unable to perform its function, 
demonstrating a loss of function by mutant FUS.   
Accumulating evidence makes a strong case for a role of FUS in the DNA 
damage response and that ALS-linked mutants are deficient in this function 
makes defective DNA damage repair a plausible mechanism for ALS.  Damaged 
DNA accumulates normally as a function of age, presumably due to a life-time 
exposure to DNA damaging agents and a decline in quality control pathways 
(reviewed in (Gorbunova et al., 2007)). Defects in DNA repair due to FUS 
mutations are therefore expected to manifest in adulthood, which coincides with 
the mean age of onset (~55 years) for FUS-ALS.  Neurons may be particularly 
susceptible to accumulated DNA damage, as they lack the ability to replicate and 
self-renew. In support of this, post-mortem brain sections from the motor cortex 
of ALS patients harboring either FUS R521C or P525L mutations display 
increased levels of the γH2AX DNA damage marker relative to control brain 
sections (Wang et al., 2013).  However, it should be noted that γH2AX levels also 
correlate with apoptosis (Rogakou et al., 2000), which is an established cell-
death pathway in both ALS and related disorders (Pasinelli and Brown, 2006).  
Therefore, an alternative interpretation of these data is that there are increased 
levels of apoptosis in these end-stage diseased tissues, which is to be expected.   
A recent transgenic mouse however, that expresses FUS R521C and exhibits 
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severe motor defects and death 4-6 weeks after symptom onset, exhibited 
elevated levels of several DNA damage markers (e.g., γH2AX, phosphorylated 
p53, and ATF3) in the central nervous system in the absence of apoptosis 
markers (Qiu et al., 2014). Comet assays performed on isolated neurons 
supported this observation, with >50% of neurons from R521C mice 
demonstrating comet tails compared to the ~20% from non-transgenic control 
littermates.  These neurons lacked cleaved caspase-3 signal and were TUNEL-
negative, indicating that damaged DNA and motor neuron death do not result 
from apoptosis (Qiu et al., 2014).   
 
Conclusion 
Together, this evidence supports a disruption of DNA damage repair as a 
function of mutant-FUS expression.  Whether this is causative for ALS is yet to 
be determined and perhaps investigating additional FUS variants for DNA repair 
efficiency in vivo will offer more conclusive evidence.  Loss of other nuclear 
functions of FUS however, could just as easily be the determining factor in ALS 
pathogenesis.  To investigate the cellular effects of FUS depletion outside of this 
one candidate pathway, we further characterized the FUS knockdown-induced 
proliferation defect and using quantitative proteomics, identified several other 
cellular pathways modified by FUS depletion, as discussed in Chapter III. 
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Materials and Methods 
Tissue culture.  All cell lines used herein have been described previously: NSC-
34 cell lines expressing inducible shFUS1 of shSC (Sama et al., 2013), NSC-34 
cell lines constitutively expressing exogenous human wild-type FUS or mutant 
R495X (Baron et al., 2013), and HEK-293T cells expressing inducible GFP-
tagged human FUS, wild-type or mutant R495X (Bosco et al., 2010a).  For the 
induction of shRNA or GFP-tagged FUS in NSC-34 or HEK-293T cells 
respectively, cells were treated with 1μg/ml doxycycline (Sigma, D9891) or 0.1 
μg/ml tetracycline (Fisher Scientific, BP912-100). 
 
siRNA knockdown of FUS 
RNA oligonucleotides for FUS (sequences below) and a scrambled control 
sequence (guide: 5’-aauucuccgaacgugucacgu-3’; passenger: 5’-
gugacacguucggagaaucuu-3’) were purchased through Sigma-Aldrich and 10μM 
annealed stocks were prepared by combining guide and passenger strands in 
the following buffer:  100mM potassium acetate, 30mM HEPES-KOH pH 7.4, 
2mM magnesium acetate.  For knockdown in HEK-293T cells, cells were plated 
in a 24-well plate at 2,000 cells/well and allowed to adhere overnight.  
Transfection was performed in OPTI-MEM (Invitrogen, 31985070) using 0.4μl 
Lipofectamine RNAiMax (Invitrogen, 13778030) and 0.2nM siRNA per well 
(guide: 5’-uugggugaucaggaauuggaa-3’; passenger: 5’-ccaauuccugaucacccacuu-
3’).  For knockdown in NSC-34 cells, cells were plated in a 24-well plate at 
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10,000 cells/well.  Transfection was performed as above, but with 0.5μl RNAiMax 
and 10nM siRNA per well (guide: 5’-uaggguagucugacacacaca-3’; passenger: 5’-
ugugugucagacuacccucuu-3’). 
 
Cell proliferation assays. For cell counting experiments, inducible NSC-34 cells 
were plated in 6-well plates at 40,000 cells/well and induced with 1μg/ml 
doxycycline the following morning, or left uninduced.  Four days later, cells were 
resuspended in 3ml phosphate buffered saline (Invitrogen, 10010-049) and 
counted in triplicate using a hemocytometer. For MTT assays, NSC-34 and HEK 
cells were plated in technical triplicate in a 24-well plate and induced to express 
shRNA or transfected with siRNA the following morning, as described above.  
After four days, the media from each well was removed and replaced with 400μl 
fresh media and 100μl of 5mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide; Invitrogen, M-6494).  After a 35 min incubation at 37ºC, 
300μl lysis buffer (10% SDS in 1:1 N,N_-dimethylformamide:water/2% acetic 
acid/2.5% HCl 1M)(Reixach et al., 2004) was added to each well.  Plates were 
covered with a seal and incubated at 37ºC overnight followed by OD 
quantification at 550nm. Results are expressed as % cell viability relative to 
untreated controls using the following equation:  100 x (ODRNAi – 
ODblank)/(ODuntreated – ODblank).  The ODblank was determined by wells containing 
MTT and tissue culture media without cells.  
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Immunofluorescence.  Cells grown on glass coverslips were fixed for 5-10 min 
with 4% paraformaldehyde and blocked with PBSAT (1X PBS/1% BSA/0.5% 
Triton-X 100) for 30-60 min at room temperature. Primary antibodies were diluted 
in PBSAT and added to the coverslips at room temperature for 1 hr.  Primary 
antibody dilutions were as follows: 1:500 for anti-FUS (Bethyl laboratories, A300-
293A), 1:500 for γH2AX (Millipore, 05-636), and 1:500 for cleaved caspase-3 
(Cell Signaling, 9664). After primary antibody incubation, coverslips were washed 
with PBSAT and incubated for 45 minutes with Alexa Fluor 488-conjugated 
donkey anti-rabbit IgG (Jackson ImmunoResearch Labs, 711-545-152) or donkey 
anti-mouse Cy3 (Jackson ImmunoResearch Labs, 715-165-151), diluted at 
1:2000 in PBSAT. Lastly, cells were stained with 34 ng/mL DAPI and coverslips 
were mounted with ProLong Gold anti-fade reagent (Invitrogen, P36930). 
 
Western blotting.  Cells were lysed for 30 min at 4ºC with either 50 mM Tris HCl 
(pH 7.5) containing 0.5M NaCl, 1% NP-40, 1% deoxycholic acid, 0.1% SDS, and 
2mM EDTA or RIPA buffer (Boston BioProducts, BP-115-500), supplemented 
with protease (Roche, 11836170001) and phosphatase (Roche, 4906837001) 
inhibitors. Concentration of cell lysates was determined using a bicinchoninic 
acid (BCA) assay (Thermo Scientific Pierce, 23227) and samples were prepared 
in Laemmli SDS-sample buffer (Boston BioProducts, BP-111R).  Standard 
western blotting procedures were followed, using Tris-glycine SDS-PAGE and 
electrotransfer onto PVDF membrane at 100V for 1 hour at 4ºC.  Membranes 
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were blocked for 1h at room temperature with Odyssey Blocking Buffer (LiCor, 
927–40003) diluted 1:1 with PBS containing 0.1% tween-20 (PBST), followed by 
overnight incubation at 4ºC with primary antibodies diluted in PBST.  Primary 
antibody dilutions were as follows:  1:500 anti-FUS (Genscript, generated against 
C-terminal peptide CKFGGPRDQGSRHDSEQDNSD)(Sama et al., 2013), 1:500 
anti-tubulin (Sigma, T9026), 1:500 anti-cleaved PARP1 (Cell Signaling, 9544), 
1:500 anti-cleaved caspase-3 (Cell Signaling, 9664), and 1:100 anti-γH2AX 
(Millipore, 05-636). Following primary antibody incubation, membranes were 
washed with PBST and incubated for 1h with secondary antibody diluted 
1:10,000 in 1:1 Odyssey Blocking Buffer:PBST. Secondary antibodies included 
anti-mouse IRDye 680 (Licor, 926-68072) or IRDye 800 (LiCor, 926-32210) and 
anti-rabbit IRDye 680 (LiCor, 926-68023) or IRDye 800 (Licor, 926-32211). After 
washing with PBST, membranes were imaged with an Odyssey Infrared Imager 
(LiCor, Model 9120) and protein band intensities were quantified with the 
Odyssey Software (LiCor, V3.0). 
 For separation of human and mouse FUS protein in NSC-34 cell lysates, 
~25µg of total protein lysate was loaded per sample onto a 15% Tris-glycine gel, 
which was run at 215V at 4ºC for ~5 hours, until the 50kDa ladder band reached 
the bottom of the gel.  Electrotransfer onto PVDF membrane and antibody 
conditions were performed as described above. 
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DNA electrophoresis.  DNA was purified from NSC-34 cells using an Apoptotic 
DNA Ladder Kit (Roche, 11835246001). DNA samples (2µg) were loaded onto a 
1.0% agarose gel containing SYBR Safe DNA stain (Life Technologies, S33102) 
and run at 75V in TBE buffer (Tris-borate-EDTA) for 1.5hr, followed by imaging 
with a UV light source. 
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PREFACE TO CHAPTER III: 
 
The work and analysis presented in this chapter was performed by Catherine L. 
Ward with the following exceptions:  
 
Mass spectrometry was performed by Dr. Kristin Boggio (mass spectrometry 
core facility, UMMS), high-throughput small molecule screen was performed and 
analyzed by Dr. Bethann Johnson with assistance from Drs. Justin Boyd and 
Marcie Glicksman (Laboratory for Drug Discovery in Neurodegeneration, Harvard 
NeuroDiscovery Center), and live-cell imaging was performed by Stephen R. 
Douthwright (Sluder lab, UMMS). 
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CHAPTER III: A LOSS OF FUS/TLS FUNCTION LEADS TO IMPAIRED 
CELLULAR PROLIFERATION 
 
Abstract 
Fused in Sarcoma/Translocated in liposarcoma (FUS/TLS or FUS) is a 
multifunctional RNA/DNA-binding protein that is pathologically associated with 
cancer and neurodegeneration.  To gain insight into the vital functions of FUS 
and how a loss of FUS function impacts cellular homeostasis, FUS expression 
was reduced in different cellular models through RNA interference.  Our results 
demonstrate that a loss of FUS expression severely impairs cellular proliferation.  
A quantitative proteomics analysis performed on cells undergoing various 
degrees of FUS knockdown revealed protein expression changes for known RNA 
targets of FUS, consistent with a loss of FUS function with respect to RNA 
processing.  Proteins that changed in expression as a function of FUS 
knockdown were associated with multiple processes, some of which influence 
cell proliferation including cell-cycle regulation, cytoskeletal organization, 
oxidative stress and energy homeostasis.  FUS knockdown also correlated with 
increased expression of the closely related protein EWS (Ewing’s sarcoma). We 
demonstrate that the maladaptive phenotype resulting from FUS knockdown is 
reversible and can be rescued by re-expression of FUS or partially rescued by 
the small-molecule rolipram.  These results provide insight into the pathways and 
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processes that are regulated by FUS as well as the cellular consequences for a 
loss of FUS function. 
 
Introduction 
Fused in sarcoma/translocated in liposarcoma, FUS/TLS (or FUS), is a 
member of the TET family of proteins that also includes Ewing’s sarcoma (EWS) 
and TATA-binding protein-associated factor 15 (TAF15).  TET-proteins carry out 
RNA/DNA processing activities in the context of diverse cellular functions (Tan 
and Manley, 2009a).  FUS is predominately expressed in the nucleus where it 
plays a role in transcription, splicing and DNA damage repair (Dormann and 
Haass, 2013) and also shuttles to the cytoplasm, where it has been found in 
translationally active RNA/protein foci (Yasuda et al., 2013) as well as stress 
granules formed in response to osmotic stress (Sama et al., 2013).   
With such a broad host of cellular functions, it is not surprising that FUS is 
associated with several human diseases.  For example, FUS is part of an onco-
fusion protein that causes malignant myxoid liposarcoma.  The N-terminal 
transcriptional activation domain of FUS is fused to the transcription factor CHOP 
(also known as DDIT3), forming FUS-CHOP (Crozat et al., 1993; Rabbitts et al., 
1993) which accounts for more than 90% of myxoid liposarcoma cases 
(Antonescu et al., 2000). In fact, onco-fusion proteins containing TET-family 
proteins cause nearly half of all sarcomas (Riggi et al., 2007).  FUS also has a 
strong presence in neurodegenerative disorders such as adult onset 
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(Kwiatkowski et al., 2009; Vance et al., 2009) and juvenile amyotrophic lateral 
sclerosis (ALS), (Baumer et al., 2010) different subtypes of frontotemporal lobar 
degeneration (FTLD) (Rademakers et al., 2012) including atypical FTLD-U, 
(Neumann et al., 2009b; Urwin et al., 2010) neuronal intermediate filament 
inclusion disease (Neumann et al., 2009a) and basophilic inclusion body disease 
(Munoz et al., 2009) (collectively referred to as FTLD-FUS (Mackenzie et al., 
2010)), and polyglutamine diseases such as Huntington’s disease and 
spinocerebellar ataxia (Doi et al., 2009; Woulfe et al., 2009). The pathological 
role of FUS in these disorders has not been elucidated, although the observation 
that FUS is depleted from the nucleus and/or becomes sequestered into 
aggregates within neurons and glia during the course of neurodegeneration is 
consistent with a mechanism involving a loss of FUS function (Mackenzie et al., 
2011; Rademakers et al., 2012; Dormann and Haass, 2013).  FUS is also 
associated with essential tremor (ET), an adult-onset movement disorder (Merner 
et al., 2012; Rajput et al., 2013; Wu et al., 2013; Zheng et al., 2013). A loss of 
FUS function in the context of ET is proposed based on a non-sense mutation in 
FUS that causes the mRNA to become degraded through the non-sense 
mediated decay pathway (Merner et al., 2012). 
To study the impact of FUS depletion on cell survival and homeostasis, we 
developed cellular models of FUS knockdown and discovered FUS to be critical 
for cellular homeostasis. Knockdown of FUS in both HEK-293T and neuronal 
NSC-34 cells caused a significant defect in cellular proliferation with moderate 
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signs of cell death.  Importantly, the cell proliferation defect induced by FUS 
depletion is reversible, as both re-expression of FUS and treatment with rolipram, 
a phosphodiesterase-4 inhibitor that suppresses oxidative stress, ameliorated 
this phenotype.  A quantitative proteomics analysis revealed 61 proteins that 
changed as a function of FUS knockdown.  Interestingly, several of these 
proteins correspond to known RNA binding targets of FUS.  The proteins and 
pathways uncovered through this analysis not only define the consequences of 
FUS depletion from the cell, but also serve as potential therapeutic targets for 
ameliorating adverse phenotypes arising from a loss of FUS function.  
 
Results 
Cell number and viability directly correlate with FUS protein expression.  To 
investigate the cellular consequences of a loss of FUS function, FUS expression 
was knocked down in both NSC-34 (neuroblastoma x spinal cord)(Cashman et 
al., 1992) and HEK-293T cells. NSC-34 cell lines stably expressed tetracycline 
inducible shRNA specific for exon 5 of FUS (shFUS1 and shFUS2; Figure III-1A) 
or a scrambled shRNA control (shSC) (Sama et al., 2013).  After shFUS 
induction for four days, FUS expression was knocked down ~95% (Figure III-
1B).  In addition, we designed siRNA to target the 3’UTR of either human or 
mouse FUS (Figure III-1A) as well as a scrambled siRNA control.  Transient 
transfection of 3’UTR siRNA (si3’UTR) for four days resulted in ~85% knockdown 
of FUS in HEK-293T cells (Figure III-1B).  Cell viability as determined by the 
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MTT assay was reduced 40-50% in NSC-34 cells stably expressing shFUS and 
HEK-293T cells expressing si3’UTR relative to control cells expressing 
scrambled RNA sequences (Figure III-1C). Transient transfection of siRNA was 
less efficient in NSC-34 cells (Figure III-1D), resulting in only ~55% FUS 
knockdown (Figure III-1B) and a modest 15% decrease in cell viability compared 
to scrambled control siRNA (Figure III-1C).  A reduction in viability (~20%) was 
also observed upon expression of scrambled control sequences, likely reflecting 
the toxicity associated with transient transfection, continuous shRNA production 
and/or doxycycline exposure (Ahler et al., 2013).  Nonetheless, these data 
demonstrate a reduction in cell viability as a consequence of FUS knockdown, 
achieved by targeting several unique sequences within FUS in two different cell 
lines.  
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Figure III-1.  FUS knockdown causes a reduction in cell viability. (A) FUS 
was targeted for knockdown by doxycycline induction of stably expressed 
shRNA directed at non-overlapping regions in exon 5 (shFUS1, shFUS2) or by 
transient transfection of siRNA targeting the 3’UTR of either the human or 
mouse FUS sequence. (B)  Western blot analyses of the indicated cell lysate 
derived from FUS knockdown experiments. After four days of shFUS induction 
in NSC-34 cells (top) or transient transfection of 3’UTR FUS siRNA in HEK-
293Tcells (bottom left), FUS expression was reduced by ~95% and ~85%, 
respectively, compared to controls.  A less efficient FUS knockdown of ~55% 
was observed for NSC-34 cells (bottom right) transiently transfected with 
3’UTR FUS siRNA. Numbers below the blots refer to densitometry 
measurements of the experimental condition (doxycycline-induced or 
transfected) relative to the untreated control condition for the respective cell 
line.  SC refers to a scrambled (RNA) control sequence. Tubulin serves as a 
loading control.  (C) MTT analyses revealed a decrease in cell viability upon 
FUS knockdown after four days compared to SC expressing cells (left, shRNA 
in NSC-34 cells; middle, 3’UTR FUS siRNA in HEK-293T cells; right, 3’UTR 
FUS siRNA in NSC-34 cells).  All conditions are reported as percent viability 
relative to untreated cells.  Data shown are the average of 3 independent 
experiments + standard error. Statistical significance was determined by a 
student’s t-test (**P <0.01). (D) Representative immunofluorescence images 
demonstrating the degree of endogenous FUS (green) knockdown in NSC-34 
cells induced to express shFUS1 versus transiently transfected with 3’UTR 
FUS siRNA for four days. Nuclei are stained with DAPI (blue).  Arrow = 
detectable FUS knockdown, arrowhead = no detectable knockdown.  Scale 
bar = 10 μm. 
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To further investigate the relationship between FUS expression and 
cellular homeostasis, we quantified cell number and cellular viability as a function 
of FUS depletion over time using the inducible shFUS1 NSC-34 cell line (unless 
otherwise noted, this line was used for all subsequent experiments).  With 
continuous induction of shFUS with tetracycline in NSC-34 cells, FUS protein 
levels gradually decreased over time relative to uninduced cells and remained 
low for 10 days (Figure III-2A).  Uninduced cells exhibited an exponential growth 
rate with a 3.5-4 -fold increase in cell number every two days, whereas this 
growth rate decreased to 2-fold in cells subjected to continuous FUS knockdown 
(Figure III-2B).  Plotting cellular viability by the MTT assay as a function of FUS 
expression across multiple experiments further demonstrates the direct 
correlation between FUS expression and cellular homeostasis (Figure III-2C).  
Tetracycline was removed from shFUS expressing cells after 24h in a ‘wash-out’ 
experiment, wherein FUS levels returned to baseline within six days (Figure III-
2A).  It is noted that FUS expression was not restored when cells were induced 
with doxycycline due to the longer half-life of doxycycline relative to tetracycline.  
Interestingly, re-expression of FUS rescued the defect in cellular proliferation; the 
rate of cell growth was the same in shFUS cells under the wash-out condition as 
uninduced cells between days 8 and 10 (Figure III-2B).  Therefore, the adverse 
effects of FUS knockdown are reversible.  
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Figure III-2. Decreased cell viability correlates with the degree of FUS 
knockdown. (A) NSC-34 cells expressing shFUS1 were uninduced, induced 
with tetracycline for 24h after which tetracycline was removed (induction + 
wash-out) or subjected to continuous induction and FUS knockdown.  Western 
blot analyses of the indicated FUS knockdown experiment reveal FUS 
expression is restored in the wash-out condition by day six.  Numbers below 
the blots refer to densitometry measurements that were normalized to ‘day 
zero’, which represents the starting-point of the experiment.  Tubulin serves as 
a loading control. (B) Quantification of cell number as a function of time for the 
indicated conditions. Cells with continuous FUS knockdown exhibited the 
slowest growth rate between days 2 and 4 (inset) and throughout the 10-day 
experiment.  Upon re-expression of FUS, the growth rate for cells in the wash-
out condition was accelerated and became similar to that of the uninduced 
condition. Data shown are the average of 3 independent experiments + 
standard error.  Statistical significance was determined by a student’s t-test 
(*P <0.05; **P <0.01; ***P <0.001; day 6 significance is for the continuous 
induction condition).  (C) Cell viability, as determined by the MTT assay, 
correlates with the level of FUS protein expression, as determined by 
western/densitometry analyses. Data are compiled from three independent 
FUS knockdown experiments, where shSC or shFUS1 was induced in NSC-34 
cells for 1-5 days. An exponential fit of this data was created with GraphPad 
prism. 
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Apoptosis is not activated during the cellular response to FUS knockdown. 
Several factors influence the rate of cellular proliferation: the rate of cell division, 
the percentage of cells undergoing cell division, and cell death (Andreeff M GD, 
2000).  Overt cell death (i.e., a large percentage of cells detaching from the 
culture dish) was never observed during FUS knockdown experiments.  Western 
blot analyses confirmed that levels of the apoptosis markers cleaved-PARP1 and 
cleaved-caspase 3 remained unchanged throughout a 96h FUS knockdown time-
course and were markedly lower than cells treated with staurosporine, an initiator 
of apoptosis (Figure III-3A). To rule-out apoptosis occurring through a caspase-
independent pathway, we probed for nuclear translocation of apoptosis inducing 
factor (AIF) (Joza et al., 2001) at 24h intervals of FUS knockdown. Cells treated 
with ethacrynic acid (EA) as a positive control exhibited a robust nuclear 
translocation of AIF, whereas AIF nuclear translocation was not detected at any 
time point for FUS knockdown cells (shown for FUS knockdown cells after 96h, 
Figure III-3B).  
Time-lapse video microscopy was employed next to track the fate of a 
single population of cells during FUS knockdown. Imaging was initiated 24h after 
shRNA induction and continued for the duration of a 4 day induction. A normal 
frequency of cell division was observed in shSC cells, with cells nearing 
confluency by the end of the experiment (Figure III-3C).  A lack of cell division 
events was observed in cells expressing shFUS. Quantification of cell number in 
still frame images revealed a consistent ~1.7-fold increase in cell number every 
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24h for control cells, whereas the relative change in cell number decreased over 
time for shFUS cells (Figure III-3D), consistent with a reduction in cell 
proliferation (Figure III-2).  Live-cell imaging also allowed us to address the 
occurrence of cell death, which was detected when cells lifted from the coverslip.  
The total number of cells decreased for the shFUS line between days 3 (195 
cells) and 4 (165 cells), providing evidence of cell death during FUS depletion.  
These data demonstrate that a modest level of cell death occurred as a function 
of FUS knock down, possibly through a necrosis pathway as there was no 
evidence of apoptosis (Figure III-3A and III-3B).  Rather than cell death, our 
data point to a decrease in the frequency of cell division as the main factor that 
leads to reduced cell number and viability upon FUS knockdown.  
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Figure III-3. Apoptosis is not activated during the cellular response to 
FUS knockdown. (A) Levels for apoptosis markers, cleaved-PARP1 and 
cleaved-caspase-3, do not change with FUS knockdown as determined by 
western blot analyses of cell lysates derived from the indicated time points. As 
a positive control for apoptosis, NSC-34 cells were treated with 1μM 
staurosporine (ST) for 2 hours. Tubulin serves as a loading control (B) 
Representative immunofluorescence images demonstrating localization of 
apoptosis inducing factor (AIF; green) in NSC-34 cells.  AIF translocates to the 
nucleus in cells treated with 100μM ethacrinic acid (EA) for 8h but not upon 
shFUS1 induction for 96h.  Images are representative of 2 independent 
experiments. Nuclei are stained with DAPI (blue).  Scale bar = 10μm. (C) Still 
frame images from time-lapse video microscopy obtained every 24h.  One day 
after the induction of shSC (top) or shFUS1 (bottom), cells were filmed using 
time-lapse microscopy for the duration of a 4d knockdown.  The average 
number of cells from three independent counts of each image is indicated at 
the bottom right.  Scale bar = 100μm.   (D) The change in cell number at 24h 
time points relative to the previous time point, where ratios >1.0 are indicative 
of cell growth and ratios <1.0 of cell death. Data shown are the average of 
three independent counts of the still frame images + standard deviation. 
Statistical significance was determined by a student’s t-test (**P <0.01; ****P 
<0.0001). 
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A phosphodiesterase-4 inhibitor, rolipram, partially rescues the cell proliferation 
defect induced by FUS knockdown.  In addition to rescuing the proliferation 
defect by re-expressing FUS (Figure III-2), we sought to determine whether 
small molecules could exert a similar protective effect.  To test this possibility, a 
small-molecule screen was performed to identify compounds that prevented the 
FUS knockdown phenotype.  The assay was first converted from a 24-well to a 
384-well format and high-content imaging of Hoechst stained nuclei was used to 
count viable cells (see Methods).  Using this platform, the effect of FUS 
knockdown on cell viability was reduced from ~40% (Figure III-1C) to ~25% 
(Figure III-4), perhaps due to the reduced plate format and cell plating.  This 
small signal window was a challenge for high throughput screening and therefore 
compounds were screened in triplicate.  Nonetheless, we were able to screen a 
chemical library consisting of 1086 small molecules, 606 of which were drugs 
approved by the Food and Drug Administration (FDA) and 480 of which were 
purified natural products. Eight compounds were initially identified (0.74% hit 
rate) that reversed the FUS knockdown phenotype, and five-point dose-response 
curves in the range of 0.1 to 30 μM were generated for each.  Although seven 
compounds were not confirmed after retesting by this analysis (data not shown), 
one compound, rolipram (Figure III-4A), was found to partially restore the 25% 
decrease in cell number induced by FUS knockdown; rather than a 25% 
decrease in cell number upon FUS knockdown there was only ~10% decrease 
with rolipram doses between 0.1 and 10 μM.  Therefore, rolipram conferred a 
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protective effect (Figure III-4B). Rolipram is an inhibitor of cAMP specific 
phosphodiesterase-4 with antidepressant and anti-inflammatory functions, (Zhu 
et al., 2001)  including suppression of nitric oxide production (Beshay et al., 
2001).  The protective effect was less pronounced at 30 μM, suggesting rolipram 
might exert toxicity at higher doses.  Rolipram also recovered the slight cell 
number deficit caused by shSC expression, indicating rolipram may exert a 
general effect on cell proliferation.  However, this effect was modest relative to 
shFUS1 cells and was not statistically significant (Figure III-4B).  A western blot 
analysis demonstrated that the protective effect of rolipram was not due to re-
expression of FUS (Figure III-4C).  These data suggest that rolipram or related 
compounds could be further explored in the context of therapeutics for disorders 
arising from a loss of FUS function.   
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Figure III-4. Rolipram partially rescues the cell proliferation defect 
induced by FUS knockdown. (A) Molecular structure of rolipram.  (B) NSC-
34 cells were induced to express shSC or shFUS1 followed by the addition of 
rolipram at various concentrations (0 - 30μM). After four days, cell number was 
quantified relative to uninduced controls by Hoechst staining. In the absence 
of rolipram, cell number was reduced 25% by shFUS1 induction and 8% by 
shSC (n = 28 replicate wells from two independent experiments). This defect 
was significantly reversed at all rolipram concentrations in shFUS1 cells (n = 
20 replicate wells from two independent experiments; **P <0.01, ***P <0.001).  
To a lesser extent, rolipram also recovered the deficit in shSC cells (n = 20 
replicate wells from two independent experiments).  Error bars represent + 
standard error. Statistical significance was determined by comparing cells 
condition using the Student’s t-test. (C) Western blot analysis of cell lysates 
corresponding to the indicated conditions. FUS was knocked down only in 
cells induced with doxycycline to express shFUS1 and remained knocked 
down in the presence of 1µM rolipram. Tubulin serves as a loading control.  
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Proteomic changes resulting from FUS knockdown.  Next we sought to better 
understand the pathways involved in the reduced cellular proliferation phenotype 
observed upon FUS depletion.  To this end, we performed quantitative 
proteomics using tandem mass tags (TMT) and mass spectrometry to assess 
changes in the proteome at both an early (24h) and late stage (96h) of FUS 
knockdown (Thompson et al., 2003; Dayon et al., 2008).  This approach labels 
peptides from each cell lysate condition with unique isobaric tags. The samples 
are then combined and processed simultaneously allowing for an accurate 
comparison of protein levels between conditions (Figure III-5A). The 24h time 
point is expected to reveal initial cellular changes occurring relatively early in 
response to FUS knockdown, when FUS protein expression was reduced by only 
~55% (Figure III-5B) and cell viability by only ~25% (Figure III-2C).  The 96h 
time point was expected to reveal more robust changes, in part because the FUS 
knockdown phenotype is more severe (Figure III-5B and Figure III-1C) and also 
because this later time point allows for an accumulation of protein expression 
changes, which depend on the timescale of both protein translation and turnover.  
Although it is standard to only compare cells with a specific gene knocked down 
to cells expressing a scrambled RNA sequence, we also included the uninduced 
condition in the quantitative proteomics pipeline (Figure III-5A) to ascertain 
whether a particular protein changed in expression solely as a consequence of 
FUS knockdown, or whether the process of shRNA induction also influenced the 
expression of that protein. 
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Figure III-5. Quantification of the cellular proteome after FUS depletion. 
(A) Schematic of mass spectrometry pipeline. Briefly, NSC-34 cells were 
induced with doxycycline for 24 or 96h to express either scrambled control 
shRNA (shSC) or shRNA targeting FUS (shFUS1). Uninduced cells were 
included as an additional control.  Denatured lysates were digested and the 
resulting peptides were labeled with unique isobaric mass tags (tandem mass 
tags: TMTs 126-131) and combined for mass spectrometry (MS) analysis.  (B) 
Western blot analysis confirmed FUS knockdown in lysates used for 
proteomics. Three biological replicates (BR 1, green; BR 2, blue; BR 3, red) 
were included. Tubulin serves as a loading control.  (C)  A total of 2,355 
proteins were quantified by mass spectrometry over three biological replicates 
(BR 1-3). (D)  Proteins differentially expressed between the shSC and shFUS1 
samples by a fold change of at least +0.25 in two of three replicates were 
grouped into functional categories based on the literature (Table 1).   
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First, changes in the proteome arising from a loss of FUS were assessed 
by comparing shFUS and shSC samples, as shSC cells control for expression 
changes resulting from shRNA expression and doxycycline exposure. A total of 
2,355 proteins were quantified, with ~60% (1,370 proteins) overlap between the 
three biological replicates (Figure III-5C). Only those proteins differentially 
expressed between the shFUS and shSC samples by a fold change of at least + 
0.25 in two of three replicates with a p-value < 0.05 were included in our final 
analysis.  Sixty-one proteins, in addition to FUS, met this criterion at either 24 or 
96h (Table III-1).  Interestingly, 16 of these hits were previously identified as 
RNA binding targets of FUS, raising the possibility that these expression changes 
stem from a loss of FUS function and/or interaction with the corresponding 
transcripts (Table III-1, asterisks).(Hoell et al., 2011; Colombrita et al., 2012; 
Nakaya et al., 2013) Of the 61 hits, 31 were various histone variants which we 
grouped into five main histone clusters (H1, H2A, H2B, H3 and H4) due to the 
redundancy of the peptides used to identify each protein. Similarly, KAP0 and 
KAP1, the regulatory subunits of protein kinase A, were counted as a single hit 
due to a lack of unique peptides identified for each protein. With this condensed 
list of only 34 proteins, DAVID analysis (Database for Annotation, Visualization, 
and Integrated Discovery) could not identify significant enrichment of GO terms 
or functional categories. Thus, hits were assigned categories manually based on 
information provided by UniProtKB, the National Center for Biotechnology 
Information (NCBI) and GeneCards (Figure III-5D and Table III-1).  Chromatin 
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organization represented the most common category for proteins differentially 
expressed between shFUS and shSC cells at 24h.  Categories for which there 
were at least four differentially expressed proteins at either 24 or 96h included 
cellular proliferation, kinases/phosphatases, cytoskeletal organization, energy 
homeostasis, calcium-related and metal ion binding.  Of these, energy 
homeostasis, calcium-related and metal ion binding were more prominent at 96 
than 24h, suggesting changes in these proteins and/or pathways are triggered by 
FUS knockdown and become more pronounced during the cellular response to 
FUS depletion.   
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Table III-1.  Fold change and functional categories of proteins differentially 
expressed after 24 or 96 hours of FUS knockdown in at least 2 of 3 biological 
replicates. Due to a lack of unique peptides identified between histone variants, 
these hits were combined into the five major histone families (H1, H2A, H2B, H3, 
and H4). Similarly, KAP0 and KAP1 were grouped due to a lack of unique 
peptides identified for each protein.  Asterisks denote transcripts previously 
determined to be bound by FUS; FC = fold change 
+ denotes FC between │0.25│ and │0.50│ 
++ denotes FC between │0.50│ and │1.0│ 
+++ denotes FC between >│1.0│ 
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Next we sought to validate protein-hits that exhibited the largest changes 
in expression upon FUS knockdown.  The 96h time point revealed the most 
robust expression changes, and therefore we focused first on proteins with the 
largest expression changes at 96h.  S100A6, also known as calcyclin due to 
roles in both calcium binding and the cell cycle,(Lesniak et al., 2009) exhibited a 
relatively large decrease in expression in shFUS cells compared to shSC cells at 
96h (Table III-1).  By comparing both lines to the uninduced condition, it became 
apparent that this difference is due in part to an increase in expression of 
S100A6 in shSC cells (Table III-2).  Differential expression of S100A6 was 
validated by both western blot (Figure III-6A) and qPCR analyses at 96h (Figure 
III-6B) and qPCR at 24h (Figure III-6C). Metallothionein-2 (MT2), a 
multifunctional protein involved in zinc homeostasis and antioxidation,(Vasak and 
Meloni, 2011)  exhibited a large increase in expression in shFUS cells relative to 
shSC cells at 96h (Table III-1).  The differential expression of MT2 in shFUS and 
shSC cells was validated by qPCR at 96h (Figure III-6B) and 24h (Figure III-
6C), however we were unable to quantify the expression of this protein by 
western blot analysis, presumably due to the relatively small size of this protein 
(6kDa).  The RNA-binding protein EWS, which like FUS is a member of the TET-
family of proteins, also increased in expression in shFUS cells (Table III-1, 
Figure III-6B and Figure III-6D) as well as in HEK-293T cells transiently 
transfected with si3’UTR for FUS knockdown (Figure III-6D). This appears to be 
a specific relationship between FUS and EWS expression as FUS knockdown 
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did not influence the expression of other related RNA binding proteins such as 
TDP43 and hnRNPA1, or the other TET-family member TAF15 (data not shown).  
Similar to EWS, thymosin beta-10 (TYB10), a monomeric-actin binding protein 
that inhibits actin polymerization,(Sribenja et al., 2009) also increased in 
expression upon FUS knockdown (Table III-1 and Figure III-6B), but could not 
be validated by western blot presumably due to the small size of the protein 
(5kDa).  
Lastly we validated the differential expression of histones, which 
decreased in expression by 20-65% after 24h of FUS but appeared to recover by 
96h.  This difference arises from an increase in expression of histones in shSC 
cells relative to both shFUS and uninduced cells (Table III-2), which was 
validated by western blot analysis for histones H2B and H3 (Figure III-6E).   
Histones H2A and H4, which were investigated based on availability of PCR 
primers, were not significantly different between lines by qPCR analysis (Figure 
III-6C) suggesting that the change in histone expression may predominately 
occur at the protein rather than mRNA level.  
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Table III-2. Relative protein fold-changes. Three comparisons were made: 
cells expressing shFUS1 compared to cells expressing shSC, cells expressing 
shSC to uninduced cells, and cells expressing shFUS1 to uninduced cells. 
Values highlighted in red and green show a positive or negative fold change of at 
least 0.25, respectively, between shFUS1 and shSC cells. Proteomic analysis 
was performed on three biological replicates however, only those replicates 
having a significant expression change between shFUS and shSC are shown for 
clarification (for full heatmap see Table III-1).  Differential expression for those 
proteins below the double line at 24h and 96h is due to a change in the shSC 
cells that is lacking in shFUS1 cells. Transcripts bound by FUS are denoted by 
an asterisk.  Due to a lack of unique peptides identified between histone variants, 
these hits were combined into the five major histone families (H1, H2A, H2B, H3, 
and H4). Similarly, KAP0 and KAP1 were grouped due to a lack of unique 
peptides identified for each protein.  
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Figure III-6. Western and qRT-PCR validation of proteins differentially 
expressed upon FUS depletion.   (A) Western blot analysis of lysates from 
uninduced NSC-34 cells (-) and cells induced to express scrambled control 
shRNA (S) or shRNA targeting FUS (F) for 96h. Numbers below the blots refer 
to densitometry measurements relative to uninduced cells and demonstrate 
increased expression of S100A6 in shSC cells with a concomitant decrease in 
shFUS1 cells. Tubulin serves as a loading control.  (B-C) Quantitative RT-
PCR analysis after 96h (B) or 24h (C) of shRNA induction. mRNA expression 
relative to uninduced cells was determined for the indicated genes after shSC 
or shFUS1 induction in NSC-34 cells. Data shown are the average of 3 
independent experiments + standard error. Statistical significance was 
determined by a Student’s t-test (*P <0.05; **P <0.01; ***P <0.001).  (D) 
Representative western blot analysis of lysates from NSC-34 cells or HEK-
293T cells after 96h demonstrating increased expression of EWS with FUS 
knockdown relative to controls. (E) Representative western blot analysis of 
lysates from NSC-34 cells induced to express shRNA for 24h demonstrating 
increased histone expression in shSC cells with a concomitant decrease in 
shFUS1 cells.  
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Discussion 
Elucidating the vital functions of FUS is a complex but important objective.  
Genetic alterations in FUS cause human diseases such as cancer and 
neurodegeneration.  A loss of FUS function has been suggested to cause the 
neurodegenerative diseases ALS, FTLD and ET, however the multifunctional 
nature of FUS has made it difficult to discern which functions of FUS are relevant 
to these disorders (Dormann and Haass, 2013).  The effect of FUS knockdown or 
knockout in vivo has produced conflicting results, as some reports describe 
animal lethality (Hicks et al., 2000; Huang et al., 2011; Sasayama et al., 2012; 
Xia et al., 2012) whereas others report no effect of FUS knockdown on 
survival.(Kuroda et al., 2000; Kabashi et al., 2011; Lagier-Tourenne et al., 2012) 
Consistent with the latter, signs of apoptosis or gross cellular death were not 
observed here upon knockdown of FUS in cultured mammalian cells (Figure III-
3).  Rather, we demonstrate for the first time that a reduction in FUS expression 
impairs cell proliferation (Figure III-1,2,3). To gain insight into the mechanism for 
FUS-mediated inhibition of cell proliferation, quantitative proteomics was 
performed on cells undergoing various degrees of FUS knockdown, as no other 
study to date has performed a comprehensive analysis of protein expression 
changes as a function of FUS knockdown or knockout. 
As one might expect, proteins associated with cell proliferation changed in 
expression upon FUS knockdown at 24 and 96h (Figure III-5D, Table III-1).  One 
of these proteins, S100A6, exhibited reduced expression in shFUS lines after 
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96h (Table III-1, Figure III-6).  This finding is consistent with previous 
observations of S100A6 knockdown correlating with reduced cell-proliferation in 
other cell types.(Ohuchida et al., 2005; Lesniak et al., 2009) (Ohuchida et al., 
2005) (Lesniak et al., 2009)  Moreover, FUS binds the promoter of S100B,(Tan et 
al., 2012) a family member of S100A6, raising the possibility that S100A6 
expression is directly modulated by FUS.  FUS also binds the CCND1 promoter 
and inhibits expression of the cell-cycle protein cyclin D1 in response to DNA 
damage signals (Wang et al., 2008).  A general role for FUS in cell-cycle 
regulation is also suggested by RNA binding targets of FUS identified through 
RIP/CHIP experiments (Colombrita et al., 2012).  However, we did not detect 
expression changes for these targets or any other classical cell-cycle related 
proteins through our proteomics analysis, suggesting that additional factors 
contribute to the observed cell proliferation defect.  
Cytoskeletal dynamics is another factor that is fundamentally important for 
cell proliferation (Provenzano and Keely, 2011). Proteins belonging to the 
cytoskeletal organization category changed in expression upon FUS knockdown 
at 24 and 96h (Figure III-5D), including RAP1A and the actin binding proteins 
MARCS and TYB10 (Table III-1).  TYB10 binds and sequesters actin monomers 
thereby inhibiting actin polymerization and has been implicated in neurite 
formation (Sribenja et al., 2009). Altered expression of these cytoskeletal 
proteins upon FUS knockdown could therefore contribute to the cell proliferation 
defect observed here, and is also consistent with impaired neurite outgrowth 
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upon FUS depletion reported by others (Kabashi et al., 2011; Orozco et al., 
2012).   
MT2 exhibited one of the largest changes in expression between shFUS 
and shSC cells (Table III-1).  MT2 plays a protective role against metal toxicity, 
oxidative stress and ionizing radiation.  Accordingly, levels of this protein were 
shown to increase in response to these stressors (Aschner et al., 2006; Vasak 
and Meloni, 2011).  That expression of MT2 was higher in shFUS cells relative to 
shSC cells at 24h, a difference that became more pronounced at 96h (Figure III-
6, Table III-1), implicates a role for one of the aforementioned stressors in the 
FUS knockdown-induced proliferation defect.  We speculate that oxidative stress 
may be the relevant stressor, as FUS regulates the transcription of oxidative-
stress protection genes and a loss of this function leads to elevated ROS 
(Sanchez-Ramos et al., 2011).  In support of this notion, rolipram partially 
rescued the proliferation defect upon FUS knockdown through a mechanism that 
did not involve increased expression of FUS (Figure III-4).  Rolipram has been 
shown to boost expression of antioxidizing enzymes, (Gorur et al., 2008) 
suppress nitric oxide levels (Beshay et al., 2001; Gorur et al., 2008) and exert a 
protective effect in animal models of spinal cord injury (Nikulina et al., 2004) and 
neurodegeneration (Gong et al., 2004; Yang et al., 2008; Smith et al., 2009). 
While the impact of rolipram on cellular proliferation was strongest for shFUS 
cells, we note an increase in cell number for the control line in response to 
certain doses of rolipram that may signify a general effect of rolipram on cell 
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proliferation. (Nakagawa et al., 2002; Xiao et al., 2011) Therefore, rolipram would 
need to be further assessed in additional in vitro and appropriate in vivo models 
of loss of FUS function.  
We also detected an increase in EWS expression upon FUS knockdown 
(Table III-1, Figure III-6).  EWS and FUS are both members of the TET family of 
proteins and exhibit overlapping functions (Tan and Manley, 2009a), raising the 
intriguing possibility that increased EWS expression serves as a compensatory 
mechanism for the loss of FUS function in cells.  It follows that exogenous 
expression of this protein could ameliorate the proliferation defect observed upon 
FUS knockdown, analogous to the re-expression of FUS (Figure III-2). An 
alternative, though not mutually exclusive, explanation for elevated levels of EWS 
is that regulation of EWS at the RNA level is directly impacted by FUS 
knockdown, as discussed below.  
In agreement with previous studies, our proteomics analysis revealed 
protein expression changes induced by doxycycline and/or shRNA expression 
(i.e., proteins that changed in shSC cells relative to uninduced cells; Table III-2) 
(Khan et al., 2009; Jackson and Linsley, 2010; Ahler et al., 2013).  In fact, a 
recent study reported that expression of genes involved in glycolysis and cellular 
metabolism were altered upon doxycycline treatment.(Ahler et al., 2013)  We 
also detected differential expression for proteins associated with energy 
homeostasis (FPPS, IDHC, and KAD1) upon shSC induction at 96h.  Intriguingly, 
these same changes were not detected in shFUS cells (Table III-2).  Thus, 
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doxycycline exposure and/or shRNA expression elicited changes in gene 
expression, possibly in response to a stress associated with these stimuli (Grimm 
et al., 2006; Jackson and Linsley, 2010; Ahler et al., 2013), but under conditions 
of FUS knockdown this response was impaired.  In other words, cells lacking 
FUS failed to respond as expected.  These results underscore the importance of 
including an untreated control condition to assess the direction of change for the 
experimental condition, shFUS in this case.  For example, without the untreated 
condition we would have reported a decrease in histones for shFUS cells at 24h, 
when in fact there was an increase in shSC and no response in shFUS cells 
(Table III-2).  The reason histones are increased in shSC cells at 24h is unclear, 
however the association of FUS with different histone-related processes may 
explain the lack of response in shFUS cells (Wang et al., 2008; Kim et al., 2010; 
Colombrita et al., 2012; Takahama et al., 2013).      
Which protein expression changes are directly triggered by a loss of FUS, 
and which reflect downstream consequences to these initial triggers? Of the 
sixty-one proteins identified here, none have been reported to have differential 
mRNA expression upon FUS knockdown. (Hoell et al., 2011; Ishigaki et al., 2012; 
Lagier-Tourenne et al., 2012; Rogelj et al., 2012; Nakaya et al., 2013) Sixteen, 
however, correspond to reported RNA binding targets of FUS (Table III-1, 
asterisks). (Hoell et al., 2011; Colombrita et al., 2012; Nakaya et al., 2013)  We 
posit that the protein expression changes for these targets are a direct 
consequence of a loss of FUS function with respect to RNA processing.  For 
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example, FUS binds RNA corresponding to several differentially expressed 
proteins discussed above including EWS, cytoskeletal-related proteins (RAP1A 
and MARCS) and energy homeostasis-related proteins (IDHC, Kap0, Kap1 and 
Cox5A) (Hoell et al., 2011).   
The results of our study have important implications for disease, 
particularly neurodegenerative disorders that may be mediated through a loss of 
FUS function.  Although mature neurons are post-mitotic and do not proliferate, 
the loss of FUS function may adversely impact neurodevelopment during a stage 
when cellular proliferation is critical.   Moreover, the processes and proteins that 
are altered here upon FUS knockdown, particularly those relating to cytoskeletal 
organization, oxidative stress and calcium handling, are relevant to the 
homeostasis of mature neurons (Mattson and Magnus, 2006). We also note that 
glia cells, which do proliferate, play both neuroprotective and pathogenic roles in 
neurodegeneration (Aguzzi et al., 2013).  That FUS is aggregated and depleted 
from the nucleus of glia cells in some neurodegenerative disorders(Mackenzie et 
al., 2011; Suzuki et al., 2012) raises the possibility that glial proliferation and 
function may also be impaired. Importantly, our data demonstrate it is possible to 
reverse the adverse effects of FUS depletion by replacing the FUS protein or by 
small-molecule intervention.  Proteins that exhibit differential expression upon 
FUS knockdown (Table III-1) may also serve as therapeutic targets for 
ameliorating the loss of FUS function in disease.  
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Materials and Methods 
Tissue culture. The creation of and culture conditions for NSC-34 cell lines 
expressing shFUS1 or shSC have been described previously. (Sama et al., 
2013) The tetracycline-inducible shFUS2 line was created and cultured in the 
same manner (shFUS2: 5’-GAGTGGAGGTTATGGTCAA-3’).  For the expression 
of shRNA, cells were treated with 1μg/ml doxycycline (Sigma, D9891) or 0.1 
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μg/ml tetracycline (Fisher Scientific, BP912-100). Naïve NSC-34 cells (a kind gift 
from Dr. Neil Cashman) were cultured in Dulbecco’s modified Eagle’s medium 
with sodium pyruvate (Invitrogen, 10313) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich, F4135), 2mM L-glutamine (Invitrogen, 25030081)  and 1% 
penicillin and streptomycin solution (Invitrogen, 15140122). HEK-293T cells were 
maintained in Minimum Essential Media (Invitrogen, 10370) supplemented with 
10% fetal bovine serum (Sigma-Aldrich, F4135) and 1% penicillin and 
streptomycin solution (Invitrogen, 15140122). 
 
siRNA knockdown of FUS.  RNA oligonucleotides for FUS (sequences below) 
and a scrambled control sequence (guide: 5’-aauucuccgaacgugucacgu-3’; 
passenger: 5’-gugacacguucggagaaucuu-3’) were purchased through Sigma-
Aldrich and 10μM annealed stocks were prepared by combining guide and 
passenger strands in the following buffer:  100mM potassium acetate, 30mM 
HEPES-KOH pH 7.4, 2mM magnesium acetate.  For knockdown in HEK-293T 
cells, cells were plated in a 24-well plate at 2,000 cells/well and allowed to 
adhere overnight.  Transfection was performed in OPTI-MEM (Invitrogen, 
31985070) using 0.4μl Lipofectamine RNAiMax (Invitrogen, 13778030) and 
0.2nM siRNA per well (guide: 5’-uugggugaucaggaauuggaa-3’; passenger: 5’-
ccaauuccugaucacccacuu-3’).  For knockdown in naïve NSC-34 cells, cells were 
plated in a 24-well plate at 10,000 cells/well.  Transfection was performed as 
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above, but with 0.5μl RNAiMax and 10nM siRNA per well (guide: 5’-
uaggguagucugacacacaca-3’; passenger: 5’-ugugugucagacuacccucuu-3’). 
 
MTT viability assay. Cells were plated in technical triplicate in a 24-well plate and 
induced to express shRNA or transfected with siRNA to initiate FUS knockdown.  
After the desired duration of knockdown, the media from each well was removed 
and replaced with 400μl fresh media and 100μl of 5mg/ml MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Invitrogen, M-6494).  After 
a 35 min incubation at 37ºC, 300μl lysis buffer (10% SDS in 1:1 N,N_-
dimethylformamide:water/2% acetic acid/2.5% HCl 1M)(Reixach et al., 2004) was 
added to each well.  Plates were covered with a seal and incubated at 37ºC 
overnight followed by OD quantification at 550nm. Results are expressed as % 
cell viability relative to untreated controls using the following equation:  100 x 
(ODRNAi – ODblank)/(ODuntreated – ODblank).  The ODblank was determined by wells 
containing MTT and tissue culture media without cells. 
 
Immunofluorescence.  Cells grown on glass coverslips were fixed for 5-10 min 
with 4% paraformaldehyde and blocked with PBSAT (1X PBS/1% BSA/0.5% 
Triton-X 100) for 30-60 min at room temperature. Primary antibodies were diluted 
in PBSAT and added to the coverslips at room temperature for 1 hr.  Primary 
antibody dilutions were as follows: 1:500 for anti-FUS (Bethyl laboratories, A300-
293A) and 1:100 for anti-Apoptosis Inducing Factor (Cell Signaling, 4642). After 
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primary antibody incubation, coverslips were washed with PBSAT and incubated 
for 45 minutes with Alexa Fluor 488-conjugated donkey anti-rabbit IgG (Jackson 
ImmunoResearch Labs, 711-545-152), diluted at 1:2000 in PBSAT. Lastly, cells 
were stained with 34 ng/mL DAPI and coverslips were mounted with ProLong 
Gold anti-fade reagent (Invitrogen, P36930). 
 
Western blotting.  Cells were lysed for 30 min at 4ºC with either 50 mM Tris HCl 
(pH 7.5) containing 0.5M NaCl, 1% NP-40, 1% deoxycholic acid, 0.1% SDS, and 
2mM EDTA or RIPA buffer (Boston BioProducts, BP-115-500), supplemented 
with protease (Roche, 11836170001) and phosphatase (Roche, 4906837001) 
inhibitors. Concentration of cell lysates was determined using a bicinchoninic 
acid (BCA) assay (Thermo Scientific Pierce, 23227) and samples were prepared 
in Laemmli SDS-sample buffer (Boston BioProducts, BP-111R).  Standard 
western blotting procedures were followed, using Tris-glycine SDS-PAGE and 
electrotransfer onto PVDF membrane at 100V for 1 hour at 4ºC.  For detection of 
S100A6, Tris-tricine SDS-PAGE was used (BioRad, 456-3066) followed by 
electrotransfer onto 0.22 µm nitrocellulose at 100V for 30 min at 4ºC. Membranes 
were blocked for 1h at room temperature with Odyssey Blocking Buffer (LiCor, 
927–40003) diluted 1:1 with PBS containing 0.1% tween-20 (PBST), followed by 
overnight incubation at 4ºC with primary antibodies diluted in PBST.  Primary 
antibody dilutions were as follows:  1:500 anti-FUS (Genscript, generated against 
C-terminal peptide CKFGGPRDQGSRHDSEQDNSD)(Sama et al., 2013), 1:500 
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anti-tubulin (Sigma, T9026), 1:500 anti-cleaved PARP1 (Cell Signaling, 9544), 
1:500 anti-cleaved caspase-3 (Cell Signaling, 9664), 1:500 anti-EWS (Santa 
Cruz, sc-28327), 1:1000 anti-H2B (Active motif), 1:1000 anti-H3 (Abcam, 1791), 
and 1:200 anti-S100A6 (Cell Signaling, 13162). Following primary antibody 
incubation, membranes were washed with PBST and incubated for 1h with 
secondary antibody diluted 1:10,000 in 1:1 Odyssey Blocking Buffer:PBST. 
Secondary antibodies included anti-mouse IRDye 680 (Licor, 926-68072) or 
IRDye 800 (LiCor, 926-32210) and anti-rabbit IRDye 680 (LiCor, 926-68023) or 
IRDye 800 (Licor, 926-32211). After washing with PBST, membranes were 
imaged with an Odyssey Infrared Imager (LiCor, Model 9120) and protein band 
intensities were quantified with the Odyssey Software (LiCor, V3.0). 
 
Time-lapse video microscopy.  Stable NSC-34 cells were plated on glass 
coverslips and induced to express either shSC or shFUS1.  Twenty-four hours 
later, coverslips were assembled into chambers as previously described (Uetake 
Y, 2012) and imaged at 37ºC with BH2 (Olympus) microscopes equipped with 
phase-contrast optics using 10X objectives/ 0.3–0.32 NA. Image sequences were 
gathered using Retiga EX (Qimaging, Corp.) or Retiga EXi Fast (Qimaging, 
Corp.) cameras. Images were acquired every 3 min with C-imaging software 
(Hamamatsu Photonics) and were exported as QuickTime videos using CinePak 
compression (Apple).  
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Small-molecule high-content screen.  shFUS1 NSC-34 cells were plated onto 
384-well plates (Corning 3712) at 500 cells/well in 40 µL of culture media 
(described above) using a Multidrop automated liquid handler (Thermo Fisher 
Scientific).  Gas-permeable seals were used to reduce any uneven evaporation 
effects.  After overnight incubation, 5 μl doxycycline was transferred using a 
Biomek NX robotic liquid handler (Beckman Coulter) into each experimental well 
to attain a final concentration of 1 μg/ml.  An equal volume of doxycycline solvent 
(dd H2O) was added to control wells. Four hours after doxycycline addition, 5 μl 
of compounds from the LDDN library (described below) were transferred using 
the robotic liquid handler into experimental wells to attain a final concentration of 
1 μM and 0.1% DMSO.  An equal volume of DMSO in media was added to 
control wells.  Plates were incubated for 96h. Screening of compounds was 
performed in triplicate due to the small activity window (25%) as determined 
during assay development using this format. 
A subset of the Laboratory for Drug Discovery in Neurodegeneration 
(LDDN) chemical library was used, consisting of 606 compounds approved by 
the Food and Drug Administration (Prestwick) and 480 purified natural products. 
Compounds for high-throughput screening were stored as DMSO stocks at -20°C 
and assay-ready 384-well plates with 1.67 mM compound concentration in 100% 
DMSO were diluted in media to attain a final concentration of 1 µM in 0.1% 
DMSO just before use.   
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 After 96h, cells were fixed with 4% paraformaldehyde for 20 min and 
washed three times with phosphate-buffered saline (ELx405 plate washer, 
BioTek).  The cells were labeled with 1 μg/ml Hoechst stain to visualize nuclei.  
Images were captured on the IN Cell Analyzer 2000 (GE Healthcare).  The entire 
well was imaged in 4 fields at 25 ms exposure time using excitation filter D360/40 
and emissions filter HQ460/40 in combination with a 10X/.45 NA objective.  
Image stacks were batched and analyzed using IN Cell Workstation software 
(GE Healthcare).  For the feature extraction protocol, cells were segmented using 
the multi-target analysis algorithm and nuclei were segmented as defined with a 
minimum area of 50 µm2 with a sensitivity setting of 70. Total nuclei per well was 
used as a measure of cell count.  
 A compound was considered a “hit” and selected for confirmation if it 
rescued the shFUS1 knockdown-induced decrease in cell number by >3 
standard deviations (SD) from the mean of the shFUS1 knockdown control wells 
(shFUS1 +doxycycline) on each of the three replicate plates.  Hits were 
confirmed via a 5-point dose-response curve (0.1 to 30 μM) using compounds 
that were re-ordered from the commercial suppliers.  For confirmation studies, 
compounds were added to both shSC and shFUS1 expressing cells in the 
presence of doxycycline.  Western blot analysis of FUS expression after 96h of 1 
µM compound incubation was performed using a similar protocol to that 
described above.   
 
95 
 
 
Quantitative Proteomics.  NSC-34 cells were either uninduced, or induced to 
express shSC or shFUS1 for 24 or 96h (for a total of 6 samples), followed by 
lysis with RIPA buffer (Boston Bio Products) supplemented with protease 
inhibitors (Roche). Protein content was measured using a standard BCA Assay 
(Thermo Scientific) and lysates were treated according to manufacturers’ 
instructions, with slight method alteration in the detergent removal step. Briefly, 
100 µg of lysate was diluted to a final concentration of 1 µg/µL with 100 mM 
triethyl ammonium bicarbonate (TEAB). Disulfide bonds were reduced with 0.5 M 
tris(2-carboxyethyl)phosphine (TCEP) for 1 hour at 55°C and cysteine residues 
were alkylated with 375 mM iodoacetimide (IAA) for 30 minutes at ambient 
temperature, protected from light. Lysates were then treated for detergent clean 
up using Detergent Removal Spin Columns (Thermo Scientific) according to 
manufacturers’ instructions and digested overnight at 37°C with Trypsin 
(Promega, sequencing grade) in a 1:25 enzyme:protein digest ratio. Amine 
reactive TMT reagents (Thermo Scientific, 6-plex kit) were dissolved in 
acetonitrile and allowed to react with peptides for 1 hour at ambient temperature. 
After 1 hour, the reaction was quenched upon addition of 5% hydroxylamine 
hydrochloride and a 15 minute incubation at room temperature. Following 
labeling, the samples were combined in an equi-volume ratio (1:1:1:1:1:1) and 
dried down prior to reconstitution in 5% acetonitrile, 0.1% trifluoroacetic acid 
(TFA) for mass spectrometric analysis. The assignment of TMT tag (126 to 131) 
to each sample was random (www.random.org) to guard against bias. 
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Assignments were made such that no sample had the same tag identity between 
three independent experiments.  
Three independent experiments were tested, with each experiment 
analyzed in technical triplicate. LC-MS/MS experiments were performed on a 
QExactive hybrid mass spectrometer (Thermo Scientific) equipped with a 
nanoAcquity UPLC (Waters). Run conditions match those of the “sensitive” 
conditions previously recommended(Kelstrup et al., 2012). Briefly, approximately 
1 µg of labeled peptides were loaded on a 100 µm i.d. fused-silica precolumn 
packed with 2 cm of Magic C18AQ resin (5 µm, 200Å, Michrom Bioresources) at 
a flow rate of 4.0 µL/min for 4 min in 5% acetonitrile, 0.1% formic acid (FA) and 
eluted using a gradient at 300 nL/min onto a 75 µm i.d. analytical column packed 
with 25 cm of Magic C18AQ resin (3 µm, 100 Å, Michrom Bioresources) to a 
gravity-pulled tip. Separation was achieved by applying a 5%-35% acetonitrile 
gradient in 0.1% FA over 180 minutes at 300 nL/min. In detail, the time program 
was: 0−180 min, 5−35% B; 180−181 min, 35-90% B; 181-191 min, 90% B; 191-
192 min, 90-5% B; 192-210 min, 5% B; 210 min, stop. Solvent A was water with 
0.1% FA and solvent B was acetonitrile with 0.1% FA.  Electrospray ionization 
was enabled via liquid junction into a QExactive hybrid mass spectrometer 
(Thermo Scientific). Mass spectra were acquired over m/z 300-1750 at 70,000 
resolution (m/z 200) and data-dependent acquisition selected the top 12 most 
abundant precursor ions for tandem mass spectrometry by HCD fragmentation 
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using an isolation width of 1.2 m/z, collision energy of 30, and a resolution of 
35,000.  
Mass spectra were submitted to MASCOT (Matrix Science, v2.4.1) and 
searched against the Mouse SwissProt database (16627 entries). Search 
specifications included: allow up to two missed cleavage sites, enzyme specified 
as trypsin, MS tolerance – 10 ppm, and MS/MS tolerance – 0.05 Da. Specified 
fixed modifications include Carbamidomethyl and TMT6plex. Specified variable 
modifications include Glnpyro-Glu, Oxidation, and N-term Acetyl. 
ProteoIQ (Premier Biosoft, v2.6.03) was used to quantify reporter ion signals. 
Search specifications included: reporter ion tolerance – 0.05 Da; minimum 
peptide length – 6 amino acids; minimum # of spectra – 2; minimum # of peptides 
– 2; minimum peptide probability – 0.05; minimum protein probability – 0.5; 
maximum p-value – 0.05; minimum fold change - |0.25|; 3 external replicates; 
data centroided. Reporter ions were normalized by total labeling of each species 
and relative expression was weighted by species intensity.  
 
Quantitative real-time PCR (qRT-PCR).  RNA was harvested from cells (BioRad, 
732-6820) and converted to cDNA (BioRad, 170-8841), according to the 
manufacturer’s instructions.  Quantitative real-time PCR was performed in 
technical triplicate using PrimePCR primer assays (BioRad, 100-25636) and 
SYBR Green Supermix (BioRad, 172-5121) according to manufacturer’s 
guidelines and using the following PCR program in a CFX384 Touch Real-Time 
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PCR Detection System (BioRad):  95ºC for 2 min, 40 cycles of 95ºC for 5 sec 
and 60ºC for 30 sec, and a melt-curve of 65-95ºC (0.5ºC increments/5 sec).  
Quantification of differential mRNA expression was calculated by the 
comparative Ct method using Bio-Rad CFX Manger 3.1 software.  Briefly, 
threshold cycle (Ct) values were normalized to the B2M reference gene Ct value 
to obtain ΔCt values.  The ΔCt value for the control condition was subtracted 
from the ΔCt of the experimental condition to calculate a ΔΔCt.  Fold change 
relative to the control samples was then calculated by 2-(ΔΔCt).   
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CHAPTER IV: DISCUSSION AND FUTURE DIRECTIONS 
 
ALS is a devastating neurodegenerative disease that results in death for 2 
out of every 100,000 people a year.  Disease onset is nearly unpredictable, 
treatments are limited and ineffective, and a cure is nonexistent.  After onset, the 
disease progresses very quickly with survival typically only 3-5 years, during 
which time the affected individual loses all motor function until they are unable to 
speak, eat, move, or even breathe on their own.  While statistics report “ALS 
affects about 1-2 individuals per 100,000 per year” (Robberecht and Philips, 
2013), this number is far greater when considering the impact ALS has on friends 
and families of an ALS patient.  As the patient’s motor abilities quickly decline 
their need for assistance quickly increases and it is estimated that for every year 
a person lives with ALS, an average of $63,000 is required for their care (study 
by the Muscular Dystrophy Association, 2013).   So while ALS is a ‘rare’ disease 
with only 30,000 people living with ALS in the United States, the impact ALS has 
on the human population far exceeds this number. 
 Despite the urgent need for a treatment and the large amount of research 
being conducted, little is known about the definitive causes of ALS.  This can be 
attributed to the sporadic nature of the disease.  Only 5-10% of cases can be 
tracked by familial inheritance and of these only ~60% have been linked to 
specific genetic mutations (Sreedharan and Brown, 2013; Renton et al., 2014). 
Studying genes associated with familial ALS, however, has provided valuable 
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insight into the cellular mechanisms of this disease. The discovery of FUS 
mutations for example, has led to several important advances in the field, 
particularly adding support for defective RNA processing as a pathogenic 
mechanism and strengthening the link between ALS and FTD. 
 Here, I have investigated a loss of function hypothesis for mutant FUS in 
ALS pathogenesis. To this end, I developed several FUS knockdown mammalian 
cell culture models and assessed the cellular effects of FUS depletion.  The 
models displayed a defect in cell abundance and suggested a link between FUS 
function and DNA damage repair (Chapter II).  This link has been supported by 
several recent reports demonstrating inefficient DNA damage repair in the 
absence of FUS (Mastrocola et al., 2013; Wang et al., 2013).  Upon further 
characterization, the model revealed a FUS knockdown-induced reduction in cell 
proliferation, highlighting that FUS is essential for cell health and homeostasis 
(Chapter III).  This defect in proliferation was accompanied by expression 
changes of proteins associated with multiple processes, such as cell-cycle 
regulation, cytoskeletal organization, oxidative stress and energy homeostasis. 
Together, this work demonstrates that an array of cellular pathways respond to, 
or are influenced by, a loss of FUS function.  The way in which a loss of FUS 
function in these pathways may be important for ALS pathogenesis is discussed 
below. 
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Cell cycle regulation and ALS 
As investigated in both Chapters II and III, depletion of FUS results in decreased 
cellular proliferation.  This response may be indirect, occurring as a result of 
other cellular events, such as increased DNA damage (Chapter II), oxidative 
stress, cytoskeletal disorganization, or energy homeostasis (discussed in 
Chapter III).  Several reports however, demonstrate a direct role for FUS in cell 
cycle regulation.  For example, RIP/CHIP experiments (RNA-binding protein 
immunoprecipitation-microarray) identified an enrichment of cell cycle-related 
RNA binding targets of FUS (Colombrita et al., 2012).  FUS also binds the 
CCND1 promoter and inhibits expression of the cell-cycle protein cyclin D1 in 
response to DNA damage signals (Wang et al., 2008).  Additionally, in prostate 
cancer cells FUS mediates cell proliferation stimulated by androgen (Brooke et 
al., 2010; Haile et al., 2011), seemingly through transcriptional regulation of 
several important cell cycle proteins (Brooke et al., 2010).  
These findings seem to suggest an important role for FUS in regulating 
the cell cycle in proliferating cell types.  Motor neurons however, are post-mitotic 
and are a non-proliferating cell type.  Thus, how could regulation of cell 
proliferation by FUS be important for ALS pathogenesis?  Accumulating evidence 
suggests that inappropriate cell cycle re-entry in neurons induces apoptosis and 
may therefore be a relevant mechanism in neurodegeneration (Herrup and Yang, 
2007; Bonda et al., 2010b).  For instance, the cyclin D/CDK4,6 complex is 
responsible for reinitiating the cell cycle in non-proliferating cells (Sherr, 1994) 
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and interestingly, increased expression of cyclin D and cdk4 is evident in motor 
neurons of ALS mice and patient tissue (Nguyen et al., 2003; Ranganathan and 
Bowser, 2003). Furthermore, FUS has been shown to regulate cyclin D 
expression (Wang et al., 2008).  Thus, one could speculate that loss of FUS 
function from ALS-mutations leads to re-expression of cyclin D1 and re-initiation 
of the cell cycle, causing neuronal cell death. In support of this, ALS mutations 
cause nuclear FUS depletion or alternatively, are located in a domain of FUS 
responsible for transcriptional activity (Figure I-2), either of which could disrupt 
FUS-mediated repression of cell cycle-related transcription.   
To date, the regulation of cyclin D1 expression by FUS has only been 
demonstrated in macrophage (Wang et al., 2008) and prostate cancer cells 
(Brooke et al., 2010; Haile et al., 2011).  Preliminary steps towards investigating 
this function in neurons are discussed in Appendix I, but this work was not 
pursued as part of this dissertation.  Briefly in sum, I recapitulated the effect of 
FUS knockdown on cyclin D1 expression in macrophage cells, but did not detect 
increased cyclin D1 immunofluorescence in cortical neurons after FUS depletion.  
My investigations however, were only preliminary and were not performed in a 
rigorous manner.  Therefore, a role for FUS in neuronal cell cycle control remains 
to be fully investigated.  Additionally, the effect of mutant FUS expression on cell 
cycle regulation has not been addressed, in either neurons or mitotic cells.  
While re-expression of cell cycle proteins in neurons seems to correlate 
with apoptosis, it is still unclear whether this is an upstream event in ALS 
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pathogenesis, or just a misregulation that occurs at the final stages of the cell’s 
life. Thus, investigations of this phenomenon may advance our understanding of 
how motor neurons die, but may not answer the question of why motor neurons 
die and therefore provide little therapeutic insight. 
 
DNA damage and ALS 
Accumulating evidence within the literature firmly establishes the importance of 
FUS in DNA damage repair.  FUS binds both single- and double-stranded DNA 
(Baechtold et al., 1999; Liu et al., 2013), is important for homologous DNA 
pairing (Akhmedov et al., 1995; Bertrand et al., 1999) and D-loop formation 
(Baechtold et al., 1999), localizes to sites of DNA damage (Mastrocola et al., 
2013; Rulten et al., 2013; Wang et al., 2013), and is required for efficient DNA 
damage repair (Mastrocola et al., 2013; Wang et al., 2013).  Furthermore, 
evidence shown here (Chapter II) suggests an accumulation of DNA damage in 
cells depleted of FUS.  As a normal result of aging,  DNA damage accumulates 
in neurons, presumably due to a decline in quality control pathways (reviewed in 
(Gorbunova et al., 2007)).  That mutations in FUS cause inefficient DNA damage 
repair in neurons (Wang et al., 2013), could worsen this problem, resulting in a 
faster accumulation of damaged DNA and neuronal apoptosis.  In support of this, 
post-mortem brain sections from the motor cortex of ALS patients harboring 
either FUS R521C or P525L mutations display increased levels of the γH2AX 
DNA damage marker relative to control brain sections (Wang et al., 2013).  
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Furthermore, a transgenic mouse expressing FUS R521C also exhibits elevated 
levels of DNA damage markers (e.g., γH2AX, phosphorylated p53, and ATF3) in 
the central nervous system (Qiu et al., 2014).  Together, this evidence points 
towards inefficient DNA damage repair as a relevant model for FUS-mediated 
ALS. 
 While no other ALS-linked proteins have been directly linked to DNA 
damage repair, more general evidence of DNA damage as a pathogenic 
mechanism in ALS exists.  Post-mortem patient tissue of ALS show elevated 
levels of DNA damage, including 8-hydroxy-2’-deoxy-guanosine (8-oxo-G), and 
decreased activity of DNA repair enzymes (Coppede, 2011). 8-oxo-G results 
from oxidation of nucleic acids and is one of the most common DNA lesions in 
neurons (reviewed in (Coppede, 2011)).  That oxidative stress is a pathological 
hallmark of ALS suggests that DNA damage arising from reactive oxygen 
species (ROS) may represent a general mechanism of ALS pathogenesis.  FUS 
appears to also play a role in controlling ROS levels as a co-transcriptional 
regulator of oxidative stress protection genes, as knockdown of FUS resulted in 
decreased transcription of these genes with a concomitant increase in ROS 
levels (Sanchez-Ramos et al., 2011).  Therefore, FUS appears to function both 
upstream and downstream of DNA damage, as a transcriptional regulator 
stimulating expression of oxidative stress protection genes and as a member of 
the DNA damage repair pathway. As FUS animal models continue to be 
investigated and additional neuronal models are created, I predict an important 
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link between mutant-FUS and DNA damage repair will come to light and prove to 
be important for understanding ALS pathogenesis. 
 
Insights from gene expression studies 
FUS is a multifunctional protein with roles in numerous fundamental processes 
(Figure I-2).  A challenge is to determine which of these functions is affected by 
ALS-linked mutations.  As an hnRNP protein (heterogeneous ribonucleoprotein) 
and part of the FET family, it is well established that FUS is involved in mRNA 
splicing and transcriptional regulation.  In fact, several large gene expression 
studies have been performed (Table I-1) and collectively show that FUS binds 
thousands of mRNA targets and depletion of FUS alters transcriptional regulation 
and alternative splicing (reviewed in (Ling et al., 2013)).  Similarly, 
overexpression of mutant FUS affects these same processes. Mutant FUS 
lacked an interaction with ~3,000 targets shown to bind wild-type FUS and 
gained ~900 unique interactions (Hoell et al., 2011).  Furthermore, mutant-FUS 
preferentially bound the 3’UTR of its targets while wild-type FUS preferred 
intronic regions (Hoell et al., 2011).  The implications of these observations are 
that thousands of transcripts could be irregularly spliced in disease or have 
altered stability, affecting numerous cellular pathways.   
 While these studies clearly demonstrate that both FUS depletion and 
expression of mutant FUS affect mRNA processing, none of these studies 
addressed whether similar alterations occurred at the protein level or whether 
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these alterations had any effect on cell health. To this end, my work 
demonstrated a decline in cell health and homeostasis upon FUS depletion and 
investigated changes in the proteome (Chapter III).  Differentially expressed 
proteins were grouped into functional categories, revealing enrichment for 
proteins involved in chromatin organization, cytoskeletal organization, energy 
homeostasis, calcium and metal ion binding, and cellular proliferation (Table III-
1).  Consistent with oxidative stress being a hallmark of ALS, metallothionein-2 
(MT2), a multifunctional protein involved in zinc homeostasis and antioxidation 
(Vasak and Meloni, 2011), was increased 85% after FUS knockdown. That levels 
of MT2 are known to increase in response to metal toxicity, oxidative stress, and 
ionizing radiation (Aschner et al., 2006; Vasak and Meloni, 2011), suggests one 
of these stressors is induced by FUS knockdown.  Likely, this stressor is 
oxidative stress, as FUS depletion has previously been shown to increase 
reactive oxygen species (Sanchez-Ramos et al., 2011).   Also changing 
significantly with FUS depletion was protein S100A6, which decreased by 36%.  
This protein is a calcium binding protein whose levels correlate with cellular 
proliferation status and is suggested to function in cytoskeletal organization 
(Lesniak et al., 2009).  While the exact functions of this protein have not been 
fully elucidated, evidence from ALS SOD G93A mice suggests it is up-regulated 
specifically in mutant SOD1 animals as a calcium buffering protein (Hoyaux et 
al., 2000).   That FUS binds the promoter of S100B (Tan et al., 2012), a family 
member of S100A6, raises the possibility that FUS may directly regulate 
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expression of S100A6.  Loss of FUS function mutations in ALS therefore may 
affect the expression of S100A6, as shown here for FUS depletion, thereby 
limiting the calcium buffering ability of the cell and causing excitotoxicity and 
neuronal death.   
 While providing valuable insight into potential ALS-related FUS functional 
pathways, the large gene expression studies discussed above and proteomics 
analysis presented here in Chapter III, do little to confirm which altered FUS 
functions or affected pathways are actually leading to neuronal death.  Moving 
forward more studies need to be performed in neuronal models with relevant 
levels of mutant protein as opposed to overexpression.  Additionally, a complete 
loss of FUS function in ALS is unlikely, although several in vivo studies suggest 
mutant FUS may affect the levels and/or activity of wild-type (Machamer et al., 
2014; Qiu et al., 2014).  With the recent development of human induced 
pluripotent stem cells (iPSC) it is now possible to study motor neurons derived 
from patient cells expressing disease relevant copies of these ALS-linked 
proteins.  Utilizing iPS cells will undoubtedly provide important insight into the 
question of whether a loss of function or gain of function mechanism is 
contributing to FUS-mediated ALS pathogenesis. 
 
G-quadruplexes: a common link between FUS functions? 
As FUS is a multifunctional protein with links to numerous cellular pathways, it is 
difficult to determine which functions are most relevant to study in terms of ALS 
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pathogenesis. That ALS-linked mutations affect several FUS functions, such as 
DNA damage repair, transcription, and splicing, makes this task even more 
difficult and suggests disruption of any FUS-associated process is detrimental.  
For this reason, finding a common link between how FUS performs these specific 
functions could be of great value.   
One noteworthy property of FUS that spans several functions is the binding of 
FUS to G-quadruplex nucleic acid structures.  In a study that determined RNA 
polymerase II promoters bound by FUS, it was noted that many FUS-bound 
promoters are predicted to contain G-quadruplex structures (Tan et al., 2012). 
Furthermore, the complementary strand of the consensus motif most strongly 
bound by FUS is expected to form a G-quadruplex (Tan et al., 2012), suggesting 
a correlation between G-quadruplexes and the function of FUS in RNA 
polymerase II-mediated transcription.  In addition to transcription start sites, G-
quadruplexed DNA is common within telomeres. Recently, FUS overexpression 
was found to affect telomere histone methylation and telomere length and 
interestingly, the localization of FUS to telomeres required binding to G-
quadruplexed DNA (Takahama et al., 2013). FUS also binds telomeric RNA 
(termed TERRA), specifically through a G-quadruplex dependent interaction 
(Takahama et al., 2013).  The importance of telomeres in genome stability and 
cellular aging is well known. That FUS appears to play a role in regulating 
telomere length establishes an interesting area of research for FUS in cell aging 
with potential importance to neurodegeneration.   
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More well-studied than transcriptional regulation and genomic maintenance is 
the role of FUS in RNA processing.  Several genome-wide studies have been 
conducted to determine the RNA targets of FUS and whether they can be 
predicted through sequence motifs.  While early studies suggested a GGUG 
motif preference for FUS binding (Lerga et al., 2001) which is generally accepted 
and has been confirmed by a subsequent study (Lagier-Tourenne et al., 2012), 
others propose that FUS is more selective for a conformational motif (Hoell et al., 
2011; Colombrita et al., 2012; Ishigaki et al., 2012; Nakaya et al., 2013; 
Takahama and Oyoshi, 2013).  As demonstrated for telomeric RNA, this 
secondary structure could potentially be a G-quadruplex, however this possibility 
was not investigated in these studies. 
Binding to both telomeric DNA- and RNA- G-quadruplexes requires the 
arginine-glycine-glycine (RGG) domain at the C-terminus of FUS (Figure I-2) 
(Takahama and Oyoshi, 2013; Takahama et al., 2013). Similarly, the FUS-related 
protein EWS has also been reported to bind G-quadruplexed DNA and RNA 
(Takahama et al., 2011b) via a similar RGG domain (Takahama et al., 2011a), 
suggesting this binding specificity may be important for functions common 
between these two proteins. The effect of mutating residues in the RGG domain 
on binding affinity has not been determined, but several ALS-linked mutations in 
FUS are present in this domain (Figure I-4) which could conceivably affect 
binding. 
110 
 
 
 Recently an abnormal hexanucleotide GGGGCC repeat expansion in 
C9ORF72 was determined to be the most common cause of familial and 
sporadic ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011).  One 
theory as to how this leads to disease is that this repeat expansion sequesters 
RNA binding proteins, thereby inhibiting them from performing their normal 
functions (Taylor, 2014).  There have been several attempts to determine the 
RNA-binding proteins associated with this repeat expansion and numerous hits 
have been identified in vitro that co-localize with C9ORF72 RNA-foci in diseased 
patient cells (Donnelly et al., 2013; Lee et al., 2013; Mori et al., 2013; Sareen et 
al., 2013; Xu et al., 2013).  That both the DNA and RNA of this repeat expansion 
form G-quadruplexes (Fratta et al., 2012; Reddy et al., 2013; Haeusler et al., 
2014) predicts an association of FUS with this expanded repeat which may come 
to light as more comprehensive analyses are performed.  
 
A Model for ALS Pathogenesis 
 Understanding the normal functions of FUS and how these functions are 
altered by ALS-linked mutations is important for understanding the pathogenesis 
of FUS-mediated ALS.  An equally important and even more challenging 
question to consider is how mutations in so many diverse genes can cause the 
same disease.  There are over 100 genes associated with ALS with several 
having a relatively high incidence, such as SOD1, TDP-43, FUS, and C9ORF72, 
with firm genetic support of their involvement in ALS pathogenesis.  How does 
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one make sense of disease pathogenesis with so many seemingly diverse 
players involved? To this end, much research has been focused on identifying 
functional overlap between ALS-associated proteins.  Presented below is a 
discussion of two related cellular processes in which several ALS-associated 
proteins function, followed by a description of a potential pathogenic mechanism 
involving these fundamental processes. 
 
Protein misfolding 
A main suspect in ALS pathogenesis is misfolded protein.  This stems 
from investigations of mutant superoxide dismutase-1 (SOD1), the first genetic 
link to ALS (Rosen et al., 1993).  Mutant SOD1 misfolds and oligomerizes, 
leading to the induction of several cellular stresses, including proteasomal 
disruption and endoplasmic reticulum (ER) stress (Sreedharan and Brown, 
2013).  Wild-type SOD1 can also obtain a misfolded conformation which has 
been identified in cases of sporadic ALS, further implicating this misfolded 
species in disease pathogenesis (Rotunno and Bosco, 2013).  Other ALS-
associated proteins that adopt a misfolded or less stable conformation include 
TDP-43 (Mackness et al., 2014), FUS/TLS, and Pfn-1 (Bosco lab, unpublished). 
When a cell detects misfolded protein it initiates the unfolded protein 
response (UPR).  The UPR is a three pronged approach to dealing with the 
stress of protein misfolding: 1) translation of new protein is halted, 2) production 
of molecular chaperones is increased, and 3) proteins that cannot be refolded 
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are degraded by the proteasome or autophagosome.  Evidence of UPR 
activation has been seen in ALS human samples as well as ALS mouse models, 
implicating stress from misfolded proteins in ALS (Matus et al., 2013). That 
several ALS-associated proteins have known functions in protein degradation 
pathways may help provide a link between protein homeostasis and ALS 
pathogenesis.  These proteins include ubiquilin-2 (UBQLN2), optineurin (OPTN), 
p62/sequestosome 1 (p62/SQSTM1), valosin-containing protein (VCP), 
chromatin modifying protein 2B (CHMP2B), factor induced gene 4 (FIG4), Alsin, 
vesicle associated membrane protein associated protein B (VAPB), and 
C9ORF72.  VAPB associates with the endoplasmic reticulum and is thought to 
be important for activation of the UPR (Kanekura et al., 2006).  The remaining 
proteins assist in protein degradation by fulfilling important functions in the 
proteasome pathway (UBQLN2, VCP, p62/SQSTM1) or autophagy (UBQLN2, 
VCP, p62/SQSTM1, CHMP2B, OPTN, FIG4, Alsin, C9ORF72) (Farg et al., 2014) 
reviewed in (Chen et al., 2013; Ling et al., 2013; Robberecht and Philips, 2013).   
 
Stress response in ALS 
Misfolded proteins and ALS-linked mutant proteins, such as SOD1 
(Nishitoh et al., 2008), TDP-43 (Walker et al., 2013), and FUS (Farg et al., 2012), 
initiate the UPR by causing ER-stress, which is a cellular response strongly 
associated with the pathogenesis of ALS (Matus et al., 2013).  As such, 
investigations of potential biomarkers and therapeutic strategies have been 
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centered on key features of the ER-stress response (Matus et al., 2013). One 
effect of ER-stress is the formation of stress granules, which are protein/RNA 
structures that are thought to occur as a means of halting translation of proteins 
unnecessary to overcome the stress at hand (Kedersha and Anderson, 2007; 
Anderson and Kedersha, 2008; Kedersha et al., 2013).  One response of ER-
stress is the inhibition of protein translation through phosphorylation of eukaryotic 
translation initiation factor 2α (eIF2α) (Hetz, 2012), a key event in stress granule 
formation (Kedersha et al., 1999).   
In addition to being a product of ER-stress, the relevance of stress 
granules in ALS pathogenesis came to light with the discovery that ALS-linked 
mutant FUS associates with stress granules (Bosco et al., 2010a).  Furthermore, 
wild-type FUS incorporates into stress granules under conditions of 
hyperosmolar stress (Sama et al., 2013), as does TDP-43 (Dewey et al., 2010), 
which has also been seen in stress granules formed from various other stressors 
(Colombrita et al., 2009; Liu-Yesucevitz et al., 2010; Aulas et al., 2012), including 
ER-stress (Walker et al., 2013).  The effects of mutant FUS and TDP-43 on 
stress granule function are in the early stages of investigation, but have so far 
been determined to affect several characteristics of stress granules, such as 
size, number, and assembly rate (Dewey et al., 2010; Baron et al., 2013).  FUS 
and TDP-43 are two RNA-binding proteins that are genetically linked to ALS and 
share similar domain structures, are both components of inclusions in ALS and 
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FTLD, and share many functions, such as transcription, RNA splicing, and 
transport of mRNA.     
Recently, a third ALS-linked protein, profilin-1, was found to associate with 
stress granules and mutations in this protein may also affect stress granule 
dynamics (Figley et al., 2014).  Profilin-1 is an important protein in the regulation 
of actin polymerization making this finding intriguing as cytoskeletal organization 
is key for stress granule formation and disassembly (Bartoli et al., 2011). It has 
yet to be determined whether actin assembly is altered by ALS-linked profilin-1 
mutations, however one could speculate that if this were the case, stress granule 
function would be disturbed as a result.  Several other ALS-linked proteins are 
also associated with stress granules: hnRNPA1, hnRNPA2, and ataxin-2.  
Mutations in these proteins do not account for very many ALS cases, however, 
they are implicated as risk factors for the disease. 
While it is significant that six different ALS-associated proteins are all 
components of stress granules, it has also been proposed that stress granules 
could be precursors to the pathological aggregates found in ALS patient tissue 
(Dewey et al., 2012).  Several stress granule nucleating factors, such as T cell 
intracellular antigen 1 (TIA 1), nucleolysin, TIAR and eukaryotic translation 
initiation factor 3 subunit (eIF3), are present in TDP-43 containing aggregates in 
patient ALS tissue (Liu-Yesucevitz et al., 2010).  The implications of this 
observation are that stress granules, containing TDP-43, formed in response to a 
cellular stress and persisted long enough to further incorporate TDP-43 to the 
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point of forming an aggregate.  Persistent stress granules could be the result of a 
heightened state of cell stress that does not get resolved.  Alternatively, the 
incorporation of ALS-linked mutant protein, such as FUS or TDP-43, may impair 
the function of stress granules such that homeostasis is not re-established, 
resulting in a vicious cycle in which the system put in place to deal with stress 
actually causes more stress, worsening over time.  
 
Tipping the balance of proteostasis in ALS 
 That numerous ALS-associated proteins are involved in stress granules 
and protein degradation pathways suggests that these processes contribute to 
ALS pathogenesis through a common cellular event, such as the maintenance of 
protein homeostasis, also known as proteostasis (Ong and Kelly, 2011).   To 
maintain proteostasis, the cell responds to misfolded protein and ER-stress by 
eliciting a stress signal that induces stress granule formation and the stalling of 
translation while also utilizing protein degradation machinery to rid the cell of 
protein that cannot be refolded (Figure IV-1 top).  As the efficiency of the 
proteasome and autophagy systems normally decline with age , mutations in 
proteins involved in these pathways may exacerbate this effect, causing the 
system to surpass a threshold for which it can handle defects in proteostasis. 
This in turn may cause an accumulation of misfolded proteins which leads to a 
heightened level of cell stress, persistent stress granules, and eventually protein 
aggregates.  In support of this theory, many disease-associated aggregates are 
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ubiquitinated (Blokhuis et al., 2013), indicating activation of the UPR.  
Furthermore, inhibition of the proteasome has been shown to induce stress 
granule formation (Mazroui et al., 2007), demonstrating a link between these two 
cellular processes. Whether   (Figure IV – 1 bottom).  As stress granule function 
and protein degradation are intimately linked, disruption of either would be 
detrimental, leading to cell death and neurodegeneration, as supported by the 
fact that many ALS-linked proteins are associated with these processes.  
 
Neuronal vulnerability 
All cells maintain protein homeostasis using these fundamental processes 
and mutant ALS-associated proteins are expressed ubiquitously in all cell types. 
Why then are neurons susceptible to disturbances in these processes while other 
cell types appear to be impervious?  The difference is the post-mitotic status of 
neurons.   Neurons do not replicate and once a neuron is differentiated and 
established within an organism, it will remain there for the duration of the 
organism’s life.  Mitotic cells however, are turned-over as new cells are 
continuously being produced.  This is necessary as mitotic cells have a limit to 
the number of times they can divide before they are destined for apoptosis.  That 
disease onset for ALS occurs later in life implies there is a temporal factor 
involved in the development of the disease.  If protein homeostasis is 
compromised in a neuron, the level of misfolded proteins and cellular stress will 
accumulate over time. Eventually, a threshold is reached at which the cell can no 
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longer survive.  It could take decades to reach this threshold, which for a neuron 
is within its lifetime while mitotic cells reach the end of their life long before 
enough stress is accumulated to create a problem.  In this way, neurons become 
more susceptible over time to stress, eventually leading to neurodegeneration. 
 
Conclusion 
The multifunctional nature of FUS makes its role in ALS pathogenesis 
difficult to ascertain.  Investigating ALS-linked FUS mutant protein has revealed 
disruptions in the DNA damage repair, transcriptional regulation, and RNA 
splicing functions of FUS.  Additionally, mutant protein mislocalizes to the 
cytoplasm and causes abnormal stress granule formation and dissolution, having 
implications of an altered cellular stress response.  Which of these abnormal 
properties of mutant FUS protein is most relevant to ALS pathogenesis?  Is 
association with G-quadruplexes an important connection between FUS function 
and C9ORF72-mediated ALS? Since the discovery of FUS in ALS in 2009, over 
250 studies of FUS have been published.  With this expansive interest and the 
development of animal and induced pluripotent patient stem cell models, 
determining the role of FUS in ALS pathogenesis will surely come to fruition.   
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Figure IV-1.  A model of ALS pathogenesis. The normal cellular response to naturally 
occurring protein misfolding is the initiation of the unfolded protein response, resulting in 
the formation of stress granules for translation inhibition, and the upregulation of protein 
degradation machinery, such as the proteasome and autophagosome (top). In a 
diseased state, the balance between these systems may be altered.  Mutations in 
various proteins could lead to higher levels of misfolded protein and aggregates, 
increased levels of ER-stress, accumulation and improper function of stress granules, 
and inefficient protein degradation by autophagy and the proteasome, which are already 
known to be less efficient with age. Over time the cell reaches a threshold of stress at 
which it can no longer survive, culminating in neuronal loss and disease onset. 
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PREFACE TO APPENDIX I: 
 
All of the work presented in this appendix was performed by Catherine L. Ward.  
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APPENDIX I:  INVESTIGATING A ROLE FOR FUS/TLS IN SUPPRESSION OF 
NEURONAL CELL CYCLE REINITIATION 
 
The Cell Cycle 
The cell cycle is a vital process that is fundamental to all life. It is crucial 
during development and for the replenishment of cells that have undergone 
apoptosis. The cell cycle is composed of two main stages: interphase and 
mitosis.  Interphase is broken up into three phases, Growth1 (G1), S-phase, and 
Growth 2 (G2) which each play specific roles in preparing the cell for mitosis.  
During G1, the cell grows in size and produces the proteins and nucleic acids 
necessary for undergoing DNA replication, which occurs during S-phase.  After 
S-phase is complete and the cell contains two copies of DNA, the cell enters G2 
where it rapidly grows in size and increases protein synthesis.  After G2, the cell 
undergoes mitosis and it divides into two daughter cells, with each containing 
one copy of DNA (reviewed in (Vermeulen et al., 2003)).   
 
Cell cycle progression.  Progression through each stage of the cell cycle is 
regulated by the interactions of several specific proteins: cyclins and cyclin-
dependent kinases. As their name implies, levels of cyclins fluctuate, correlating 
with specific phases of the cell cycle.  Cyclin E for example, increases throughout 
G1, is highest during the G1-S transition and decreases throughout S phase.  
Cyclin A, on the other hand, increases during S-phase and reaches its peak 
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during G2.  Regulating the levels of cyclins is important as these proteins are 
required during specific cellular stages for the function of cyclin-dependent 
kinases (CDKs).  Cyclin D1 for example, starts being expressed in G1 and forms 
a complex with cyclin-dependent kinases 4 (CDK4), which is turn phosphorylates 
retinoblastoma, allowing for the transcription of genes required for S-phase.  As a 
complex, cyclins are the regulatory subunits while CDKs are the catalytic 
subunits, inactive until bound to their corresponding cyclin.  
 In addition to cyclins and cyclin-dependent kinases which promote cell 
cycle progression, there are additional proteins that inhibit cell cycle progression.  
There are two families of inhibitory proteins: the cip/kip (CDK interacting 
protein/kinase inhibitory protein) and the INK4a/ARF (inhibitor of kinase 
4/alternative reading frame) families.  As their name implies, the INK4a/ARF 
family inhibits the activity of CDK4, arresting the cell cycle in G1.  The cip/kip 
family on the other hand, is active throughout the entire cell cycle, inhibiting the 
activity of numerous cyclin/CDK complexes (reviewed in (Vermeulen et al., 
2003)). 
 
Checkpoints: maintaining DNA integrity.  Throughout the cell cycle, several 
quality control checkpoints exist to ensure DNA integrity is maintained before the 
cell progresses to the next phase.  Before leaving S-phase, DNA is assessed to 
ensure complete replication and in mitosis there is a checkpoint to ensure 
spindles are formed properly before the two sets of DNA are separated.   The 
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two growth phases, G1 and G2, each contain a checkpoint to determine whether 
any DNA damage has occurred prior to allowing the cell entry into S-phase or 
mitosis, respectively, where the integrity of DNA is crucial.  If any abnormalities 
are discovered during these checkpoints, the cell cycle will arrest until the error 
has been corrected.  Cell cycle arrest is achieved by the rapid induction of 
inhibitors and signaling cascades which ultimately shut down expression of 
proteins required for cell cycle progression (reviewed in (Vermeulen et al., 
2003)).   
 
FUS and cell cycle regulation.   Several pieces of literature exist demonstrating a 
role for FUS in cell cycle regulation.  Presented here in Chapter III, in response to 
FUS knockdown, proliferation of NSC-34 cells was reduced and could be 
recovered with FUS re-expression, demonstrating a direct correlation between 
FUS levels and cell proliferation status.  The expression of several proteins 
associated with cellular proliferation was also altered upon FUS knockdown.  
That a previous study demonstrated an enriched binding of FUS to mRNAs 
encoding for cell cycle related proteins (Colombrita et al., 2012) suggests FUS 
affects cellular proliferation through its role in RNA processing.   In support of 
this, a study in RAW264.7 macrophage cells showed that FUS is recruited to the 
promoter of cyclin D1 in response to ionizing radiation and inhibits its expression 
(Wang et al., 2008).  This finding is an example of how FUS may be important for 
cell cycle arrest after the induction of DNA damage.  This study further 
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demonstrated that knockdown of FUS in RAW264.7 cells resulted in an increase 
in cyclin D1 mRNA expression (Wang et al., 2008); a finding which was 
reproduced in our lab at both the mRNA (Figure AI-1A) and protein level (Figure 
AI-1B,C).  While appropriate experiments were not performed to test this, this 
increase in cyclin D1 expression would suggest active cell proliferation in the 
absence of FUS, whereas in NSC-34 cells, knockdown of FUS caused a defect 
in cell proliferation (Chapter III).  This could be suggestive of FUS having a bi-
directional role in cell cycle regulation; normally FUS promotes cell cycle 
progression whereas under conditions of cell stress, FUS promotes cell cycle 
arrest. 
Two other studies have suggested a role for FUS in cell cycle regulation, 
specifically in terms of androgen stimulated proliferation of prostate cancer cells. 
In a study by Haile et al., a four day knockdown of FUS in prostate cancer cells 
reduced cellular proliferation stimulated by androgen (Haile et al., 2011).  In 
contrast however, Brooke et al. show that a three day knockdown of FUS 
increased androgen-dependent cell cycle progression (Brooke et al., 2010).  
Moreover, they show FUS promotes cell cycle arrest by reducing levels of CDK6 
and cyclin D1 and by increasing inhibitors of proliferation, such as the CDK 
inhibitor, p27 (Haile et al., 2011).  The discrepancy between these two studies 
has not been explained.  Together however, in addition to the study by Wang et 
al. and the work presented in Chapter III, it is evident that FUS may have 
important functions in controlling proper activity of the cell cycle. 
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Figure AI-1.  Knockdown of FUS causes an increase in cyclin D1 
expression in RAW264.7 macrophage cells.  RAW264.7 macrophage cells 
were transfected with 20pmol of siRNA specific for FUS.  (A) Twenty-four 
hours post-transfection, RNA was harvested and levels of FUS and cyclin D1 
mRNA were measured by qRT-PCR.  Data shown is the average of two 
independent experiments run in technical quadruplicate + standard error.  (B) 
Representative western blot of the indicated cell lysates demonstrating 
increased expression of cyclin D1 after knockdown of FUS. Tubulin serves as 
a loading control.  (C)  Western blot densitometry analysis demonstrating a 
decrease in FUS expression at 24h of siRNA transfection with a concomitant 
increase in cyclin D1.  Data shown is the average of four independent 
experiments + standard error.  Statistical significance was determined by a 
student’s t-test (**P <0.01; ***P <0.001).  
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The post-mitotic neuron 
Neurons are specialized cell types that differ from non-neuronal cells in a 
number of ways.  One characteristic that sets them apart is their post-mitotic 
status.  During development and neuronal differentiation, neurons exit the cell 
cycle and enter a phase called G0 (Herrup and Yang, 2007).  Very little is known 
about how neurons exit the cell cycle after development, but accumulating 
evidence suggests keeping the cell cycle suppressed is essential for neuronal 
health and viability.    
 
Cell cycle re-initiation and neurodegeneration.  It is widely established that 
neurons do not proceed through the cell cycle once the developmental process is 
complete and neurons are considered matured. Cell cycle proteins are almost 
undetectable in adult neurons and machinery for DNA replication is non-existent.  
However, accumulating evidence demonstrates that neuronal tissue from various 
neurodegenerative disease cases have elevated levels of numerous cell cycle 
proteins (Herrup and Yang, 2007).  This is suggestive of loss of neuronal cell 
cycle control in late onset neurodegeneration.  For instance, in patient tissue 
from Alzheimer’s disease (AD), re-expression of several cell cycle proteins has 
been observed including, cyclin A, B, D, and E, as well as CDKs, CKD inhibitors, 
and the proliferating cell nuclear antigen protein (PCNA) indicative of S-phase 
(reviewed in (Herrup and Yang, 2007)). Furthermore, these proteins were only 
expressed in neuron types susceptible in AD and were present before any signs 
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of classic AD pathology, such as amyloid β deposition (reviewed in (Bonda et al., 
2010a; Herrup, 2012)).   There have also been reports of cell cycle protein re-
expression in other neurological conditions including, ataxia telangiectasia, 
Parkinson’s disease, stroke, and ALS (Herrup and Yang, 2007).  In ALS mice 
and patient tissue, evidence of increased cyclin D and CDK4 expression has 
been noted in motor neurons, the cell type susceptible in ALS (Nguyen et al., 
2003; Ranganathan and Bowser, 2003).  That the cyclin D/CDK4 complex is 
responsible for reinitiating the cell cycle in cells maintaining a resting G0 state 
(Sherr, 1994) it follows that cell cycle reinitiation could be occurring in ALS motor 
neurons.  Interestingly, experimental expression of cell cycle proteins in neurons 
initiates apoptosis, further supporting a link between these two events. 
 
Conclusion 
While cell cycle reinitiation is an interesting model for neurodegeneration-
associated neuronal death, the hypothesis is still in its early stages and is not 
currently a widely accepted model.  Furthermore, it is not certain whether this 
reinitiation is an upstream event, or a downstream event occurring as an early 
stage of apoptosis.  As several reports have demonstrated a role for FUS in 
maintaining cyclin D1 levels and regulating cellular proliferation, one could 
speculate that FUS may also play a role in suppressing the cell cycle in neurons. 
Thus, the nuclear depletion of FUS by ALS-linked mutations, could potentially 
lead to expression of cyclin D1 and an aberrant cell cycle reinitiation.  To date, 
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the regulation of CCND1 by FUS has only been demonstrated in macrophage 
cells (Wang et al., 2008) and prostate cancer cells (Brooke et al., 2010; Haile et 
al., 2011), and remains to be investigated in neurons.   Further studies of the role 
of FUS in neuronal gene expression are necessary for concluding whether FUS 
plays a role in cell cycle-related neuronal death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
 
PREFACE TO APPENDIX II: 
 
The following chapter is a manuscript published in the Journal of Cellular 
Physiology (Publisher: John Wiley and Sons; License #3397800087634). 
 
My contributions to this manuscript included intellectual input, experimental 
design strategies, and the establishment of the cell viability protocol (MTT assay) 
used herein.  Additionally, I performed preliminary MTT assays and aided in the 
analysis of MTT assay results and provided reagents and consulting for the 
culture of NSC-34 cells stably expressing inducible shRNA. 
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PREFACE TO APPENDIX III: 
 
The following chapter is a manuscript published in Molecular Neurodegeneration. 
(Publisher: BioMed Central; no permission or license required for reproduction) 
 
My contributions to this manuscript included intellectual input, experimental 
design strategies, and the creation and establishment of NSC-34 stable cell lines 
expressing exogenous human wild-type or R495X FUS used in figure 2.  
Additionally, I was responsible for the maintenance and culturing of these cells 
for experimental use and performed the western blot analysis shown in figure 2A. 
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PREFACE TO APPENDIX IV: 
 
The work presented in this appendix was performed by Catherine L. Ward with 
the following exceptions:  
 
Mass spectrometry analysis was performed by either Murat Karabacak 
(previously of Jeffery Agar’s lab, Brandeis University) or John Leszyk (UMMS, 
mass spectrometry core facility) and p38α activity was determined by Sun Kyong 
Lee (previously of Gerardo Morfini’s lab, University of Illinois at Chicago). 
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APPENDIX IV:  EXPRESSION, PURIFICATION AND CHARACTERIZATION 
OF ACTIVATED P38 MAPK FROM E-COLI 
 
Abstract 
P38α is a ubiquitously expressed mitogen-activated protein kinase 
(MAPK) involved in a diverse set of physiological and disease-related processes 
including the control of gene expression, apoptotic cell death, inflammation, 
tumorigenesis and neurodegeneration.  In vivo, p38α activation involves dual 
phosphorylation of a threonine and tyrosine residue within its activation loop by 
either upstream MAPKs or through autophosphorylation.  However, singly 
phosphorylated p38α or p38α with phosphomimetic mutations also exhibit kinase 
activity, indicating dual phosphorylation is not an absolute requirement for 
activity.  Here, we report single and double phosphorylation of recombinant p38α 
expressed in Escherichia coli.  This result is unexpected, since mammalian 
recombinant proteins are not typically phosphorylated when expressed in 
Escherichia coli.  We describe a simple procedure to produce a relatively large, 
highly purified source of active p38α. This procedure involves a few simple steps, 
and does not require ion exchange chromatography or sophisticated protein 
purification equipment. While commercially available sources of p38α activated 
by upstream MAPKs in vitro are commercially available, an economic source of 
active p38α that can be produced in most basic science laboratories is expected 
to benefit many fields of biomedical research. 
161 
 
 
Introduction 
P38 mitogen-activated protein kinase (MAPK) is a member of the MAPK 
superfamily that also includes extracellular signal-regulated kinases (ERKs) and 
c-jun N-terminal kinases (JNKs) (Krishna and Narang, 2008).  P38 MAPKs and 
JNKs are also known as stress-activated protein kinases (SAPKs) because they 
are activated in response to cellular stressors such as oxidative stress, inducers 
of DNA damage, and proinflammatory cytokines (Krishna and Narang, 2008).  Of 
the four isoforms of p38 that include p38α, p38β, p38γ and p38δ, p38α has been 
the most extensively studied. Activation of p38α is generally accomplished by 
upstream kinases called MAPK kinases (MKKs), which phosphorylate both the 
Thr and Tyr residues within the activation loop sequence Thr-Gly-Tyr.  MKKs are 
in turn phosphorylated and thus activated by MAPK kinase kinases (MKKKs); 
together the MAPKs, MAPKKs and MAPKKKs comprise a MAPK signaling 
cascade (Zarubin and Han, 2005). P38α can also become activated by factors 
outside of this MAPK signaling cascade.  For example, TAB-1 (transforming 
growth factor-b-activated protein kinase 1) binds and induces the 
autophosphorylation of p38α (Ge et al., 2002).  P38α substrates include various 
transcription factors, kinases and cytoskeletal proteins.  A role for active p38α 
has been reported in several biological processes including gene regulation, 
inflammation, apoptosis and cell cycle (Krishna and Narang, 2008), as well as in 
human diseases such as cancer and neurodegeneration (Morfini et al., 2009; 
Kim and Choi, 2010).  
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In light of the important roles that p38α plays in various pathways, 
including our recent finding that p38α may play a role in amyotrophic lateral 
sclerosis (ALS) pathogenesis (Morfini et al., 2009; Bosco et al., 2010b), we 
sought to express and purify recombinant p38α for biochemical studies.  
Unexpectedly, we discovered that p38α is phosphorylated during its expression 
in Escherichia coli, in a manner independent of upstream mammalian MKKs. 
Thus, p38α might represent a rare example of a mammalian protein that is post-
translationally modified by one or more E. coli kinase(s). Significantly, 
phosphorylated p38α isolated from our preparations displays kinase activity, and 
may therefore substitute commercially available forms of activated p38α that are 
too costly for many laboratories.  To ensure that most basic science labs benefit 
from this finding, we describe a straightforward protocol to isolate milligram 
quantities of highly purified, active p38α. Importantly, this protocol does not 
require a protein purification instrument, such as an FPLC. An economic source 
of active p38α  is expected to benefit laboratories studying the biological 
functions of this kinase.  
 
Results 
Expression and purification of p38α MAPK from E. coli. His-tagged p38α was 
expressed and purified using a strategy similar to previous methods ((Wang et 
al., 1997; Bukhtiyarova et al., 2004) and Materials and Methods). In agreement 
with previous reports (Bukhtiyarova et al., 2004), we obtained significantly 
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greater yields of p38α when expressed in E. coli Rosetta (DE3) cells compared to 
E. coli BL21(DE3) cells (data not shown), with an average yield of 10-15 mg of 
protein per liter of bacterial culture. The cobalt-based TALON resin, as opposed 
to a more common nickel-based resin, was employed for affinity purification of 
his-p38α.  While TALON resin is advertized to prevent non-specific binding of 
host proteins, the purity of his-p38α was only ~85% after the first TALON 
purification step (Figure AIV-1, lane 2 and 2a).  Next, we employed the 
commercially available thrombin protease to cleave the his-tag, and reapplied the 
thrombin/his-p38α cleavage reaction to the TALON resin.  Tag-free p38α was 
eluted in the flow-through of this chromatography step with a purity of ~95% as 
assessed by SDS-PAGE and Coomassie Brilliant blue staining (Figure AIV-1, 
lane 3).  Non-specific host proteins and uncleaved p38α were both retained by 
the TALON resin (Figure AIV-1, lane 4).  Residual thrombin was removed by 
applying the tag-free p38α to a Benzamidine column, which removes serine 
proteases such as thrombin (Figure AIV-1, lane 5).  
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Figure AIV-1.  Expression and purification of p38α MAPK from E. coli.  
His-tagged p38α was expressed and purified as described in Materials and 
Methods.  Samples from several steps of the purification process were 
subjected to SDS-PAGE and Coomassie Brilliant blue staining and assessed 
for purity.  Lane 1 shows a sample of the unpurified lysate from E. coli induced 
to express his-tagged p38α.  This lysate was applied to a TALON resin column 
and imidazole-eluted proteins are shown in lane 2, with the most abundant 
species corresponding to the expected molecular weight (~43,300 kDa) of his-
tagged p38α.  Eluted proteins were subjected to Thrombin protease treatment 
to cleave the his-tag from p38α and then reapplied to the TALON column. 
Tag-free p38α eluted in the flow-through (lane 3), whereas uncleaved his-
tagged p38α and non-specific host-proteins were bound to the TALON resin 
and eluted with imidazole (lane 4).  The protein eluting in the flow-through 
(lane 3) was applied to a Benzamidine column to remove the Thrombin (lane 
5).  A more diluted sample corresponding to lane 2 is shown in lane 2a such 
that pure p38α (lane 5) can be directly compared to impure p38α after the first 
TALON column. 
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Other purification procedures have been reported for his-p38α and 
untagged p38α, however these require additional chromatography steps and 
generally employ an anion exchange column with a salt gradient (Wang et al., 
1997; Keesler et al., 1998; Bukhtiyarova et al., 2004; Diskin et al., 2004).  We 
show here that simply removing the his-tag eliminates the non-specific host 
proteins that bind to the TALON resin.  Because our protocol can easily be 
carried out in batch-mode or with gravity filtration, we expect this protocol to be 
particularly useful for molecular biology laboratories researching p38α, but that 
lack protein purification technology such as a fast protein liquid chromatography 
(FPLC) system.  Moreover, a tag-free protein is advantageous for biological and 
biophysical assays wherein a tag could potentially interfere with the experiment.  
 
Recombinant p38α expressed in E. coli is phosphorylated.  We expressed and 
purified p38α with the intention of performing in vitro activation assays.  Western 
blot analysis using an antibody raised against a peptide sequence including 
phosphorylated Thr180 and Try182 residues of p38α suggested that at least a 
fraction of p38α from our E. coli preparation was dually phosphorylated (Figure 
AIV-2A, lane 1).  Treatment of p38α with lambda protein phosphatase, which 
removes phosphate groups from serine, threonine and tyrosine residues, 
abolished this immunoreactivity (Figure AIV-2A, lane 2), further supporting the 
presence of phosphorylated p38α in our preparations.   
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Figure AIV-2.  The activation loop of his-p38α isolated from E. coli is 
phosphorylated.  Purified his-p38α was dephosphorylated using lambda 
protein phosphatase as described in Materials and Methods. (A) Both 
untreated and dephosphorylated p38α (lanes 1 and 2 respectively), were 
analyzed by western blotting.  Similar p38α loading was confirmed using a 
phosphorylation-independent anti-p38 antibody from Sigma (p38). In contrast, 
a phosphorylation-dependent anti-p38 antibody (p-p38) raised against a 
phosphopeptide containing Thr180 and Tyr182 showed reduced 
immunoreactivity in lambda phosphatase-treated samples, compared to 
untreated samples.  (B) Quantification of the data in A is shown. The 
densitometry of the pp38 bands in lanes 1 and 2 are normalized to the total 
amount of p38α detected using the phosphorylation-independent anti-
p38antibody (p38). A ~100-fold reduction in p-p38 immunoreactivity was seen 
in lambda phosphatase-treated samples, compared to control, untreated 
samples. 
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Fourier-transform mass spectrometry (FT-MS), which provides a high 
mass-accuracy and high resolution relative to most mass spectrometry 
techniques (Scigelova et al., 2011), was employed to confirm the phosphorylation 
status of p38α.  The FT-MS spectrum revealed unphosphorylated (m/z 43,319), 
monophosphorylated (m/z 43,399) and bisphosphorylated (m/z 43,479) p38α 
peptide species (Figure AIV-3).  While it is not possible to quantify the exact ratio 
of each species based on their relative intensities in the mass spectrum, the 
unphosphorylated species appears to be present at the highest relative 
abundance and the bisphosphorylated form at the lowest relative abundance.   
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
 
 
 
 
 
 
 
 
Figure AIV-3.  Fourier-transform mass spectrometry confirms that p38α 
MAPK isolated from E. coli is phosphorylated.  Shown is the charge 
deconvoluted FT-MS spectrum that was reconstructed as charge +1 (Data 
Analysis, Bruker Daltonics). The spectrum reveals the presence of 
unphosphorylated (average m/z 43,319), monophosphorylated (average m/z 
43,399) and bisphosphorylated (average m/z 43,479) p38α species. The 
monophosphorylated species is present at a higher relative abundance than 
the bisphosphorylated species. 
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Next, we designed a mass spectrometry approach to identify 
phosphorylation sites within our E. coli derived p38α. P38α was first excised from 
an SDS-PAGE/Coomassie Brilliant blue stain gel and proteolytically digested. A 
titanium dioxide (TiO2) column was used to enrich for phosphorylated p38α 
peptides. MALDI-TOF revealed the presence of two phosphopeptides with 
masses corresponding to 1575.58 and 1591.60 (Figure AIV-4).  Based on the 
results of the Mascot MS/MS database search, peptide 1575.58 corresponds to 
the p38α peptide monophosphorylated at site Thr180, and peptide 1591.60 
corresponds to the oxidized (+16 on Met179) form of this same peptide.  The 
MASCOT scores decrease significantly for both the reduced and oxidized forms 
of the peptide when the phosphate group is modeled onto Tyr182 (Table AIV-1). 
Using this approach, we were unable to detect p38α peptides dually 
phosphorylated at Thr180 and Tyr182. Thus, the monophosphorylated species at 
relatively high abundance in the FT-MS spectrum likely corresponds to p38α 
phosphorylated at Thr180. 
 
 
 
 
 
 
 
170 
 
 
 
 
 
 
 
 
 
 
 
Figure AIV-4.  MALDI-TOF reveals the presence of two phosphorylated 
p38α MAPK peptides.   P38α was excised from an SDS-PAGE gel stained 
with Coomassie Brilliant blue and proteolytically digested.  Enrichment of 
phosphorylated p38α peptides was accomplished with a titanium (TiO2) oxide 
column. MALDI-TOF revealed the presence of two phosphopeptides with 
masses corresponding to 1575.58 and 1591.60, representing a peptide 
monophosphorylated at Thr180 (see Table AIV-1) with and without oxidation, 
respectively. No other phosphorylated peptides were identified; smaller peaks 
represent non-specific binding peptides. 
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Peptide mass 
(observed) Peptide sequence
1 Score2 
1575.5751 R.HTDDEMTGYVATR.W 91.5 
 R.HTDDEMTGYVATR.W 58.5 
 R.HTDDEMTGYVATR.W 42.6 
 R.HTDDEMTGYVATR.W 26.2 
1591.6010 R.HTDDEMTGYVATR.W 64.6 
 R.HTDDEMTGYVATR.W 32.6 
 
 
 
 
 
 
 
 
 
 
 
Table AIV-1.  Results of MASCOT database search of phosphorylated 
p38α peptides.  1The sites of phosphorylation and oxidation are in bold and 
underlined within the peptide sequence that corresponds to the observed 
mass in the left column.  2The highest scoring sequences from the MASCOT 
search for the 1575.5751 and 1591.6010 peptides are shown.  The scores 
correlate directly with the accuracy of the corresponding phosphorylation and 
oxidation sites. 
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Phosphorylated p38α MAPK derived from E. coli exhibits kinase activity. To 
determine whether recombinant p38α in our preparation exhibits kinase activity, 
we performed a kinase assay in the presence of recombinant cJun, a well-
characterized p38α substrate (Yamagishi et al., 2001). Phosphorimager scanning 
(32P) revealed that E. coli-derived p38α effectively phosphorylates cJun.  In 
contrast, phosphorylation of cJun is not detected in reactions containing 
dephosphorylated, lambda phosphatase-treated p38α (Figure AIV-5), confirming 
that the activity of recombinant p38α expressed in E. coli depends upon 
phosphorylation.  Collectively, these data demonstrate that recombinant p38α is 
phosphorylated during expression in E. coli, resulting in activation of a fraction of 
the total p38α expressed.  
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Figure AIV-5.  Phosphorylated p38α MAPK expressed in E. coli is 
catalytically active.  Recombinant, GST-tagged cJun (cJun), a known 
substrate of p38α, was incubated in the presence of radiolabelled [-32P] ATP 
with either untreated p38α (p-p38) or p38α treated with lambda protein 
phosphatase (d-p38). Reactions were separated by SDS-PAGE and 
processed for autoradiography. Phosphorimager scanning (32P) shows 
marked phosphorylation of cJun by untreated p38α (p-p38), but not by 
dephosphorylated p38α (d-p38), indicating that p38α derived from E. coli is an 
active kinase.  Coomassie Brilliant blue (CB) staining shows equivalent 
amounts of recombinant p38α and cJun substrate in all reactions. Control 
reactions included cJun, p-p38, and d-p38. 
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Discussion 
Despite many reports for recombinant p38α expression and purification in 
E. coli, observations of p38α phosphorylation have not been cited.  The bacterial 
strain and growth conditions described herein are similar to those described by 
others (Wang et al., 1997; Bukhtiyarova et al., 2004).  However, most purification 
protocols employ at least one anion exchange column (Wang et al., 1997; 
Keesler et al., 1998; Bukhtiyarova et al., 2004; Diskin et al., 2007), which is 
known to separate proteins with different phosphorylation states. Our results 
indicate that phosphorylated p38α represents a subspecies, and suggest that the 
non-phosphorylated form is present in the highest relative abundance (Figure 
AIV-3).  Thus, it is conceivable that other protocols enriched for the more 
abundant, unphosphorylated p38α protein at the expense of phosphorylated 
p38α species.   
To our knowledge, there is only one report by Han et al. that describes a 
recombinant form of p38α from E. coli that is recognized by an anti-
phosphotyrosine antibody and that phosphorylates the myelin basic protein 
(MBP) substrate. However, these data were not shown, nor were the specific 
phosphorylation sites identified (Han et al., 1994).  Alternative possibilities for 
why active, phosphorylated forms of p38α from E. coli is not generally described 
are that researchers did not probe for activity, or that the kinase activity was 
below the limit of detection for the various assays employed.  
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The p38α protein in our preparation is comprised of heterogeneous 
species, as defined by their phosphorylation state. Mass spectrometry data 
unequivocally identified non-phosphorylated and singly-phosphorylated pools of 
p38α. Western blots using an antibody raised against a peptide dually 
phosphorylated at Thr180 andTyr182 suggest that our preparation also includes 
this dually phosphorylated p38α species.  Since we did not detect 
phosphorylated Tyr182 in our MALDI-TOF spectrum, we cannot rule out the 
possibility that this antibody cross-reacts with singly phosphorylated p38α.  An 
alternative explanation is that the abundance of dually phosphorylated p38α is 
below the limit of detection for our MALDI-TOF experiment and that the antibody 
is relatively more sensitive.  Should most of the p38α in our preparation be 
singly-phosphorylated at Thr180, as suggested by our mass spectrometry 
studies (Figure AIV-4), it would be possible that this protein preparation exhibits 
less activity than p38α preparations dually phosphorylated in vitro at Thr180 and 
Try182 by upstream MAPKs.  However, a recent report showed p38α 
monophosphorylated at Thr180 displays significant kinase activity that was only 1 
order of magnitude lower than bis-phosphorylated p38α (Zhang et al., 2008; 
Askari et al., 2009).  Taken together, these observations suggest that a 
significant portion of the observed kinase activity in our p38α preparation stems 
from p38α monophosphorylated at Thr180.   
That p38α is phosphorylated and activated in E. coli was unexpected, 
since E. coli does not typically modify recombinant mammalian proteins post-
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translationally. P38α may be autophosphorylated in E. coli, perhaps through a 
protein-interaction similar to mammalian TAB-1 that induces p38α 
autophosphorylation (Ge et al., 2002). Accordingly, autophosphorylation has 
been proposed as the mechanism of phosphorylation for the Lck protein-tyrosine 
kinase when expressed in E. coli (Jullien et al., 1994).  An alternative explanation 
is that recombinant p38α is phosphorylated by bacterial kinases, as suggested 
for bacterially expressed recombinant p68 RNA helicase (Yang and Liu, 2004).  
The exact mechanisms underlying phosphorylation of mammalian p38α 
produced in E. coli are unknown. 
In sum, we describe a simple method for the production and purification of 
active p38α from E. coli that would be useful to researchers in the MAPK field. In 
addition, our findings identify p38α as another example of a mammalian protein 
that is post-translationally modified when expressed in E. coli. This observation 
suggests that careful characterization of post-translational modifications might be 
needed for other mammalian protein expressed in bacteria.  
 
Materials and Methods 
Reagents.  [-32P] ATP was purchased from MP Biomedicals. Recombinant GST-
tagged cJun (1-79) was from Calbiochem. The antibodies employed in this study 
include anti- phosphorylated p38α (Cell Signaling, 9215) and anti-total p38 
(Sigma, M0800).  Lambda protein phosphatase was purchased from New 
England Biolabs (P0753S), Rosetta DE3 cells were from Novagen (EMD 
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Chemicals, 71400-4), and TALON Metal Affinity Resin from ClonTech (635502). 
Thrombin protease was purchased from GE/Pharmacia (27-0846-01), and 
HiTrap Benzamidine Fast Flow column from GE Healthcare. Isopropyl-1-thio-s-D-
galactopyranoside (I6758), trypsin (T6567), iodoacetamide (I6125), and 
lysozyme (L6876) were purchased from Sigma-Aldrich.  ProteaseMAX surfactant 
(V2072) was purchased from Promega, TiO2 NuTip (NT1TIO.96) from Glygen 
Corp., and alpha-cyano-4-hydroxycinnamic acid (186002331) from Waters 
MassPREP. 
 
Expression and purification of His-tagged p38α MAPK.  The pET-14b plasmid 
containing the murine p38α MAPK gene was a generous gift from Dr. Jiahuai 
Han (The Scripps Research Institute, La Jolla CA). The plasmid encodes full-
length murine p38α (Accession Number #NM_011951) with a Histidine (His) tag 
and a thrombin cleavage site (MGSSHHHHHHSSGLVPRGSH) at the amino 
terminus.  This plasmid was transformed into Rosetta DE3 cells using a standard 
heat-shock protocol.  Transformed colonies from LB/ampicillin plates were grown 
at 30°C in 5 mls Luria-Bertani (LB) broth, supplemented with 100μg/ml ampicillin 
(amp) and 34μg/ml chloramphenicol (cam), referred to here as LBAC media.  
After 8-10 hours these cultures were added to 50 mls of fresh LBAC media and 
grown overnight at 30°C.  Twenty-five to 50 mls of this culture was added to 2L of 
fresh LBAC media until an OD600 between 0.05 and 0.10 was reached.  Cells 
were then allowed to grow at 30°C until an OD600 of 0.6-0.7, at which point p38α 
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expression was induced by the addition of 1mM isopropyl-1-thio-s-D-
galactopyranoside (IPTG) for 4 hours.  Cells were harvested by centrifugation at 
8,000 rpm for 15 minutes.  Cell pellets were stored at -80°C or immediately used 
for his-p38α purification. 
 Bacterial cells were resuspended in lysis buffer (50mM Tris, 500mM NaCl, 
10mM imidazole, and protease inhibitor) (Wang et al., 1997).  Lysozyme  (1 
mg/ml) and NP-40 (0.3%) was added to the lysate, which was then sonicated in a 
Sonic Dismembrator (Fisher Scientific, Model 500) as follows: once at 10% for 12 
sec, three times at 20% for 12 sec, and once at 30% for 12 sec.  The lysate was 
cleared by centrifugation at 15,000 rpm for 30 minutes at 4°C, and then applied to 
TALON resin equilibrated in Buffer A (50mM sodium phosphate, 300mM NaCl, 
and 5mM imidazole, pH 7.0) inside a 50 mL conical tube and incubated with 
gentle rocking at room temperature for 30 minutes.  The resin was centrifuged at 
2000 rpm for 5 minutes and the supernatant was removed.  The resin was 
washed 3 times with 10 bed volumes of Buffer A before eluting the his-tagged 
p38α with Buffer B (50 mM sodium phosphate, 300 mM NaCl, and 150mM 
imidazole, pH 7.0). The protein was then buffer exchanged into phosphate 
buffered saline (PBS) supplemented with 2mM dithiothreitol (DTT).  Yields were 
typically 10-15mg of ~85% pure protein per liter of LBAC media. 
 
Thrombin cleavage of His-tagged p38α MAPK.  For cleavage of the his-tag from 
p38α, the purified protein was buffer exchanged into Buffer A and treated with 10 
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units of thrombin protease per mg of fusion protein overnight at 4°C.  The protein 
was then applied to TALON resin a second time to remove the cleaved his-tag 
and residual un-cleaved p38α.  To remove the thrombin protease, the protein 
was applied to a HiTrap Benzamidine FF column equilibrated with Buffer A.  The 
p38α eluted in the flow-through, and was subsequently buffer exchanged into 
PBS supplemented with 2mM DTT and stored at -80oC.  Protein purity was 
assessed as ~95% based on SDS-PAGE and Coomassie Brilliant blue staining 
analysis. 
 
Dephosphorylation of p38α MAPK by lambda phosphatase. His-tagged p38α (1.3 
mg) was incubated with 8000 units of lambda protein phosphatase at 30°C 
overnight, and the reaction was applied to TALON resin as described above.  
The lambda phosphatase was removed by washing the resin with Buffer A.  
Dephosphorylated his-tagged p38α was eluted with Buffer B and buffer 
exchanged into PBS as described above.  
 
In vitro p38α MAPK activity assay.  Phosphorylated and dephosphorylated 
(lambda protein phosphatase treated) forms of his-tagged p38α (500nM each) 
were incubated with GST-cJun (13.5M) in kinase buffer (20mM Hepes, pH 7.4, 
2mM EGTA, 10mM Magnesium Sulfate, 1mM DTT) at 30°C.  Reactions were 
started by addition of 100M, -32P labeled ATP. After 10 minutes incubation, 
kinase reactions were stopped by addition of 10µl Laemmli sample buffer. 
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Reactions were separated by SDS-PAGE and stained with Coomassie Brilliant 
blue. After destaining, gels were dried and processed for Phosphorimager 
Typhoon scanning. 
 
Determination of the exact mass of p38α MAPK proteins. The exact masses 
associated with the his-tagged p38α species in our preparation were determined 
using Electrospray Ionization Fourier transform ion cyclotron resonance (FT-ICR, 
FT-MS) mass spectrometer (apex Qe-94, Bruker Daltonics) as described 
previously (Bosco et al., 2010b).  Briefly, purified samples were diluted into either 
50% methanol/49.1% water/0.1% formic acid 2 mM ammonium Bicarbonate or 2 
mM ammonium bicarbonate in water. Similar phosphorylation patterns were 
obtained with both solvents, with the acidified solution giving a higher 
signal/noise ratio. 
 
Mass spectrometry based-identification of phosphorylation sites in recombinant 
p38α. Phosphorylated and dephosphorylated (lambda protein phosphatase-
treated) p38α preparations were processed for tryptic digestion and mass 
spectrometry analyses as follows. His-tagged p38α proteins were resolved by 
SDS PAGE analysis and visualized by Coomassie Brilliant blue staining.  Bands 
corresponding to p38α were excised and placed into 1.5ml eppendorf tubes with 
1ml of water for 1 hr.  The water was removed and 25 l of 250 mM Ammonium 
Bicarbonate was added.  To reduce the disulfide bond in the proteins, 5 l of a 45 
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mM solution of DTT was added and the samples were incubated at 50°C for 30 
min.   The samples were cooled to room temperature.  Alkylation of the cysteines 
(to prevent disulfide bond formation) was accomplished with the addition of 5 l 
of a 100 mM Iodoacetamide solution.  After 30 min, the gel slices were washed 
twice with 1 ml water aliquots.  The water was removed and 1ml of 50:50 (50mM 
Ammonium Bicarbonate: Acetonitrile) was placed in each tube and samples were 
incubated at room temperature for 1hr.  The solution was then removed and 200 
l of Acetonitrile was added to each tube.  After the gel slices turned opaque 
white, the acetonitrile was removed and gel slices were further dried in a Speed 
Vac.  Dried gel slices were rehydrated in 50 l of 2ng/l trypsin in 0.01% 
ProteaseMAX Surfactant: 50mM Ammonium Bicarbonate.  Samples were then 
incubated at 37°C for 21hrs. The supernatant of each sample was then removed 
and placed in a separate 0.5 ml eppendorf tube.  Gel slices were further 
dehydrated with 60 l of 80:20 (Acetonitrile: 1% formic acid).  The extract was 
combined with the supernatants of each sample. The samples were then dried 
down to a 10 l volume in a Speed Vac. 
Aliquots of the extracted peptide digest were then enriched for 
phosphorylated peptides as follows.  Several microliters of the extracted peptide 
digest was diluted in 10 l of binding solvent (75:19:6 Acetonitrile: Water: TFA).  
A 1-10 l TiO2 NuTip was washed two times with 10 l aliquots of binding 
solvent.  Phosphopeptides were then bound by repetitive pipetting (20 times) of 
the 10 l sample volume.  The NuTip was then washed 5 times with binding 
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solvent and then 5 times with 0.1% TFA.  Phosphopeptides were then eluted in a 
separate tube with a 10 l volume of 6% NH4OH after repetitive pipetting (10 
times).  A 3 l aliquot of 5% TFA was then added to acidify the sample. The 
phosphopeptides were further purified prior to MALDI analysis using a micro C18 
ZipTip. 
Samples containing digested peptides from p38α proteins were deposited 
onto the MALDI sample target with 1l of Acetonitrile: 0.1% TFA (80:20) followed 
by addition of 0.5l of Matrix solution which consisted of 5 mg/ml of Alpha-
Cyano-4-hydroxycinnamic acid in Acetonitrile: 0.1% TFA (50:50).  Samples were 
allowed to air dry prior to insertion into the mass spectrometer.  Analyses were 
performed on a Shimadzu Biotech Axima TOF2 (Shimadzu Instruments) matrix-
assisted-laser desorption/ionization Time-of-Flight (MALDI-TOF) mass 
spectrometer.  Peptides were analyzed in positive ion Reflectron mode. The 
instrument was externally calibrated using a local spot to the sample of interest 
with Angiotensin II (1046.54), P14R (1533.86) and ACTH (18-39) 2465.20 Da.  
Collision Induced Dissociation (CID) and/or a Post-Source-Decay (PSD) analysis 
were performed on the same instrument using a dual timed ion gate for high 
resolution precursor selection with a laser power about 20% higher than for MS 
acquisition.  CID/PSD fragments were separated in a Curved Field Reflectron 
(CFR) allowing for a full mass range acquisition of the MS/MS spectrum.  All 
spectra were processed with Mascot Distiller (Matrix Sciences, Ltd.) prior to 
database searching.  Database searches were performed in house with Mascot 
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(Matrix Sciences, Ltd.).  For MS searches the Peptide Mass Fingerprint program 
was used with a peptide mass tolerance of 100 ppm.  For MS/MS searching 
(CID/PSD spectra) the MS/MS Ion Search program was used with a Precursor 
tolerance of 100 ppm and a fragment tolerance of 1.5 Da. 
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PREFACE TO APPENDIX V: 
 
The work presented in this appendix was performed by Catherine L. Ward with 
the following exceptions:  
 
Mass spectrometry was performed by the mass spectrometry core facility 
(UMMS) and cross-linking experiments were largely performed by Michelle 
Dubuke during her lab rotation (UMMS).  All figures were prepared by Catherine 
L. Ward. 
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APPENDIX V: P38 MAPK PREFERENTIALLY BINDS FALS-LINKED MUTANT 
AND OXIDIZED WILD-TYPE SOD1 PROTEINS 
 
Abstract 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, 
is a rapidly progressive and fatal motor neuron disease.  The mitogen activated 
protein kinase, p38, is thought to play a role in the pathogenesis of ALS due to 
aberrant activity of the kinase and in association with mutant superoxide 
dismutase-1 (SOD1).   Here, we investigate the relationship between SOD1 and 
p38.  Using several familial ALS-linked SOD1 variants and oxidized WT SOD1, 
as a model for sporadic ALS, we show that p38 MAPK, both alpha and beta 
isoforms, preferentially bind the mutant and oxidized forms of SOD1, 
independently of p38 activation. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS), is a rapidly progressive and fatal 
disease characterized by the death of motor neurons.  Approximately 10% of 
ALS cases are familial (fALS), or inherited, with the remaining 90% classified as 
sporadic cases (sALS).  Of the familial cases, ~20% are caused by mutations in 
the gene superoxide dismutase-1 (SOD1), which was found over two decades 
ago to be involved in ALS (Rosen et al., 1993). SOD1 is an enzyme which 
catalyzes the conversion of superoxide anions to hydrogen peroxide.  Over 150 
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mutations in SOD1 have been found to cause ALS, which is thought to occur by 
a gain of toxic function, as suggested by lack of neurotoxic phenotype in SOD1 
knock-out mice (Reaume et al., 1996).  This toxic function is thought to be related 
to the tendency of mutant SOD1 to misfold and aggregate.  Wild-type (WT) 
SOD1 is found to aggregate upon being oxidized (Rakhit et al., 2004; Furukawa 
et al., 2006)  and once oxidized, SOD1 mimics the toxicity and binding 
interactions of mutant SOD1 (Ezzi et al., 2007). WT SOD1 could therefore be 
playing a role in sALS pathogenesis through its ability to gain toxic properties 
similar to those seen with mutated SOD1. 
Also shown to be important in the pathogenesis of ALS are the mitogen-
activated protein kinases (MAPKs).  MAPKs are serine-threonine protein kinases 
which regulate cellular activities through a signaling cascade initiated by cues 
from various extracellular or intracellular stimuli.  The basic MAPK pathway 
consists of three components: a MAPK kinase kinase (MAP3K), which 
phosphorylates a MAPK kinase (MAP2K), which in turns phosphorylates a MAPK 
(Kim and Choi, 2010).  Upon phosphorylation, these kinases become activated 
allowing for further transmission of the signal cascade.  One member of the MAP 
kinase family associated with ALS is p38.  This protein has several isoforms, α, 
β, γ, δ, and is activated by many cellular stresses, including osmotic shock, 
cytokines, and oxidative stress. Aberrantly activated p38α can lead to elevated 
levels of phosphorylated neurofilament heavy chain, which when accumulated, is 
a pathological feature of ALS (Ackerley et al., 2004).  Aberrant activation of p38 
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also correlates with disease progression in SOD1 G93A mice (Tortarolo et al., 
2003) while the p38 inhibitor, SB203580, prevents SOD1 induced apoptosis of 
motor neurons (Dewil et al., 2007).  Additionally, activated p38 was found to be a 
component of inclusions in human ALS patients and G93A SOD transgenic mice 
(Bendotti et al., 2005).  In light of the associations between p38 MAPK and SOD1 
in ALS, we tested the hypothesis that there is a direct binding interaction 
between modified SOD1 proteins and p38 MAPK.  We found that p38 binds 
SOD1 mutants A4V, G37R, G41D, G85R, and G93A, as well as oxidized WT, 
while having little affinity for the unmodified WT protein.  This binding interaction 
was direct and independent of p38 activation. 
 
Results 
P38 MAPK co-purifies with fALS-linked mutant SOD1, but not WT-SOD. In light 
of the correlation between p38 and SOD1 in ALS we sought to determine the 
relationship between these two proteins, starting with probing for a binding 
interaction.  Neuro-2A (N2A) cells stably expressing either WT-SOD1 or a fALS-
linked mutant SOD1 (G37R, G41D, or G85R) were lysed and incubated with His-
tagged p38α.  Using affinity chromatography, the His-tagged p38α was isolated 
from the reaction.  Western analysis of the extracted protein shows that G37R, 
G41D, and G85R have a 3.7, 4.2, and 5.2 fold increase in affinity for p38α, 
respectively, as compared to WT SOD1 (Figure AV-1).  To account for non-
specific binding of the SOD1 proteins to the affinity column, p38α was omitted 
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from the reactions and the amount of SOD1 eluted from the column (Figure AV-
1; background) was quantified and subtracted from the experimental values.  An 
equal amount of His-p38α was isolated in each sample, indicating that mutant 
forms of SOD1 bind p38α to a significantly higher degree than WT-SOD1 (Figure 
AV-1).   
 
FALS-linked mutant SOD1 proteins bind directly to P38 MAPK.  Once a mutant 
specific binding interaction was established it was next necessary to determine if 
this binding was a result of a direct interaction.  Purified His-tagged p38α was 
incubated with purified WT SOD1 or the fALS-linked SOD1 mutant A4V.  
Western analysis following extraction of p38α via affinity chromatography 
revealed a direct binding interaction of p38α and SOD1 which was exclusive for 
the mutant protein (Figure AV-2, lanes 1 and 2).  Comparison of Western blot 
band density between WT and mutant A4V revealed a ~23 times greater amount 
of mutant protein present than WT. 
 To substantiate the direct binding interaction observed from the affinity 
pull-downs, crosslinking experiments between fALS-linked mutant SOD1 and 
p38α were performed.  Purified p38α and SOD1 proteins were incubated with the 
crosslinking agent, dimethyl suberimidate (DMS), which functions to covalently 
link proteins between the amino groups of lysines at their binding interface.  WT-
SOD1 and mutants A4V, (Figure AV-3) G85R, and G93A, (Figure AV-4) were 
included in the analysis.  The crosslinking reactions were analyzed via Western  
189 
 
 
 
 
 
 
 
Figure AV-1.  Recombinant p38α preferentially binds to fALS-linked 
mutant SOD1 proteins from N2A cell lysates.  Lysates from N2A cells 
stably expressing fALS-linked SOD1 mutants G85R, G41D, or G37R or SOD1 
WT were incubated with the alpha (α) isoform of His-tagged p38 MAPK. The 
binding reactions were applied to Ni-NTA spin columns and then eluted with 
imidazole.  The elutions were subjected to Western blot analysis using 
antibodies against p38 and SOD1 as indicated.  The Western blots were 
analyzed and quantified by densitometry.  The quantification shows that 
G37R, G41D, and G85R have a 3.7, 4.2, and 5.2 fold increase in affinity for 
p38α, respectively, as compared to WT SOD1, demonstrating that p38α 
preferentially binds fALS-linked mutant SOD1 proteins. 
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blot using antibodies against p38 and SOD (Figure AV-3A and AV-4A).  Several 
crosslinked species were observed, with molecular weights correlating to a p38α 
dimer, an SOD1 dimer, and a p38α monomer crosslinked to a SOD1 monomer  
(Table AV-1).  From the density of the Western blot bands probed with anti-p38, 
the percentage of p38 crosslinked to SOD1 was calculated.   7.62% of WT SOD1 
and 11.91% of A4V bound to p38α (Figure AV-3B).  Comparison of WT, G85R, 
and G93A showed 9.85%, 8.99%, and 11.54% of SOD1 protein, respectively, 
bound to p38α (Figure AV-4B)   The Western blots were also probed with SOD1 
to confirm the crosslinking and to calculate the percentage of SOD1 crosslinked 
to p38α.  Comparison of WT and the A4V mutant showed 1.74% of total WT 
SOD1 bound to p38α and 17.42% of total A4V (Figure AV-3C).  7.88% of total 
WT SOD1, 8.85% of total G85R, and 12.69% of total G93A was bound to p38α 
(Figure AV-4C).   
To verify these results, the crosslinking samples were analyzed via SDS-
PAGE with silver staining.  The protein bands with a molecular weight of 60-65 
kD were excised and subjected to mass spectrometry analysis.  The analysis of 
these bands revealed no p38α present in the WT SOD1 crosslinking reaction, 
indicating that if any p38α was present, it was below the limit of detection (Table 
AV-2).  Through these experiments using isolated, purified protein it was 
established that the binding of p38α and SOD1 was a direct interaction 
preferential for mutant SOD1. 
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Figure AV-2.  Recombinant p38α preferentially binds to recombinant 
fALS-linked SOD mutant A4V and aberrantly oxidized SOD1 WT (SODox) 
proteins.  Recombinant SOD1 WT, fALS-linked mutant A4V, and SODox (a 
model protein for sALS) were incubated with the alpha (α) isoform of His-
tagged p38. The binding reactions were applied to Ni-NTA spin columns and 
then eluted with imidazole.  The elutions were subjected to Western blot 
analysis using antibodies against p38 and SOD1 as indicated.  The Western 
blots were analyzed by densitometry and the quantification was corrected for 
non-specific binding of SOD1 proteins (background).  The quantification 
revealed a ~23 and ~28 times greater affinity of A4V and SODox for p38α, 
respectively, as compared to WT.  Per the Western blot and quantification, it is 
evident that the mutant and oxidized forms of SOD1 bind p38α to a much 
higher degree than the unmodified WT protein. 
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Oxidized WT-SOD1 mimics fALS-linked mutant SOD1 in its ability to bind p38. 
As a model for sALS, an oxidized form of the wildtype SOD1 protein (referred to 
here as SODox) was also incubated with p38α and analyzed for a binding 
interaction via affinity chromatography and Western blot.  As with the fALS-linked 
mutant proteins, the oxidized WT protein had a significantly higher binding affinity 
for p38α than the unmodified WT protein (Figure AV-2A, lanes 1 and 3).  
Comparing the Western blot band density between the amount of unmodified WT 
SOD1 and oxidized WT SOD1 purified with p38α reveals a ~28 times greater 
amount of oxidized WT protein.  Therefore, WT SOD1 when modified by 
oxidation, mimics the p38α binding capabilities of mutant SOD1 protein. 
 
Mutant SOD1 also binds the beta isoform of p38 MAPK.  Being 75% homologous 
in sequence to the alpha isoform of p38, the binding of the beta isoform to SOD1 
was also examined.  Recombinant, His-tagged p38β was incubated with a subset 
of the mutant protein found to bind p38α, including G37R from N2A cells and 
purified A4V and SODox.  After isolating p38β via affinity chromatography, the 
same binding interactions as observed for p38α were seen (Figure AV-5). 
Neither purified WT SOD1 nor WT SOD1 from N2A cells bound p38β.  
Comparison of the Western blot band density reveals that G37R, A4V, and 
SODox bound p38β 1.6, 1.4, and 0.5 times greater than unmodified WT SOD1, 
respectively.  These results therefore indicate that the binding of oxidized and 
mutant SOD1 to p38 is not specific for the alpha isoform. 
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Discussion 
This study has revealed a specific binding interaction between p38 MAPK 
and oxidized or mutant forms of SOD1, identifying a link between these two 
proteins relevant to ALS pathogenesis.  A series of binding assays utilizing 
affinity chromatography demonstrated a unique affinity of p38 for SOD1 mutants 
A4V, G37R, G41D, G85R, and G93A, as well as the oxidized WT protein 
(SODox), while not binding to the unmodified WT protein.  These assays also 
confirmed that the binding is due to a direct interaction of these proteins and is 
not mediated by any additional protein interactions. 
Important to the link between the familial and sporadic forms of ALS is the 
binding of p38 to the oxidized wild-type protein.  Whereas this protein has no 
mutations, it mimics the binding capabilities of the mutant protein.  This 
demonstrates that a modification, such as oxidation, to the wild-type protein is  
enough to cause it to acquire new binding partners that could be significant to the 
pathogenesis of sporadic ALS. 
That p38 interacts with mutant and modified forms of SOD1 is an 
important observation as a functional interaction between these proteins has also 
been observed.  In a model using giant squid axoplasm, modified SOD1 purified 
from sporadic ALS patient tissue, as well as recombinantly purified SOD1 mutant 
protein, inhibited axonal transport in a p38 dependent manner.   Additionally, the 
amount of mutant SOD1 bound to p38 is a very small proportion of the total 
amount expressed, suggesting that only a subpopulation of the mutant proteins 
195 
 
 
acquire this potentially toxic binding property.  Perhaps when bound to SOD1, 
p38 acquires new binding partners, altering the transmission of the kinase 
signaling cascade and activating unintended proteins. 
In addition to revealing a unique binding interaction of p38, this work has 
provided a new tool for studying the kinase activity of the protein.  Isolation of a 
doubly phosphorylated p38 species via E. coli expression was accomplished 
using affinity chromatography followed by purification with an ion exchange 
column.   Being able to purify out these different forms of p38 will enhance the 
way in which the activity of the kinase is studied. 
Studying the relationship between p38 and SOD1 has given us a new tool 
to enhance the study of p38 as well as an important observation into the activity 
of these two proteins related to ALS pathogenesis.  Further characterizing the 
nature of this binding interaction unique to mutant and modified WT SOD1 will 
lead to further insights into their roles in ALS pathogenesis. 
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Figure AV-4.  Recombinant p38α preferentially binds fALS-linked 
mutants G85R and G93A in crosslinking analyses.  Recombinant p38α 
was combined with either SOD1 WT or fALS-linked SOD1 mutants G85R and 
G93A and treated with the crosslinker dimethyl suberimidate (DMS) for 15 
minutes at room temperature.  Crosslinking occurred at lysine residues in 
SOD1 and p38α within 11 Å of each other. The crosslinked species were then 
identified by Western analysis, probing for SOD1 and p38, and are indicated 
by the arrows (A).  The proposed crosslinked species were determined based 
on molecular weight (Table AV-1).  Monomer (m) and dimer (d) proteins were 
both detected.  Densitometry was performed (n = 2) to determine the 
percentage of total p38 crosslinked to SOD1 (B) and the percentage of total 
SOD1 crosslinked to p38 (C). 
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Figure AV-5.  The beta isoform of p38 also binds mutant and modified 
SOD1 proteins. Lysates from N2A cells stably expressing fALS-linked SOD1 
mutant G37R or SOD1 WT, as well as recombinant fALS-linked SOD1 mutant 
A4V and the oxidized form of WT SOD1 (SODox), were incubated with the 
beta (β) isoform of His-tagged p38 MAPK.  The binding reactions were applied 
to Ni-NTA spin columns and then eluted with imidazole.  The elutions were 
subjected to Western blot analysis using antibodies against p38 and SOD1 as 
indicated.  The Western blots were analyzed by densitometry and the 
quantification was corrected for non-specific binding of SOD1 proteins 
(background).  The quantification shows that G37R, A4V and SODox have a 
1.6, 1.4, and 0.5 fold greater affinity for p38α, respectively, than the WT 
protein. 
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Materials and Methods 
Cell culture. Flp-in HEK cells (Invitrogen - #R75007) expressing GFP-SOD1 
constructs under control of a doxycycline-induced promoter (generous gift from 
Dr. Larry Hayward, UMMS) were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% TET-tested fetal bovine serum (Atlanta 
Biologicals,#s10350H), 2mM L-glutamine (Gibco, #25030), 1% penn/strep 
solution (Gibco, #15140), 15 mg/ml blasticidin (Invitrogen, #R210-01), and 25 
ug/ml hygromycin B (Invitrogen, #10687-010).  Neuro2A (N2A) cells stably 
expressing WT or mutant SOD were maintained in 1:1 DMEM and OPTI-MEM 
media supplemented with 12% fetal bovine serum, 400 μg/ml geneticin (GIBCO, 
#11811-031), and 1% penicillin/streptomycin/glutamine. 
 
Protein expression and Purification.  p38 MAPK plasmid was a gift from 
Goldsmith and Han labs and myc-tagged SOD1 from Dr. Zuoshang Xu, UMMS. 
Mutations to the SOD1 WT protein were constructed using mutagenic primers 
and the QuickChange Site Directed Mutagenesis method (Stratagene).  
 
SOD1 production:  Expression of GST-tagged SOD1 in Rosetta DE3 cells 
(Novagen) was induced by 1mM isopropyl-1-thio-s-D-galactopyranoside (IPTG) 
for 3 hours at 37oC.  Incorporation of metals was achieved by the addition of 
200μM CuCl2 and 200μM ZnCl2 prior to the IPTG induction.  The bacteria were 
harvested through centrifugation and lysed with lysis buffer (0.5mM dithiothreitol  
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(DTT), 0.1mM EDTA, protease inhibitor cocktail (Roche, #11873580001), in 
PBS) and gentle sonication. After centrifuging the lysate, the supernatant was 
passed through a glutathione Sepharose column, previously washed with PBS.  
The GST-SOD1 protein was eluted from the column with 10mM glutathione, 
50mM Tris (pH 9.5). Cleavage of the GST tag was achieved using six units of 
Precision Protease (GE/Amersham, 27-0843-01) per milligram of protein.  
Following cleavage, the protein was dialyzed back into PBS and was run back 
over the glutathione Sepharose column.  The untagged SOD1 protein was further 
purified using a Q-column in a 10mM Tris buffer at a pH of 8.0.  The protein was 
eluted from the column with a gradient of 10mM Tris, 300mM NaCl pH 8.0 buffer.  
Purity of the preparation was assessed using SDS-PAGE and mass 
spectrometry.  For the production of SODox, wild-type SOD1 protein was 
incubated at room temperature with 10mM hydrogen peroxide for 24 hours.  The 
reaction was quenched by buffer exchanging the protein into PBS. 
 
P38 production:   Expression of His-tagged p38 in Rosetta DE3 cells (Novagen) 
was induced by 1mM isopropyl-1-thio-s-D-galactopyranoside (IPTG) for 4 hours 
at 30oC.  The bacteria were harvested by centrifugation and lysed with lysis 
buffer (50mM Tris pH 7.4, 500mM NaCl, 10mM imidazole, protease inhibitor 
cocktail) and gentle sonication.  Cleared lysate was added to TALON resin 
(ClonTech) and purification proceeded as per manufacturer’s instructions.  The 
his-tag was then cleaved using thrombin protease (GE/ Pharmacia, #27-0846-01)  
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Binding assays with recombinant p38 MAPK and N2A cell lysates.  Total N2A 
cell lysates were prepared using a lysis buffer composed of 50 mM NaH2PO4, 
100 mM imidazole, 300 mM NaCl (pH 8.0), 12 mM deoxycholic acid, 1% NP-40, 
protease inhibitor cocktail, 50 mM NaF and 10 mM Na2VO3.  700μg of total 
protein from N2A cell lysates was incubated with 100μg of purified His-tagged 
p38 for 3 hour at 4°C with rotation.  As a control, reactions were also incubated 
without His-tagged p38.  After incubation, the binding reactions were applied to 
Ni-NTA spin columns (Qiagen), washed with 50 mM NaH2PO4, 20 mM 
imidazole, 300 mM NaCl (pH 8.0), and eluted with 50 mM NaH2PO4, 500 mM 
imidazole, 300 mM NaCl (pH 8.0).  Speed and duration of spins were as per 
manufacturer’s instructions (Qiagen).  The elutions were subjected to SDS-PAGE 
and probed for p38 and SOD1 using standard Western blot methods with anti-
p38 MAP Kinase antibody produced in rabbit (Sigma, M0800) and anti-
superoxide dismutase (Cu/Zn Enzyme) produced in sheep (Calbiochem, 
574597), respectively. 
 
Recombinant protein binding assays. 10μg of purified SOD1 protein in lysis 
buffer was incubated with 100μg of purified His-tagged p38 for 3 hour at 4°C with 
rotation.  As a control, reactions were also incubated without His-tagged p38.  
The binding reactions were applied to Ni-NTA spin columns (Qiagen), washed, 
and eluted as described above.  The elutions were subjected to SDS-PAGE and 
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probed for p38 and SOD by standard Western blotting techniques with the 
antibodies described above. 
 
Crosslinking analysis.  Proteins were buffer exchanged into 0.2M 
Triethanolamine (TEA) pH 8.5 and combined such that the final concentration of 
each protein was 2.5mg/ml.  Dimethyl suberimidate · 2HCl (ThermoScientific, 
#20700) was added in 150M excess and the reaction was allowed to proceed at 
room temperature for 15 or 30 minutes after which the reaction was quenched by 
the addition of SDS sample loading buffer and boiling. (as per the manufacturer’s 
instructions)  Samples were analyzed via Western blot probing for p38 and SOD1 
with the antibodies described above.  For verification by mass spectrometry 
analysis, the samples were first run on an SDS-PAGE gel and subjected to silver 
stain (Bio-Rad).  The bands corresponding to the predicted size of the 
crosslinked species were then extracted and sent to the Mass Spectrometry Core 
Facility at UMMS for digestion and analysis. 
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